EP2750629B1 - Dispositif d'arthroplastie avec interposition élastique - Google Patents

Dispositif d'arthroplastie avec interposition élastique Download PDF

Info

Publication number
EP2750629B1
EP2750629B1 EP12827020.4A EP12827020A EP2750629B1 EP 2750629 B1 EP2750629 B1 EP 2750629B1 EP 12827020 A EP12827020 A EP 12827020A EP 2750629 B1 EP2750629 B1 EP 2750629B1
Authority
EP
European Patent Office
Prior art keywords
implant
joint
bone
knee
femur
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP12827020.4A
Other languages
German (de)
English (en)
Other versions
EP2750629A4 (fr
EP2750629A2 (fr
Inventor
R. Thomas Grotz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP2750629A2 publication Critical patent/EP2750629A2/fr
Publication of EP2750629A4 publication Critical patent/EP2750629A4/fr
Application granted granted Critical
Publication of EP2750629B1 publication Critical patent/EP2750629B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/30—Joints
    • A61F2/38—Joints for elbows or knees
    • A61F2/3859—Femoral components
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/56—Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor
    • A61B17/562—Implants for placement in joint gaps without restricting joint motion, e.g. to reduce arthritic pain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/30—Joints
    • A61F2/30756—Cartilage endoprostheses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/28—Materials for coating prostheses
    • A61L27/34—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3817—Cartilage-forming cells, e.g. pre-chondrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
    • A61L27/3843—Connective tissue
    • A61L27/3852—Cartilage, e.g. meniscus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/56—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/58—Materials at least partially resorbable by the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/064—Surgical staples, i.e. penetrating the tissue
    • A61B17/0642—Surgical staples, i.e. penetrating the tissue for bones, e.g. for osteosynthesis or connecting tendon to bone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/56—Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor
    • A61B2017/561—Implants with special means for releasing a drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/30—Joints
    • A61F2/38—Joints for elbows or knees
    • A61F2/3872—Meniscus for implantation between the natural bone surfaces
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/30—Joints
    • A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
    • A61F2002/30003—Material related properties of the prosthesis or of a coating on the prosthesis
    • A61F2002/3006—Properties of materials and coating materials
    • A61F2002/30062—(bio)absorbable, biodegradable, bioerodable, (bio)resorbable, resorptive
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/30—Joints
    • A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
    • A61F2002/30316—The prosthesis having different structural features at different locations within the same prosthesis; Connections between prosthetic parts; Special structural features of bone or joint prostheses not otherwise provided for
    • A61F2002/30535—Special structural features of bone or joint prostheses not otherwise provided for
    • A61F2002/30563—Special structural features of bone or joint prostheses not otherwise provided for having elastic means or damping means, different from springs, e.g. including an elastomeric core or shock absorbers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/30—Joints
    • A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
    • A61F2002/30316—The prosthesis having different structural features at different locations within the same prosthesis; Connections between prosthetic parts; Special structural features of bone or joint prostheses not otherwise provided for
    • A61F2002/30535—Special structural features of bone or joint prostheses not otherwise provided for
    • A61F2002/30576—Special structural features of bone or joint prostheses not otherwise provided for with extending fixation tabs
    • A61F2002/30578—Special structural features of bone or joint prostheses not otherwise provided for with extending fixation tabs having apertures, e.g. for receiving fixation screws
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/30—Joints
    • A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
    • A61F2002/30316—The prosthesis having different structural features at different locations within the same prosthesis; Connections between prosthetic parts; Special structural features of bone or joint prostheses not otherwise provided for
    • A61F2002/30535—Special structural features of bone or joint prostheses not otherwise provided for
    • A61F2002/30581—Special structural features of bone or joint prostheses not otherwise provided for having a pocket filled with fluid, e.g. liquid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/30—Joints
    • A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
    • A61F2002/30667—Features concerning an interaction with the environment or a particular use of the prosthesis
    • A61F2002/30688—Means for allowing passage or sliding of tendons or ligaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/30—Joints
    • A61F2/30721—Accessories
    • A61F2002/30754—Implants for interposition between two natural articular surfaces
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/30—Joints
    • A61F2/38—Joints for elbows or knees
    • A61F2/3859—Femoral components
    • A61F2002/3863—Condyles fitted on an anchored base
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A61L2300/406—Antibiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602—Type of release, e.g. controlled, sustained, slow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/64—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/10—Materials for lubricating medical devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/06—Materials or treatment for tissue regeneration for cartilage reconstruction, e.g. meniscus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/24—Materials or treatment for tissue regeneration for joint reconstruction

Definitions

  • This invention relates to arthroplasty, and more particularly, to an implant for use in arthroplasty when hyaline articular cartilage is damaged, it breaks down and joint space is lost.
  • Inflammatory enzymes such as from the Cox-1, Cox-2 and/or 5-Lox systems are released and loose bodies form adding to the degradation of joint function.
  • Such joint damage is conventionally treated by physical therapy, analgesics, pain medication and injections.
  • the traditionally accepted treatment option is arthroplasty implantation or replacing the joint with an artificial joint construct.
  • Current arthroplasty techniques typically use "plastic and metal" implants that are rigid and which ultimately fail due to loosening or infection or debris from wear.
  • Conventional materials for the artificial joint components include chrome-cobalt-molybdenum alloy (metal) and high molecular weight polyethylene (plastic). Each is often fixed by a cement-like mixture of methyl methacrylate to the ends of the bones that define the joint that is the subject of the arthroplasty, or coated with a surface that enables bone in-growth.
  • Current hip joint replacements typically last about 10-15 years and knee replacements typically last about 5 -10 years.
  • Ankle joint replacements are not very successful, and often fail in the first several years after surgery.
  • Conditions requiring arthroplasty include traumatic arthritis, osteoarthritis, rheumatoid arthritis, osteonecrosis, and failed surgical procedures.
  • WO 2011/091005 (Grotz) relates to a resilient knee implant including a balloon with an inflatable interior and having a first appendage for coupling the balloon to the femur of the knee joint.
  • the present invention is directed to an orthopedic implant configured for deployment between opposing members of a joint structure that addresses many of the shortcomings of prior artificial joints.
  • the arthroplasty implants embodying features of the invention are configured to preserve joint motions while removing the pain and dysfunction following the development of arthritis or joint injury.
  • the arthroplasty implant in accordance with the present invention achieves improved physiologic motion and shock absorption during gait and acts as a resilient spacer between moving bones during limb movement.
  • the combined characteristics of the implant include anatomic design symmetry, balanced rigidity with variable attachment connections to at least one of adjacent normal structures, and durability which addresses and meets the needs for repair or reconstruction thus far missed in the prior art.
  • the implant should be secured to at least one of the bones of the joint structure.
  • a resilient implant for implantation into human or animal joints to act as a cushion allowing for renewed joint motion.
  • the implant may endure variable joint forces and cyclic loads while reducing pain and improving function after injury or disease to repair, reconstruct, and regenerate joint integrity.
  • the implant may be deployed in a prepared debrided joint space, secured to at least one of the joint bones and expanded in the space, molding to surrounding structures with sufficient stability to avoid extrusion or dislocation.
  • the implant may pad the damaged joint surfaces, may restore cushioning immediately and may be employed to restore cartilage to normal by delivering regenerative cells.
  • a resilient interpositional arthroplasty implant for application into human or animal joints to pad cartilage defects, cushion joints, and replace or restore the articular surface, preserving joint integrity, reducing pain and improving function.
  • the implant may endure variable joint compressive and shear forces, and millions of cyclic loads, after injury or disease requires intervention.
  • the implant may repair, reconstruct, and regenerate joint anatomy in a minimally morbid fashion, with physiologic solutions that improve upon the rigid existing joint replacement alternatives of plastic and metal.
  • the polymer walls of some embodiments of the implant can capture, distribute and hold living cells until aggregation and hyaline cartilage regrowth occurs.
  • the implant may be deployed into a prepared debrided joint space, molding and conforming to surrounding structures with sufficient stability to avoid extrusion or dislocation. Appendages of the implant may serve to repair or reconstruct tendons or ligaments. Appendages of the implant may serve to repair or reconstruct fibrocartilage as in menisci, or the labrum tissues of hips or shoulders.
  • the implant comprises at least one attachment element in the intercondylar notch. In some embodiments, the implant comprises at least one attachment element in the medial region of the intercondylar notch. In some embodiments, the implant comprises at least one attachment element in the lateral region of the intercondylar notch. In some embodiments, the implant comprises at least one attachment element superiorly at the distal end of the femur anteriorly. In some embodiments, the implant comprises at least one posterior reign configured to cinch up the implant from inside a posterior intercondylar notch toward a connection site around the femur. In some embodiments, the implant comprises at least one suture-like lanyard configured to cinch up the implant from inside a posterior intercondylar notch toward a connection site around the femur.
  • first portion comprises a first wall
  • second portion comprises a second wall
  • side portion comprises a side wall
  • the at least one condyle is the medial condyle. In some embodiments, the at least one condyle is the lateral condyle. In some embodiments, the retropatellar surface could be the anatomic region padded. In some embodiments, the tibia-medial or lateral or both is capped. In certain knee implant embodiments, the implant articulates against cartilage of the first bone, second bone, and/or the third bone
  • the implant is fabricated to resemble a certain anatomic region over which the implant is stretched or pulled into place.
  • the implant then may settle into its angle of repose via inherent elasticity.
  • the ambient environment of the joint via exposure to serum or temperature or acidity has a specified effect on the implant materials such as increasing the implant malleability that affects implant performance.
  • the implant comprises an in-growth matrix on at least a portion of the implant adjacent the femur.
  • the in-growth matrix comprises living chondrocytes.
  • the implant is configured to release the chondrocytes over time.
  • the implant comprises a bioabsorbable polymer configured to release the chondrocytes over time.
  • the implant comprises a polymer configured to release the chondrocytes over time, wherein the polymer is not bioabsorbable.
  • the in-growth matrix comprises cells.
  • the in-growth matrix comprises at least one of: stem cells, differentiated cells, pluripotent cells, post-mitotic cells.
  • the cells restore an articular surface of the femur. In other embodiments, the cells repair an articular surface of the femur.
  • the implant comprises a bioabsorbable polymer configured to release the cells over time. In some embodiments, the implant comprises a polymer configured to release the cells over time, wherein the polymer is not bioabsorbable.
  • the in-growth matrix comprises at least one of: autologous cells, allograph cells, and xenograph cells to restore an articular surface of the femur. In some embodiments, the in-growth matrix comprises at least one of: autologous cells, allograph cells, and xenograph cells to repair an articular surface of the femur.
  • the in-growth matrix comprises a pharmacologic substance.
  • the patch implant comprises a matrix that is coated with a hydrophilic or a hydrophobic polymer.
  • the patch is vessicular with or without matrices in the wall components.
  • the patch is a solid compliant material.
  • the walls or material construct is responsive or performs in a dynamic fashion to exogenous joint forces. For non-limiting example, in bone under normal physiologic stress of bearing weight, calcification yields sufficient bone density so as to deter fracture. However, in circumstances wherein prolonged dearth of weight bearing stress is produced by immobilization the bone becomes osteoporotic and pathologic.
  • the implant herein may have smart features to adjust to stimulate healing and tissue regeneration. In some embodiments such materials can be composed of macromolecules or dendritic connections that regulate permeability and transfer of adjacent media.
  • the implant comprises couplers that couple the appendage to the femur.
  • the coupler is bioabsorbable.
  • the coupler is at least one of: a screw, a snap, a washer, a suture, a suture anchor, a rivet, a staple, a staple having teeth, a magnet, an electromagnet, a microminiature transmitter that regulates implant fixation or performance responsive to patient need as perceived by the patient or a care giver, a stabilizer, a glue, a hook, a wire, a string, a lasso, a lanyard, a spike, and combinations thereof.
  • the implant may also and/or alternatively be attached via bone in-growth.
  • the implant is attached via bone in-growth as described in Vasanji A, In vivo bone growth assessment in preclinical studies and clinical trials, Bonezone, 2012, p. 12-17 .
  • the implant comprises a pharmacologic agent.
  • the pharmacologic agent is on a surface of the implant adjacent the femur.
  • the pharmacologic agent is released from the implant over time.
  • the pharmacologic agent is released from within the implant over time.
  • the pharmacologic agent is released from within the balloon over time.
  • the agent is released as a combination of vessicular and matrix origins using internal or external stimuli from normal or exogenous sources.
  • At least a portion of the implant is configured to anneal to a periphery of a cartilage defect.
  • the implant comprises vacuoles of pharmacologic substances. In some embodiments, the vacuoles may be on a bone-engaging portion of the implant. In some embodiments, the implant comprises bubbles comprising an active substance such as a pharmacologic substance or other active agent. In some embodiments, the active agent comprises at least one of: stem cells, growth factors, antibiotics, antifungals, antituberculous, antitumor, antigout agents and viscolubricants. In some embodiments, the active agent comprises iatrigenically gene mutated cells.
  • the implant comprises enzyme absorptive microscopic sponges that could be sucked out or evacuated at or around the time of implant delivery to the joint.
  • the interior comprises a honeycomb structure. In some embodiments, the interior comprises a mesh structure. In some embodiments, the interior comprises a sponge structure. In some embodiments the implant comprises a sponge structure. In some embodiments the implant comprises a compliant membrane.
  • the implant comprises spaces filled with an active substance such as a pharmacologic substance or other active substance.
  • the implant comprises spaces for deliverables (e.g., biologics, antibodies, cells, pharmacologic substances, biomolecules, molecules, compounds).
  • the implant comprises spaces for compressibles (e.g., gas, air).
  • the spaces comprise nanovesicles.
  • the nanovasicles comprise deliverables (e.g., biologics, antibodies, cells, pharmacologic substances, biomolecules, molecules, compounds).
  • the nanovesicles comprise compressibles (e.g., gas, air).
  • the implant is configured to fit within a cannula having a distal end inner diameter of at most 10 millimeters. In some embodiments, the implant is configured to fit within a cannula having a distal end inner diameter of at most 9 millimeters. In some embodiments, the implant is configured to fit within a cannula having a distal end inner diameter of at most 5 millimeters. In some embodiments, the implant may be configured to be introduced surgically arthroscopically as with the cannula 10 mm in diameter or may be introduced through minimal invasive surgery via a large conduit and plunger requiring a small arthrotomy several centimeters in diameter. In some embodiments routine open surgical insertion with a larger wound may be necessary depending on clinical condition, complexity and surgeon choice.
  • the implant is configured to fold in order to fit within a cannula having a distal end inner diameter of at most 10 millimeters. In some embodiments, the implant is configured to fold in order to fit within a cannula having a distal end inner diameter of at most 9 millimeters. In some embodiments, the implant is configured to fold in order to fit within a cannula having a distal end inner diameter of at most 5 millimeters.
  • the implant is configured to be delivered to a joint through a cannula having a distal end inner diameter of at most 10 millimeters. In some embodiments, the implant is configured to be delivered to a joint through a cannula having a distal end inner diameter of at most 9 millimeters. In some embodiments, the implant is configured to be delivered to a joint through a cannula having a distal end inner diameter of at most 5 millimeters.
  • the implant is configured to fold in order to fit within a cannula having a distal end inner diameter of at most 10 millimeters. In some embodiments, the implant is configured to fold in order to fit within a cannula having a distal end inner diameter of at most 9 millimeters. In some embodiments, the implant is configured to deliver by dissolution of the implant material. In some embodiments, the implant is configured to deliver by release through pores of the implant. In some embodiments, the implant is configured to deliver by release through spaces of the implant. In some embodiments, the implant is configured to deliver by release through nanovesicles of the implant. In some embodiments, the implant is configured to deliver by fracture of a vacuole by a catalyst such asultrasound or pressure or other fracturing catalyst. In some embodiments the release of contents may be over time as a function of normal cumulative limb use forces.
  • the implant is configured to at least one of: pad cartilage, cushion the joint, deliver a pharmacologic substance, remove noxious enzymes, debride upon implantation, debride the joint following implantation, deliver a therapeutic substance, deliver a biologic substance, and deliver living stem cells.
  • the implant is configured to deliver a cell or tissue to a bone or surrounding tissue.
  • the cell is at least one of: stem cell, differentiated cell, pluripotent cell, and post-mitotic cell.
  • the implant is configured to deliver a chemotherapeutic agent to a bone or other surrounding tissues.
  • the implant is configured to deliver an anti-infectious medication to a bone or other surrounding tissues.
  • the implant is configured to deliver at least one of an antibiotic, antifungals, and analgesics agent. In some embodiments, the implant is configured to deliver an antibody. In some embodiments the implant is configured as a targeting structure for treatment of proximate pathophysiology. In some embodiments, the implant comprises a transmitter or a sensor that can emit or receive actionable instruction. In some embodiments, the implant comprises a sensor, for non-limiting example: a gauge, camera, fiberoptic, or other meter, to provide information of clinical relevance as it relates to proximate tissue. In some embodiments, the information received from the implant is transferred to the patient to enhance wound healing or other desired effects.
  • a method comprising: implanting a knee implant as described herein into a subject, wherein the implant reverses arthritis in the subject.
  • a method comprising: implanting a knee implant as described herein into a knee joint of a subject and treating a component of the knee joint of the subject with at least one of an allograph tissue, an autograph tissue, and an xenograph tissue.
  • the implanting step is at least one of: prior to the treating step, simultaneous with the treating step, and following the treating step.
  • a method comprising: implanting a knee implant as described herein into a subject, wherein the implant at least one of: restores joint function and controls arthopathies.
  • the implanting spares existing anatomy.
  • a method comprising: debriding a femur condyle of a knee joint of a subject, and implanting a knee implant as described herein into the knee joint of the subject, whereby the implant is configured to anneal to the cartilage of the subject.
  • the debriding is achieved by steam application.
  • a method comprising implanting a knee implant as described herein into a joint previously treated with a joint replacement.
  • the method comprises removing the joint replacement prior to implanting the knee implant.
  • the method comprises clearing infectious matter from the joint and/or surrounding tissues.
  • the method comprises implanting a second implant of any implant described herein following removing the implant previously implanted in the joint.
  • the method comprises replacing the joint of the subject following removing the implant previously implanted in the joint.
  • the method comprises debriding the bone of the joint, and implanting an implant of any implant described herein.
  • the method comprises repeating the debriding and implanting steps.
  • the implant is delivered non-arthroscopically through an incision that is at least 1 centimeter long. In some embodiments, the implant is delivered through an incision that is over about 10 centimeters long. In some embodiments, the implant is delivered through an incision that is at up to about 40 centimeters long.
  • the implant replaces periosteum.
  • the polymer forming the side wall may be semi-compliant or elastic.
  • the polymer forming the side wall may be non-compliant (non-elastic).
  • the first and second walls of the implant need not have the same properties as the side wall.
  • parts of the implant such as the side wall portion may be compliant and the first and second wall portions in contact with the bone or other joint structure may be non-compliant.
  • the various walls or portions thereof may also be reinforced with non-compliant or semi-compliant polymer strands, beads or gel coating such as biologic or polymer latticework.
  • the thicknesses of the first, second and side walls may be varied to accommodate for the needs of the joint structure from the standpoint of strength, elasticity and wear resistance.
  • the walls of the implant may be provided with joint tissue regeneration agents that rebuild the joint structure in which the implant is deployed.
  • the regeneration agent may be incorporated into the wall of the implant prior to delivery or placed between the surface of the implant and the joint structure which it contacts after delivery.
  • All or part of the walls of the implant may also be made of a biodegradable polymer, by minimally manipulated autograph, allograph or xenograph tissues, or a combination thereof.
  • the method of surgery may incorporate a progressive application of the implant embodiments depending upon clinical needs.
  • the walls of the implant may serve one or more functions, including but not limited to filling space, attachment, strengthening, and any physiological function.
  • the implant is preferably formed of suitable biocompatible polymeric materials, such as Chronoflex (e.g., ChronoFlexAR®, ChronoFlex AL®, ChronoFlec C®), which is a family of thermoplastic polyurethanes based on a polycarbonate structure (Al, the aliphatic version, Ar, the aromatic version and C, the casting version) available from AdvanSource Biomaterials, Corp.
  • Chronoflex e.g., ChronoFlexAR®, ChronoFlex AL®, ChronoFlec C®
  • Other polymers include BIONATE 80, 80A, 90A, 75D, 65D, 55D, 55 or 56, BIONATE I, or BIONATE II, which are also thermoplastic polyurethane polycarbonate copolymers, available from PTG Medical LLC., an affiliate of the Polymer Technology Group located in Berkeley, CA.
  • PurSil® e.g., PurSil® 10, 20, 35, 40 80A, AL-10 75A
  • CarboSil® e.g., CarboSil® 10 90A, 20 55D, 20 80A, 20 90A, 40 90A, 5) which is a thermoplastic silicone polycarbonate urethane
  • ElasthaneTM e.g., ElasthaneTM 55D, 75D, 80A
  • Biospan which is a segmented polyurethane.
  • the implant may be formed by casting, or by joining sheets of polymeric material by adhesives, laser welding and the like. Other methods of forming the implant may also be suitable. Example methods include melting beads and compression molding.
  • the walls may also be provided with reinforcing strands which are located on the surface of the walls or incorporated within the walls.
  • the implant material should be biocompatible, non-toxic, and non-carcinogenic and should be resistant to particulation.
  • the present invention provides an improved joint implant which is designed to endure variable joint forces and cyclic loads enabling reduced pain and improved function.
  • there may be linear or curvilinear motion between the first and second walls, rotational motion between the first and second walls or both linear and curvilinear motion and rotation motion between the first and second walls.
  • a space is maintained between the inner surfaces of the first and second walls to avoid erosion and wear there between.
  • the walls may be opposite sides of the same solid.
  • the resilient arthroplasty implant embodying features of the invention is preferably deployed as a minimally invasive procedure to deliver the implant into a prepared space in a preselected joint structure, where upon it is inflated to create a cushion, to cover damaged or arthritic cartilage and to be employed to deliver stem cells or living chondrocytes or other tissue regeneration agents.
  • the goal of such deployment is to reduce pain and improve function, to reverse arthritis, to fill in osteochondral defects succinctly, thereby avoiding living with both dysfunctional and ablative metal/plastic prostheses or the pathophysiologic state necessitating the procedure.
  • the operative plan is simple, systematic, and productive of new joint space with regrowth potential involving joint debridement by routine arthroscopic coblation, electronic chondroplasty methods or steam application, followed by implantation of the implant.
  • the implant provides three things, namely a covering or patch for the damaged or worn joint surface or compliant polymer as in normal walking in the lower extremity, and delivery of regenerative cells on the cartilage remnant surface.
  • the stem cells may be injected as the implant is being expanded and/or directed into the adjacent hyaline cartilage via an implant coating or perfused cell template.
  • Viscolubricants such as Synvisc or Hyalgan, analgesics such as Lidoderm, anti-inflammatory and/or antibiotic coatings as well as those stimulating cell growth may accompany the composite external implant.
  • the implant is left in place as long as feasible, at least until regenerative cells can attach to the adjacent natural joint surface (usually in about 24 hours), or until wound healing (which may take up to 28 days or more depending on the joint structure).
  • the implant is designed stay within the joint structure for years, providing inert padding, cushioning and a new cell source.
  • the implant may be used in weight bearing and non-weight bearing interfaces. Animal, such as in horses and dogs, can benefit from usage of the implant following hip and knee injuries.
  • the implant is intended primarily for mammalian use. In humans, the implant may be used in any upper or lower extremity joint and temperomandibular joint.
  • the present invention is directed to arthroplasty implants and procedures for a wide variety of joints such as, for example, hips, knees, shoulders, ankles, elbows, wrists, fingers, toes, temporomandibular joints and the like, but for clarity, as well as brevity, the discussion herein will focus on an implant for a knee joint or hip joint and an implant for replacing the talus bone of a patient's ankle.
  • Knee interpositional arthroplasty can replace existing total joint metal/plastic technology. It intends to fill the gap (literally in some embodiments of the implant) in cases where arthroscopic debridement fails to provide cure, since we can only 'polish arthritis' and 'clean up the joints' to date.
  • the polymer medically inflatable implants may physiologically restore joint function. Padding is provided where cartilage is damaged, cushioning to both the femoral tibial and patella femoral joints when narrowed or pathologic.
  • the implant in some embodiments is adapted to deliver cells, autologous (from the patient), allograph (from another member of the same species) or xenograph (from another species,) that restore articular surfaces. Since cartilage is an immunologically privileged tissue, the antigens are buried in the cartilage matrix and antibodies do not reject the refurbished surface coating.
  • the gap (or gaps) filled by the balloon or balloons of the implant may provide compliance between opposing joint surfaces (the femoral condyle or condyles and tibial plateau).
  • the femur may have some portion (of not all) of the retropatellar rounded facet "V" shape of hyaline, normally about 5 mm thick, or it may not have such hyaline when the implant is inserted.
  • the tibial plateau may have some portion of meniscal fibrocartilages, including all of said fibrocartilages, none of said fibrocartilages, or some portion thereof.
  • the implant buffers the femoro-tibial joint.
  • the implant balloon apposition is more between the trochlear groove portion of the anterior distal femur (groove between the condyles on the 'front of the knee') and the patella.
  • the knee anatomy is unique to other joint anatomies and thus has a unique set of challenges that are addressed by the implant embodiments described herein.
  • the knee is not a ball and socket joint like a hip; it is a combination of two joints-- the femoral-tibial joint and the patellar-femoral joint.
  • the bones of the knee have facets and irregularities that must be accommodated by a conformable implant directed to the particular shapes of the bones without impeding the joints' functions and movements, and/or which minimizes impedance to such function and movement.
  • the joints of the knee work together to allow extension and flexion of the knee, but the joints of the knee are also designed to allow rotational movement in a screw-like manner.
  • the joints are uniquely designed to allow this twist, but to limit the twist as well.
  • the knee joints are able to withstand forces that vary depending on the particular movement of the individual, not only in force strength, but in direction as well.
  • the implants as described herein are uniquely designed to account for these factors and result in a knee having preserved natural tissues as well as preserved function and movement as compared to typical arthroplasty procedures (such as partial or full knee replacements).
  • an implant conform to the patient's own joint features not only in that it can be pre-molded and/or adapted to couple to the contours of the patient's bone (condyle, etc), but in that it has a balloon having an inflation medium that is conformable to the joint anatomy and allow freedom of joint movement much like natural joint while preserving the joint and bone natural tissues as much as possible.
  • the implant can additionally have leveling capabilities and alignment capabilities.
  • Knees may be swollen, malaligned or show crepitus (palpable crunching on movement.)
  • Indications for use of implants provided herein may be those patients recognizing greater than or equal to 2 Sq cm of 3-4+/4 traumatic arthritis (ala Carticel).
  • the cartilage defect is often precisely locally symptomatic, with point tenderness, clicking if a loose cartilage flap exists, and may be visible on MRI and/or arthroscopic inspection and/or through palpation.
  • the implants used herein may additionally and/or alternatively be appropriate when existing techniques such as 'picking', K wire drills, and/or allograph implants fail.
  • Pathognomonic symptoms for meniscal tearing include locking, clicking, giving way from wear or twisting the knee.
  • Aching diffusely may arise from arthritis or synovitis; anterior knee pain is generally patella-femoral, increased with stair use due to magnified body weight forces.
  • Diagnosis should be accurate as distinguished from pain through the knee actually arising in the back caused by L4 nerve root irritation.
  • Physical Exam findings of pathologic knees include observed swelling, redness, or deformity. Palpation often aids focus on which compartments are involved.
  • the patella inhibition test position connotes retropatellar pathology, and often tracking problems that warrant soft tissue or boney correct.
  • Improved limb alignment may increase benefits, and can in part accrue from selective inflation of embodiments of the implants provided herein.
  • X-rays of the knee are best evaluated in weight bearing views, and should be coupled with other data including MRI or CT. Relative compartment narrowing suggests cartilage degradation.
  • the appearance of a knee with such implant should resemble a normal joint X-ray. Knee distension is from saline and/or air insufflation. Knee implant patients will benefit from tailored rehab programs, cautious weight bearing, early motion, and potential the use of constant passive motion machine regimens.
  • a resilient implant for implantation into human or animal joints to act as a cushion allowing for renewed joint motion.
  • the implant may endure variable joint forces and cyclic loads while reducing pain and improving function after injury or disease to repair, reconstruct, and regenerate joint integrity.
  • the implant may be deployed in a prepared debrided joint space, secured to at least one of the joint bones and expanded in the space, molding to surrounding structures with sufficient stability to avoid extrusion or dislocation.
  • the implant may pad the damaged joint surfaces, restores cushioning immediately and may be employed to restore cartilage to normal by delivering regenerative cells.
  • the implant according to the invention has no inflation chamber (inner space).
  • the implant may have varying thicknesses at different locations.
  • the implant may have different features at different locations. Inflation may involve singular balloons for cushioning or realignment, multiple separate or connected vesicles, or small vacuoles that contain gas, fluid, gel, fluid that becomes solid, or combinations thereof. Inflation may be invoked on either both surfaces of the implant or any surface of the implant inside or between variable walls (which can be considered layers in certain embodiments). Cushioning while intending to address deficiencies in cartilage may accrue from inflation or the use of compliant materials without inflation (and without a balloon per se for that matter) or both.
  • a resilient interpositional arthroplasty implant for application into knee joints to pad cartilage defects, cushion joints, and replace or restore the articular surface, preserving joint integrity, reducing pain and improving function.
  • the implant may endure variable knee joint compressive and shear forces, and millions of cyclic loads, after injury or disease requires intervention.
  • the implant may repair, reconstruct, and regenerate knee joint anatomy in a minimally morbid fashion, with physiologic solutions that improve upon the rigid existing joint replacement alternatives of plastic and metal.
  • the polymer walls of some embodiments of the implant can capture, distribute and hold living cells until aggregation and hyaline cartilage regrowth occurs.
  • the implant may be deployed into a prepared debrided knee joint space, molding and conforming to surrounding structures with sufficient stability to avoid extrusion or dislocation. Appendages (or tabs) of the implant may serve to repair or reconstruct tendons or ligaments. There may be no defined inner chamber, however at a particular location in the device the implant may have different features to aid in cushion, therapeutic effect, wear resistance, defect correction, or the like.
  • a resilient orthopedic implant configured for deployment between a first bone and at least one second bone of a joint.
  • the first bone may be a femur, a tibia, or a patella.
  • the second bone may be a tibia, a patella or a femur.
  • first portion comprises a first wall
  • second portion comprises a second wall
  • side portion comprises a side wall.
  • first portion comprises a first wall
  • second portion comprises a second wall
  • side portion comprises a side wall.
  • each of the terms the "first portion”, the "second portion”, and the "side portion” is used to describe a part of the implant and may not be separate parts in some embodiments.
  • each portion or wall is named in order to indicate the general geometry and location of each portion relative to the other of the portions and/or relative to bones and/or ligaments and/or tendons of the joint.
  • each of the terms the "first wall”, the “second wall”, and the “side wall” is used to describe a part of the balloon or cushioning implant, and may not be separate parts of the balloon in some embodiments. Rather, in some embodiments, each of the walls is named in order to indicate the general geometry and location of each portion relative to the other of the portions and/or relative to bones and/or ligaments and/or tendons of the joint. In some embodiments, one wall may become the second wall with body movement changing the anatomy of the implant as it related to joint motion.
  • the first portion is a term used interchangeably with the first wall.
  • the second portion is a term used interchangeably with the second wall.
  • the side portion is a term used interchangeably with the side wall.
  • a wall (whether a first wall, a second wall, and/or a side wall) of the implant may comprise a plurality of layers.
  • the wall may comprise multiple materials to impart physical and/or therapeutic characteristics to the wall.
  • a side wall may become a first or second wall as the implant changes shape through the application of joint forces.
  • first wall and the second wall may merely be noted to show relative location, and may be a contiguous wall that has a first side (wall) and a second side (wall) where the first side is adapted to contact the first bone, and the second side is adapted to contact the second bone.
  • Walls may be touching or be made of the same materials, or they may be made of different materials, or they may have additional materials therebetween, such as microstructures, vacuoles, therapeutic agents, padding materials, gels, liquids, solid materials, rigid or semi-rigid materials, meshes, foams, honeycombed materials, capsules, urethanes, human tissues or media, soft tissues, or the like, as described herein.
  • Either of the walls themselves may be made of any of these materials and/or have any of these features.
  • a single sheet of BIONATE e.g., BIONATE I, BIONATE II, BIONATE 55D, BIONATE 65D, BIONATE 75D, BIONATE 80, BIONATE 80A, BIONATE 90A
  • BIONATE e.g., BIONATE I, BIONATE II, BIONATE 55D, BIONATE 65D, BIONATE 75D, BIONATE 80, BIONATE 80A, BIONATE 90A
  • a single sheet of Chronoflex e.g., ChronoFlexAR®, ChronoFlex AL®, ChronoFlec C®
  • Chronoflex e.g., ChronoFlexAR®, ChronoFlex AL®, ChronoFlec C®
  • the single sheet may be contiguous, having no particular separation between the walls that may be deemed a chamber or balloon.
  • each of the first wall and the second wall may be, in certain embodiments, so designated only to depict relative location-i.e. in relation to the bone each wall is adapted to contact.
  • the first wall may be so designated in order to indicate an intent that the first wall is in a position to contact the first bone
  • the second wall may be so designated in order to indicate an intent that the second wall is in a position to contact the second bone, but the first wall and the second wall are part of a contiguous implant, without any chamber or balloon therebetween.
  • the implant walls may comprise a compliant material, and there is no separation between any of the walls of the implant which could be deemed a chamber.
  • the material of the wall itself may be compliant such that the material itself accommodates cartilage irregularity and improved alignment of the joint bodies (ligaments, bones, tissue, etc.).
  • the implant comprises a sheet.
  • the sheet may be solid (e.g. comprising polyurethane or another biocompatible material), complex (e.g. comprising Dyneema mesh) or with at least one chamber of any size from a micrometer, to larger chambers as depicted and described elsewhere herein.
  • the implant may comprise Dyneema mesh.
  • the implant may comprise Dyneema fiber.
  • the implant comprises Dyneema Purity®.
  • the implant may comprise a fiber.
  • the implant may comprise a polyethylene fiber.
  • the implant may comprise a mesh.
  • the mesh may be a random structure or a repeating structure (such as a honeycomb).
  • the mesh may comprise a polymer structure of interwoven or randomly interlinked fibers or a combination thereof.
  • the mesh may comprise a metal structure of interwoven or randomly interlinked metal fibers or a combination thereof.
  • the mesh may comprise a memory metal (e.g. Nitinol or another memory metal).
  • the mesh may comprise a memory polymer.
  • the mesh may aid in fixing the implant in place.
  • the mesh may be adapted to add cushion to the bones of joint.
  • the mesh may be adapted to add durability to implant upon cyclic loading.
  • the mesh may be adapted to add padding to the bones of joint.
  • the mesh may be filled in its interstices with a softer (in durometer) polymer or other material (softer than the material of the mesh itself).
  • the mesh may be filled in its interstices with a softer (in durometer) polymer or other material (softer than the material of the mesh itself).
  • the interstices of the mesh may comprise a pharmacologic or therapeutic agent (or both) as noted herein.
  • the mesh may be filled with a harder material, or a material that becomes harder, such as methyl methacrylate.
  • the mesh may comprise a biodegradable material. In some instances, the mesh does not comprise a biodegradable material.
  • the mesh may comprise a steel wool.
  • the mesh comprises DNA strands. In some embodiments, the mesh comprises intertwined DNA strands. In some embodiments, the mesh is configured to wrap a joint end.
  • the implant may have a single composition throughout the implant, and shaped as noted herein with attachment features as noted herein.
  • distinction between the first wall and the second wall may be noted to indicate relative location, and may be a contiguous wall that has a first side (wall) and a second side (wall) where the first side is adapted to contact the first bone, and the second side is adapted to contact the second bone.
  • the implant comprises no chamber, however it comprises various regions which have different features than other regions-such as comprising a mesh between the first wall and the second wall (as noted above), a cushion between the first wall and the second wall, and/or comprising any aspects of the fill materials noted in the inflation mediums noted elsewhere herein, but not necessarily provided in a chamber which is filled following implantation or at the time of implantation. Rather, these aspects may be built into the implant during implant manufacture, by layering or other manufacturing processes, and not necessarily by filling a chamber. In some embodiments, there are multiple regions having different characteristics-cushioning, some therapeutic agent delivery, defect correction, padding, for non-limiting example, or some combination thereof.
  • the implant achieves these aspects by varying thickness of one of the walls at a particular region of the implant, for non-limiting example, at load-bearing locations.
  • Implant spacing or vacuous interspace can vary at a molecular level as allowing for macromolecular sizes or macrodendritic molecules.
  • the molecules covering the exposed or integral implant makeup may be constructed with coatings or without, that may be suspended in gas, liquid, gel, or solids with vacuoles, bubbles, balloons or bladders of a size producing a foam or trabecular framework or honeycomb that has 'inflation' not visually obvious.
  • the implant may comprise a foam between the first wall and the second wall.
  • the implant may comprise a microvoid (i.e. a void in the implant material that is in the 1 micrometer to 1 mm size range).
  • the implant comprises materials without obvious or definable inflation of any sort, producing a cushioning effect usually over one primary joint surface but potentially over multiple, providing a useful cushioning via polymers of variable albeit solid material nature and reasoned compliance.
  • the implant material per se immediately or gradually comes to conform to, accommodate, adjust and fill the indentations or defects on the side of implant in apposition to the defect.
  • a semi-fluid tendency of certain embodiments permits both immediate post insertional and delayed joint surface alignment adjustments that may be increased by injection or cannular infusion, or deceased by aspiration or valvular evacuation.
  • the first wall is secured to the end of the first bone by a skirt that extends from the first wall and the second wall engages the end surface of the second bone and may also be secured thereto.
  • the skirt 18 is called an appendage.
  • the inner surfaces of wall and skirt preferably conform to the particular surface of the head of the patient's first bone. In some embodiments, the inner surfaces of wall and skirt preferably conform to the particular surface of the patient's first bone.
  • the outer surface of the second wall is preferably configured to conform to the end surface of the second bone. In some embodiments, the outer surface of the second wall is preferably configured to conform to a surface of the second bone.
  • the edge of the implant may have a depending skirt to secure or anchor the implant to the end of bone, but may have one or more depending tabs (or appendages) that may be employed for similar functions as will be discussed in other embodiments.
  • the skirt (and/or tabs, and/or appendages) may tightly fit about the end of the first bone as shown, or the skirt can be secured by adhesive (e.g. methyl methacrylate, bone in-growth) to the supporting bone structure or be mechanically connected by staples, screws and the like.
  • the lower portion of the skirt may be secured by a purse string suture or a suitable strand (elastic or tied) that is tightly bound about the outside of the skirt.
  • the implant comprises an in-growth patch on at least one of the first portion configured to engage the first bone, the second portion configured to engage the second bone, the side portion, and the appendage.
  • the in-growth patch may be configured to encourage and/or promote tissue in-growth, such as bone in-growth, for non-limiting example.
  • the patch may be as large as the portion itself (whether the first portion the second portion, the side portion, or the appendage) or may be smaller than the portion (such as in the shape of a strip or other shaped patch).
  • the in-growth patch may comprise a surface irregularity or roughness.
  • the in-growth patch may be Velcro-like.
  • the implant comprises an in-growth patch on the first portion and/or the second portion, from (and in some embodiments including) a first appendage to a second appendage.
  • the in-growth patch aids in securing the implant to the bone.
  • the in-growth patch comprises beads and/or bead-like elements attached to the implant. Such an in-growth patch may be configured to simulate trabecular bone space of a normally cancellous latticework.
  • the beads are sintered beads of various sizes. In some embodiments, the beads are sintered beads about 400 microns in size.
  • the term "about” can mean ranges of 1%, 5%, 10%, 25%, or 50%.
  • the first bone and/or the second bone is roughened to acquire a bleeding bone to facilitate in-growth.
  • about 0.5 mm of cortical tissue is removed to facilitate in-growth.
  • the appendage of the implant comprises a hook.
  • the hook is angled.
  • the hook may comprise a piece of metal sandwiched between two polymer pieces.
  • the hook may comprise a piece of metal encased in polymer.
  • the hook may comprise a piece of metal and a portion of the metal piece may be encased in polymer.
  • the hook may comprise a piece of metal and a portion of the metal piece may be sandwiched between two polymer pieces.
  • the metal of the hook may reinforce the appendage tabs for securing the implant to the bone of the joint.
  • the metal of the hook is formed of a 1 centimeter by 1 centimeter metal piece.
  • the metal of the hook may protrude from the appendage.
  • the metal may be bent toward the bone to which it is configured to attach.
  • the metal may be bent at about a 270 degree angle (as compared to the non-bent portion of the metal, or as compared to the rest of the appendage, for non-limiting example).
  • the term about when referring to angle of bend of the metal of the hook can mean variations of 1%, 5%, 10%, 20%, and/or 25%, or variations of 1 degree, 5 degrees, 10 degrees, 15 degrees, 20 degrees, 25 degrees, 30 degrees, 40 degrees, 45 degrees, and/or up to 90 degrees.
  • the bone may be prepared to receive the hook, such as by a hole or slot into which the hook (or a portion thereof) is placed. In some embodiments, the bone is not prepared in advance to receive the hook, and the hook may self-seat into the bone by pressure applied to the hook into the bone.
  • the implant may comprise multiple appendages, and a plurality of the appendages has hooks. In some embodiment the implant may be screwed on or snapped on or secured with a combination of elements, such as stabilizers and sutures.
  • the implant comprises a second appendage coupling the implant to the first bone of the joint. In some embodiments, the implant comprises a second appendage coupling the implant to at least one second bone of the joint. In some embodiments, the implant comprises a second appendage configured to couple at least one of the first portion, the second portion, and the side portion to at least one of the first bone and at least one second bone of the joint. In some embodiments, the first appendage and the second appendage are configured to provide ligamentary-like support to the first bone and the at least one second bone of the joint. In some embodiments, the first appendage and the second appendage are configured to provide ligamentary-like support to the joint.
  • first appendage and the second appendage are configured to provide tendon-like support to the first bone and the at least one second bone of the joint. In some embodiments, the first appendage and the second appendage are configured to provide tendon-like support to the joint.
  • the implant may comprise vacuoles of pharmacologic substances.
  • the vacuoles may be on a bone-engaging portion of the implant.
  • the implant comprises bubbles comprising an active substance such as a pharmacologic substance or other active substance.
  • the implant may deliver by dissolution of the implant material (i.e. a biodegradable polymer which releases the active substance), and/or by release through pores of the implant (wherein the polymer is permeable to the active substance), and/or by fracture of the vacuole (or bubble, or space) by a catalyst such as ultrasound or pressure or other fracturing catalyst.
  • the implant may deliver the active substance at a time after the actual implanting of the implant into the joint, for example an hour later, less than a day later, a day later, less than a week later, a week later, less than a month later, and/or a month later.
  • stem cells that are percolating in the bubble (or vacuole, or space) may be delivered to the joint space (or a constituent of the joint) after the implant is inserted into the joint.
  • Active agents may, for non-limiting example, include cells (e.g., stem cells, differentiated cells, pluripotent cells, post-mitotic cells), growth factors, antibodies, biomolecules, biologics, chemical compounds, antibiotics, and/or viscolubricants.
  • the implant may comprise enzyme absorptive 'microscopic sponges' that could be sucked out or evacuated at or around the time of implant delivery to the joint.
  • the implant is a weight bearing spacer that allows joint motions to approach normal, whether filling the space left by an entirely collapsed joint bone or the space of ablated cartilage proximate surfaces diffusely as in osteoarthritis or succinctly as in osteonecrotic defects or localized trauma.
  • the walls of the implant may be used as a membrane for holding living cells in proximity of the osteochondral defect long enough for the cells to attach (e.g. 24 hours) or to deeply adhere (up to 28 days) or return to normal (up to one year). Weight bearing may be expected to increase as distal lower extremity joints are treated.
  • Movement (whether linear or curvilinear) between the first and second walls of the implant as a result of movement of the femur and the tibia is illustrated in the comparison between Figures 9B and 10A , or in the comparison between Figures 9C and 10B .
  • a portion of the implant whether an appendage, a wall, or some other portion of the implant
  • a joint component whether a bone, ligament, tendon or other tissue. This slippage may be in addition to wall movements within the implant per se to provide desired joint movements.
  • the second bone for example, the tibia
  • the second wall in addition to wall movements within the implant per se to provide desired joint movements.
  • the appendage (or appendages) is (are) designed to secure the implant to the joint structure so as to avoid dislocation of the implant. Movement of the joint with the implant in place may be a shared function of both the moving opposing walls of the implant but also a function of the movement of the wall which may be less attached to the joint members. There may be slight movement between the appendage, first wall and the first bone. Material choices, material dimensions, and implant dimensions, placement and/or coupling may be chosen to allow for the desired amount of compression, stretching relative movement of various joint and/or implant components. For non-limiting example, the walls of the implant may be thicker is some areas to accommodate particular loads and the side wall may be thinner and more elastic to accommodate rolling and stretching thereof.
  • the implant may be provided with a slot extending from the periphery of the implant toward the balloon of the implant to accommodate at least one ligament of the joint.
  • Knee implants may have two slots leading to separate passages for receiving the anterior and posterior cruciate ligaments.
  • Implant walls should have sufficient inherent flexibility to mold to the existing deformities imposed by either natural ligament, bone, tendon or remaining cartilage deformities of the internal joint space, and thus filled as a cushion.
  • the wall exteriors may be flat or formed with random or specific patterns for purposes of glide or trends for traction against adjacent surfaces, or as sulci or venues for cell delivery materials.
  • the exterior of the implant may have a mesh material with a plurality of chords (or appendages) for securing the implant to adjacent bones or to remnant ligaments which are attached to adjacent bones.
  • the exterior of the implant may comprise Dyneema mesh.
  • the exterior of the implant may comprise Dyneema fiber.
  • the exterior of the implant comprises Dyneema Purity®.
  • the exterior of the implant may comprise a fiber.
  • the exterior of the implant may comprise a polyethylene fiber.
  • the dimensions of the various implant walls may vary depending upon the material properties thereof as well as the needs for a particular joint. Additionally, the first and second walls may require a thickness different from the side wall. Generally, the implant may have a wall thicknesses of about 0.125 mm to about 3 mm, preferably about 0.5 mm to about 1.5 mm. The spacing between the first and second wall within the interior can vary from about 0.5 mm to about 5 mm. Thicknesses of the fixation tabs may be at least one of: about 1mm, about 2mm, about 3mm, about 4mm, about 5mm, about 6mm, about 7mm, about 1 mm to about 6mm, about 2mm to about 4mm, 1 mm to 6mm, and 2mm to 4mm, for non-limiting example.
  • the implant may comprise a reinforcing rim or a reinforced tab, which includes a change in tab material to make it stronger, or include a metal rim to reinforce the attachment location.
  • the reinforcement element may be embedded in the tab or in a wall at the periphery of the implant (for example in instances where the coupler is not located at a tab per se).
  • the inner surfaces of wall and appendage may conform to the particular surface femur, for example by being wider in particular locations and/or longer in particular areas.
  • a dual compartment implant (described herein) may have a wider section to cover the medial condyle than the lateral condyle (as shown in Figures 1, 2 , 3 , 6A , 6B , and 7 ).
  • the length of the implant the along the external edge may be longer than the length of the implant along the trochlear groove edge (as shown in Figures 11A, 11B and 11C ).
  • the width may vary along a single condyle, such as is shown in Figures 12A-12C , wherein the wider edge of the implant is adapted to fit over at least a portion of the anterior condyle, and the narrower portion is adapted to fit over at least a portion of the posterior condyle.
  • the inner surfaces of the first wall and appendages preferably conform to the particular surface of the patient's femur, and do so by not only dimensions of the implant (lengths, widths, location and shape), but also and/or alternatively due to appendage and/or tab and/or hole and/or coupler location and/or surface contours of the first wall.
  • the outer surface of the second wall may be configured to conform to the end surface of the second bone (which may be a tibia or a patella, for example). In some embodiments, the outer surface of the second wall is configured to conform to a surface of the second bone (which may be a tibia or a patella, for example).
  • the implant is configured to resemble the shape of the natural hyaline of a normal knee.
  • the normal hyaline is typically "H” shaped, thus certain embodiments of the implant are generally “H” shaped.
  • the H may be an exaggerated H form, and the notches of the H may be extended on one side, while nearly nonexistent on the other side, such as is shown in certain figures, such the "H” may look more like a "U” or "V” or contain a tab in the notch.
  • the cartilage surface shapes, implant design, and method of surgery can vary by adapting to normal anatomy in a particular patient, to expected weight bearing, and use intent.
  • the implant comprises polymer.
  • Polymers may comprise at least one of: a polyurethane (such as, for example, ChronoFlex AR, ChronoFlex AL®, ChronoFlec C®), a polycarbonate urethane, a thermoplastic polycarbonate urethane (such as BIONATE, e.g., BIONATE I, BIONATE II, BIONATE 55D, BIONATE 65D, BIONATE 75D, BIONATE 80A, BIONATE 90A, BIONATE 55 or BIONATE 80), ethylene-vinyl acetate copolymer, multiblock copolymers of poly(ethylene oxide) (PEO) and poly(butylene terephthalate) (PBT), PEG, PEO, and a polyetheylene.
  • a polyurethane such as, for example, ChronoFlex AR, ChronoFlex AL®, ChronoFlec C®
  • a polycarbonate urethane such as BION
  • the implant comprises a 125 micron thickness thermoplastic polycarbonate urethane.
  • the thermoplastic polycarbonate urethane has a low coefficient of friction.
  • the thickness of walls intends to mimic natural hyaline cartilage a the involved body location and may be one of: about 0.5mm, about 1mm, about 2mm, about 2.5mm, about 3mm, about 3.5mm, about 4mm, 0.5mm, 1mm, 2mm, 2.5mm, 3mm, 3.5mm, 4mm, 1mm-6mm, 1mm-4mm, and 1mm-3mm.
  • the implant may comprise to a plurality of layers of polymer (such as ChronoFlex AR, ChronoFlexAR®, ChronoFlex AL®, ChronoFlec C®) in a solvent and evaporating the solvent after applying each layer.
  • the implant comprises a polyurethane that is sprayed and dried (wherein the spraying and drying is repeated at least once) to a desired thickness.
  • the implant is created by dip molding a mandrel having a shape of a bone of the knee joint (the medial condyle, the lateral condyle, the tibia, for non-limiting example) into a polymer solution (for non-limiting example, a urethane polymer such as Chronoflex (e.g., ChronoFlexAR®, ChronoFlex AL®, ChronoFlec C®)).
  • a polymer solution for non-limiting example, a urethane polymer such as Chronoflex (e.g., ChronoFlexAR®, ChronoFlex AL®, ChronoFlec C®)).
  • the implant is dried for a specified time, which may be, for example, about 3 seconds, about 4 seconds, about 5 seconds, about 6 seconds, about 7 seconds, about 8 seconds, about 9 seconds, about 10 seconds, about 15 seconds, about 20 seconds, about 25 seconds, about 30 seconds, about 45 seconds, about 1 minute, about 2 minutes, about 5 minutes, about 10 minutes, about 15 minutes, and over about 15 minutes.
  • the term "about” used herein in reference to drying time of the implant can mean variations of at least one of 5%, 10%, 25%, and 50%, In some embodiments, no drying step is used.
  • the dipping may be repeated multiple times. In some embodiments a single dip is sufficient. In some embodiments, the dipping is repeated 2 times. In some embodiments, the dipping is repeated 3 times.
  • the dipping is repeated 4 times. In some embodiments, the dipping is repeated 5 times. In some embodiments, the dipping is repeated 6 times. In some embodiments, the dipping is repeated 7 times. In some embodiments, the dipping is repeated 8 times. In some embodiments, the dipping is repeated 9 times. In some embodiments, the dipping is repeated 10 times. In some embodiments, the dipping is repeated 11 times. In some embodiments, the dipping is repeated 12 times. In some embodiments, the dipping is repeated 13 times. In some embodiments, the dipping is repeated 14 times. In some embodiments, the dipping is repeated 15 times. In some embodiments, the dipping is repeated 16 times. In some embodiments, the dipping is repeated 17 times.
  • the dipping is repeated 18 times. In some embodiments, the dipping is repeated 19 times. In some embodiments, the dipping is repeated 20 times. In some embodiments, the dipping is repeated 21 times. In some embodiments, the dipping is repeated 22 times. In some embodiments, the dipping is repeated 23 times. In some embodiments, the dipping is repeated 24 times. In some embodiments, the dipping is repeated 25 times. In some embodiments, the dipping is repeated over 25 times. In some embodiments, the dipping is repeated a sufficient number of times to create an implant that is a prescribed thickness. The thickness may vary depending on the polymer and depending on the embodiment of the implant.
  • the thickness may be at least one of: about 25 microns thick, about 50 microns thick, about 100 microns thick, about 125 microns thick, about 150 microns thick, about 200 microns thick, about 250 microns thick, about 300 microns thick, about 350 microns thick, about 400 microns thick, about 25-50 microns thick, about 50 - 100microns thick, about 50-200 microns thick, about 100 -150 microns thick, about 150-300 microns thick, about 100-300 microns thick, about 100-500 microns thick, about 200-500 microns thick, and about 200-1000 microns thick.
  • the term "about” used herein in reference to thickness of the implant can mean variations of at least one of 5%, 10%, 25%, and 50%, The thickness may vary at different locations of the implant.
  • the walls of the implant embodying features of the invention may be composite structures.
  • the innermost layer may be impervious to preclude escape of inflation or other filling media
  • a central layer may be porous or otherwise contain treatment or cell regeneration agents
  • the outer layer may be a thin, but strong layer of a thermoplastic, such as a thermoplastic polyurethane for non-limiting example, which has microporosity sufficient to allow passage or egress of treatment or cell regeneration agents from the central layer (or second layer).
  • the degree of microporosity to enable egress of treatment or cell regeneration agents from the central layer is found in polymer layers such as Chronoflex (e.g., ChronoFlexAR®, ChronoFlex AL®, ChronoFlec C®) or BIONATE (e.g., BIONATE I, BIONATE II, BIONATE 55D, BIONATE 65D, BIONATE 75D, BIONATE 80A, BIONATE 90A, BIONATE 55 or BIONATE 80).
  • Chronoflex e.g., ChronoFlexAR®, ChronoFlex AL®, ChronoFlec C®
  • BIONATE e.g., BIONATE I, BIONATE II, BIONATE 55D, BIONATE 65D, BIONATE 75D, BIONATE 80A, BIONATE 90A, BIONATE 55 or BIONATE 80.
  • the external wall (and/or the bone engaging surface) of the implant may be coated and/or impregnated with a latticework of polymer that is surface sprayed or layered on the outside (or bone engaging surface) of the implant to promote cartilage tissue regeneration.
  • This most external surface coating may contain living chondrocytes (for example, as is provided in the Carticel procedure by the Genzyme company), and/or may contain stem cells with directed gene mutations to enhance adherence of the coating to the implant. Chondrocytes from companies such as Tygenix or Histogenics may be used for greater aggregation potential.
  • the bone engaging surface may comprise peaks and troughs.
  • the living cells may be imposed in between (and/or provided in the) troughs of the implant surface while the surface areas of prominence (the peaks of the surface) may be used for at least one of: space validation, traction, and cell protection.
  • the implant may be formed of suitable bioabsorbable materials so that the implant may be absorbed within a particular predetermined time frame.
  • suitable bioabsorbable materials include polylactic acid, polyglycolic acid, polycaprolactone, copolymers, blends and variants thereof.
  • Suitable bioabsorbable materials may also/alternatively include poly(hydroxyalkanoate)s of the PHB-PHV class, additional poly(ester)s, and natural polymers, particularly, modified poly(saccharide)s, e.g., starch, cellulose, and chitosan.
  • the walls of the implant may be (in whole and/or in part) bioabsorbable.
  • the balloon may be (in whole and/or in part) bioabsorbable.
  • bioabsorbable As used herein the terms bioabsorbable, bioerodable, and/or bioabsorbable may be used interchangeably.
  • the walls of the implant may release a pharmaceutical agent or an biological agent (such as stem cells, differentiated cells, pluripotent cells, post-mitotic cells, living chondrocytes, gene therapies, and the like).
  • a pharmaceutical agent or an biological agent such as stem cells, differentiated cells, pluripotent cells, post-mitotic cells, living chondrocytes, gene therapies, and the like.
  • the release of such agents may occur over time, as the wall of the implant (or as the balloon) bioabsorbs in some embodiments, or as the joint is used (i.e. through pressure, for non-limiting example).
  • the contents may contain targeting drugs such as gleevac that turn off tumor molecules as those in GIST.
  • Cell-specific drugs targeting tumors by design may require nano-sized micelles with hydrophilic shells to protect core agents.
  • hydrogels are used and tailored to swell thus releasing trapped molecules or cells through web like surfaces, controlled by internal or external triggers such as ph, magnetic fields, or temperature.
  • Dendritic macromolecules may be used in implants to deliver agents en masse deploying a controllable size and structure.
  • individual agent molecules or hubs may be incorporated via covalent bonds.
  • the implant comprises amniotic membrane (and/or a component thereof). In some embodiments, the implant comprises amniotic sac (and/or a component thereof). In some embodiments, the implant comprises amniotic tissue (and/or a component thereof). Amniotic membrane (and/or sac and/or tissue) is unique in that its mechanical properties include that it slippery on one side (lubricious, low modulus of elasticity) and sticky (adherent) on the other. In some embodiments, at least one of the first wall, the second wall and the side wall comprise amniotic membrane or a component thereof. In some embodiments, at least one of the first wall, the second wall and the side wall comprise amniotic sac or a component thereof.
  • At least one of the first wall, the second wall and the side wall comprise amniotic tissue or a component thereof.
  • the amniotic membrane and/or amniotic sac and/or amniotic tissue may be used in conjunction with other biologic agents, pharmaceutical agents, and/or therapeutic agents.
  • Amniotic tissue is used extensively in pleuripotential cells. It qualifies as HTBP (Human Tissue Based Product) because of the short term time span on the product and origin.
  • the bone engaging surface of the implant may be coated and/or impregnated with a latticework of polymer that is surface sprayed or layered on the bone engaging surface of the implant to promote cartilage tissue regeneration.
  • This bone engaging surface coating may contain living chondrocytes (for example, as is provided in the Carticel procedure by the Genzyme company), and/or may contain stem cells with directed gene mutations to enhance adherence of the coating to the implant.
  • the bone engaging surface may comprise peaks and troughs. The living cells may be provided in troughs while the surface peaks may be used for at least one of: space validation, traction, and cell protection.
  • the implant is pre-molded to fit about at least one condyle of the femur.
  • the implant comprises a memory plastic.
  • the implant comprises a wire frame.
  • the wire of the wire frame comprises a memory metal.
  • the memory metal comprises nitinol.
  • the wire frame is disposed in the periphery of the implant or a portion thereof. In some embodiments, the wire frame is configured to aid in placement against the posterior of the condyle.
  • At least a portion of the implant comprises a slippery surface.
  • the slippery surface is configured to allow for relative movement between the implant (or a portion thereof) that is coupled to the femur and the tibia. In some embodiments the slippery surface is configured to allow for relative movement between the implant (or a portion thereof) that is coupled to the femur and the patella.
  • the implant comprises a sheet.
  • the sheet is solid (e.g. comprising polyurethane or another biocompatible material), complex (e.g. comprising Dyneema mesh).
  • the implant may comprise Dyneema mesh.
  • the implant may comprise Dyneema fiber.
  • the implant comprises Dyneema Purity®.
  • the implant may comprise a fiber.
  • the implant may comprise a polyethylene fiber.
  • the implant may comprise a mesh.
  • the mesh may be a random structure or a repeating structure (such as a honeycomb).
  • the mesh may comprise a polymer structure of interwoven or randomly interlinked fibers or a combination thereof.
  • the mesh may comprise a memory polymer. The mesh may aid in fixing the implant in place.
  • the mesh may be adapted to add cushion to the bones of joint.
  • the mesh may be adapted to add durability to implant upon cyclic loading.
  • the mesh may be adapted to add padding to the bones of joint.
  • the mesh may be filled in its interstices with a softer (in durometer) polymer or other material (softer than the material of the mesh itself).
  • the mesh may be filled in its interstices with a softer (in durometer) polymer or other material (softer than the material of the mesh itself).
  • the interstices of the mesh may comprise a pharmacologic or therapeutic agent (or both) as noted herein.
  • the implant may have a single composition throughout the implant, and shaped as noted herein with attachment features as noted herein.
  • the implant comprises no chamber, however it comprises various regions which have different features than other regions-such as comprising a mesh between the first wall and the second wall (as noted above), a cushion between the first wall and the second wall, and/or comprising any aspects of the fill materials noted in the inflation mediums noted elsewhere herein, but not necessarily provided in a chamber which is filled following implantation or at the time of implantation. Rather, these aspects may be built into the implant during implant manufacture, by layering or other manufacturing processes, and not necessarily by filling a chamber.
  • the implant achieves these aspects by varying thickness of one of the walls at a particular region of the implant, for non-limiting example, at load-bearing locations.
  • the features of the implant change over time.
  • the implant may comprise a powder methyl methacrylate and a liquid that becomes a slurry upon insertion or soon thereafter, and that once implanted hardens (or cures) within the implant.
  • the methyl methacrylate (e.g. as a powder) and a catalyst liquid together become solid and are an example of a cement (or bone cement), however other cements or other materials which cure over time or with heat or with loading or by other methods (chemical or physical) are contemplated as alternatives.
  • at least one of the powder methyl methacrylate and the liquid is part of the implant at the time of implantation.
  • At least one of the powder methyl methacrylate and the liquid is injected into or loaded into the implant at the time of implantation or soon thereafter. In certain embodiments, both the powder methyl methacrylate and the liquid are injected into or loaded into the implant at the time of implantation or soon thereafter. In certain embodiments, at least one of the powder methyl methacrylate and the liquid is a fill material. In certain embodiments, the implant does not have a chamber prior to injection of (or loading of) a fill material between the first wall and the second wall. The injection (or loading) of a fill material between the first wall and the second wall creates a chamber. In certain embodiments, the implant comprises intersticeswhich are occupied by the fill material. In some embodiments, the methyl methacrylate powder and liquid catalyst are already inside the implant but only mix after intentional deployment in external or internal manners.
  • the implant in some embodiments is inserted arthroscopically through a cannula about 10 mm in diameter. Once the joint is cleaned, the implant is inserted and appropriately fixed to avoid extrusion or dislocation thereof. This may be via attachment of the implant tabs and/or by a combination of tab use plus intended friction created by implant surface coverings (analogous to Velcro) or a draw string at the smaller base of the implant.
  • the implant comprises a microminiature recorder and/or transmitter.
  • the recorder i.e. sensor
  • the recorder may collect joint loading data and comprise electronics that deliver data regarding joint loading.
  • the recorder i.e. sensor
  • the recorder may collect data regarding chemical or physiologic response at the implant location, such as the presence and composition of various biologic fluids at the sensor site.
  • the sensor may be able to detect inflammatory responses in the joint.
  • the sensor may be able to detect the spacing of the various joint components over time or at a particular time-such as the distance between the tibia and femur during a normal gait.
  • the implant may comprise electronics that deliver data regarding joint loading or the other aspects of the joint sensed as listed herein or otherwise that could be sensed.
  • the transmitters may provide feedback to the patient or to a caregiver.
  • the feedback may be real-time, or may be uploaded periodically, or may be uploaded upon request.
  • the feedback may be provided wirelessly.
  • the transmitters may provide a patient an ongoing feedback and ability to adjust the joint use based to the feedback from the transmitter. For example, the transmitter might signal to the patient that he should adjust his gait to reduce the ligamentary stress in one manner or another. In another example, the transmitter might indicate to a physical therapist that a certain ligament is being stressed during normal use, and that might indicate to the therapist that the patient should strengthen a particular muscle or muscle group to compensate for and balance the stresses in the joint.
  • the senor and transmitters transmits information regarding positioning, ligamentary stresses and other information to a graphic display of real-time feedback, enabling a surgeon to visualize and quantify joint loading and balance during implantation.
  • a surgeon can make an informed choice to modify implant positioning, adjust leg alignment and optimize soft tissue balance through a full range of motion.
  • the attachment elements of the implant comprises holes through which screws or other couplers may be placed to attach the implant to an attachment site (or connection site) in the bone of the knee.
  • the attachment elements are also or alternatively called fixation elements or couplers.
  • the holes are created arthroscopically.
  • the holes are pre-fabricated in the implant.
  • the holes may be made prior to implantation based on the patient's particular anatomy.
  • the holes are reinforced by a reinforcing material of the implant. The reinforcing material may be a polymer of sufficient durometer and/or tear resistance to reinforce the screw hole.
  • the implant may comprise tabs that are adapted to receive staples or other couplers described elsewhere herein.
  • the elasticity of the implant may allow it to stretch over the joint end and hook or snap into place, with the tendency of the material to contract acting to hold it in place (in part or wholly).
  • the implants described herein may comprise attachment elements (or tabs) which may then by attached or coupled to tissue of a component of the joint (whether to a bone or a ligament or a tendon or other joint component) by a coupling device.
  • Coupling devices may comprise at least one of screws, snaps, washers, pins, sutures, suture anchors (metal and/or biodegradable), rivets, staples (with and /or without teeth), stabilizers, glues, hooks of cylindrical wire or flattened sheet metal into bone holes or slots respectively.
  • the coupling devices may be resorbable or not.
  • the coupling devices may comprise at least one of strings (i.e.
  • the strings, reigns, lassos, sutures, and/or lanyards may join with themselves and/or other coupling devices.
  • the strings, reigns, lassos, sutures and/or lanyards may be directed not only into bone with or without anchors, but also through ligaments, tendons or loose segments of cartilage that the surgeon intends to preserve.
  • the implant comprises strings, reigns, lassos, and/or lanyards that may pass from the posterior of the implant via the intercondylar notch anteriorly to join with themselves and/or other coupling devices.
  • These couplers may be pre-coupled to the implant, and the implant and its couplers may be configured to be pulled (or cinched) from the anterior of the implant once the implant is in its general location relative to the condyle in order to finally position the implant about the condyle-in particular in order to cinch the implant about the posterior of the condyle.
  • the coupler as described are adapted to move the implant to its final position with conformity to the condyle's posterior with minimal disturbance to the joint structures at the joint's posterior (minimal cutting, minimal moving, and or minimal detachment, for non-limiting example).
  • the implant comprises a skirt (or sleeve) that conforms to the contours of the bone (whether a condyle of the femur, a patella, or a tibia) as a coupler.
  • a screw through tab having reinforced center holes may be part of the implant.
  • the implant may comprise polymer covered metal washer holes. The screw may go through the holes.
  • Another embodiment may comprise a staple having spikes as shown in Figures 13A-13D.
  • Figures 13A- 13D depict multiple views of a staple adapted to couple an implant to a bone of the joint.
  • Figure 13A depicts an embodiment of an implant 20 having a tab 10a that is coupled to bone using a staple 12.
  • Figures 13B & 13C depict a staple 12 as described herein having teeth 18.
  • Figure 13C depicts an embodiment of a tab 10a that is coupled to bone using a staple 12 having teeth 18.
  • Combinations of spikes and screws may be used in some embodiments, or combinations of other couplers.
  • the implant may be configured to allow a surgeon the option of several types and sizes of couplers, as each patient differs with regard to size and depth of lesion, bone stock, regrowth capability, and compliance with advised recovery, and each surgeon has his own strengths and comforts when working with such implants.
  • the edge of the implant may have a depending skirt to secure or anchor the implant to the end of bone (femur), but may have one or more depending tabs (or appendages) that may be employed for similar functions as are discussed in other embodiments.
  • the skirt (and/or tabs, and/or appendages) may tightly fit about the end of the femur, or the skirt can be secured by adhesive (e.g. HydroMed, Carbopol 934p, Polycarbophil AA1, xanthum gum, hydroxypropyl cellulose).
  • the lower portion of the skirt may be secured by a purse string suture or a suitable strand (elastic or tied) that is tightly bound about the outside of the skirt.
  • Figures 12A, 12B , and/or 12C alternatively may be used to describe a patch implant or a unicompartment knee implant described herein, having appendages 4a, 4c, extending from a balloon 6 and including holes 8a, 8b, 8c, and/or tabs 10a, 10b. 10c, 10d, 10e, 10f, which may be used with couplers (not shown) to couple the implant to a bone of the knee joint (which may be the femur, the tibia, or the patella).
  • couplers not shown
  • FIG. 12A, 12B , and or 12C are common to both the unicompartment knee implant (also discussed elsewhere herein) and the patch implant (also discussed elsewhere herein), although dimensions may differ as described elsewhere herein.
  • Figures 13A- 13D depict multiple views of a staple 12 adapted to couple implant 14 (such as those described herein) to a bone 16 of the joint.
  • Figure 13A depicts a staple 12 coupling a tab 10a of an appendage 4a to the bone 16 of the joint (wherein the portion of the staple 12 embedded in the bone 16 is shown as a dashed line).
  • Figure 13B depicts a view of a staple 12 having teeth 18 to grasp the tab 10a of the implant 14.
  • Figure 13C depicts a view of a staple 12 having teeth 18 to grasp the tab 10a of the implant 14.
  • Figure 13D depicts a staple 12 attaching the tab 10a of an implant to a bone 16, the dotted lines show the portion of the tab 10a that is compressed by the staple 12 and teeth 18 thereof.
  • the implant is configured such that the tabs and/or couplers of the implant couple to the bone where there is no natural cartilage.
  • the implant may be adapted by the surgeon at the time of surgery such that the tabs are positioned where there is no natural cartilage.
  • the implant comprises a tab and a hook that couples to the tab by wrapping around a component of the knee and securing the tab to the hook. In some embodiments, the implant comprises a tab and a hook that couples to the tab by wrapping around a condyle of the knee and securing the tab to the hook. In some embodiments, the implant is configured to wrap around a condyle of the knee and to secure a first appendage to a second appendage of the implant. In some embodiments the appendages are secured by couplers described herein. In some embodiments, the implant is pre-formed to fit to the condyle in such a wrapping manner.
  • the implant comprises a methyl methacrylate what is placed into a balloon chamber that fits into a bone hole. Such an embodiment would generally fix the implant to the bone once the methyl methacrylate cures to a solid.
  • the implant can be anchored with generic available sutures and suture anchors fixing and positioning material to bone with proper tensioning.
  • fixation may comprise various methods and elements.
  • the fixation to a bone may comprise any one of or a combination of a screw, a snap, a pin, a staple, bone in-growth materials, glue, a nanocomposite, and cement.
  • the implant may comprise a snap fit option for fixation.
  • the implant itself may be pre-molded to cup the first bone of the device, or the second bone of the device.
  • the implant may instead have a snap-like device which fixes the device to the bone (the first, second, and/or third bone).
  • fixation comprises glue.
  • fixation comprises a nanocomposite.
  • the nanocomposite comprises a polyurethane hierarchical nanocomposite.
  • Fixation may comprise gluing a nanocomposite to the implant.
  • fixation comprises bone in-growth materials.
  • bone in-growth may be achieved as described in Vasanji A (2012).
  • the patient's preoperative x-rays, MRI, CT scan, or physical measurements are coordinated with implant custom fit options providing for translation of pathophysiological data into solid works and rapid prototypes. This may provide the forum for anatomic fit of the implant to the patient.
  • the implant may be selected from a set of pre-selected sizes of implants and then the device may have inherent malleability which is used to couple the implant to the bone end.
  • the implant may be shaped to form a joint cap which is fixed to a first bone or a second bone or a combination thereof with a fixation element such as a screw or staple or cement or another means or combination of these or others as described herein. Cementing the implant in place is an alternative or may be used with other fixation elements (screws, snaps, ties, hooks, staples, etc).
  • the implant is secured in place only by the nature of its location and placement within the joint space. That is, it may naturally be held in place by the surrounding structures (tissue, bone, ligaments) as well as its own geometry in three dimensions.
  • fixing of the implant to bone is achieved by combining autograph, allograph, xenograph, and/or prosthetic structures.
  • the implant comprises a polymer joint cap that may be used similarly to the femoral component of a total knee replacement cement arthroplasty or like a hip resurfacing.
  • cartilage may be sacrificed exposing more bone beneath the implant, and cement could be used as a traditional fixation technique.
  • specific portions of cartilage can be removed to allow attachment of the implant undersurface with the bone by localized applications of cement, bone in-growth, tacking devices, countersunk screws, or Velcro like constructs wherein opposing surfaces are set to fix.
  • the anterior cruciate ligament could still be saved maintaining joint stability and proprioception.
  • a snap fit fixation element may alternatively (or additionally) be used.
  • a snap may be a protuberance off the posterior implant surface may be used.
  • the snap may comprise a mushroom shaped peg that may insert into predrilled bone holes.
  • the holes in some embodiments are of corresponding shape to the peg (upside-down mushroom-shaped holes, or similarly shaped holes).
  • the holes in some embodiments are columnar shaped holes.
  • the holes may be at the periphery (edge) of the implant as it opposes bone, or generally located as noted herein where other fixation elements are located (e.g. see Figures 1-4B , 11 , 12 at least).
  • the snap may also fit into more central posterior implant areas.
  • the snap may be designed as to increase stability by swelling beneath the joint cortical surface in the early post operative interval. Implant removal may be facilitated by placing a cooling device over the snap site to shrink or loosen the attachment.
  • the peg of the snap is one of: about 1mm to about 10mm in diameter, about 2mm to about 8mm in diameter, about 3mm to about 6mm in diameter, about 4mm to about 5mm in diameter, about 4.5mm in diameter, 1mm to 10mm in diameter, 2mm to 8mm in diameter, 3mm to 6mm in diameter, 4mm to 5mm in diameter, and 4.5mm in diameter.
  • the mushroom head of the snap is one of: about 1mm to about 10mm in diameter, about 2mm to about 8mm in diameter, about 3mm to about 6mm in diameter, about 4mm to about 5mm in diameter, about 4.5mm in diameter, 1mm to 10mm in diameter, 2mm to 8mm in diameter, 3mm to 6mm in diameter, 4mm to 5mm in diameter, and 4.5mm in diameter
  • the snap or protuberances may have a narrow base that extends perpendicularly from the tabs and/or implant posterior surface. The wider sphere as compared to the diameter of the snap columnar pedestal fits into a predrilled bone hole that matches the location to be fixed.
  • the snap may be more like anchor which expands into the bone upon insertion, much like a drywall anchor acts.
  • Material compliance allows the distal snap to enter through cortical to cancellous bone.
  • Exposure to joint fluid and bode temperature can expand the snap wherein the snap comprises a hydrophilic polymer to secure implant apposition.
  • a mushroom shaped protuberance off the posterior of the polymer joint implant is used, with stiff pegs that push connected spheres through a predrilled cortical bone hole.
  • the joint implant may be cap-like holding to the bone by internal elasticity of the implant and further held by the fixation elements which may be snaps or other elements.
  • a drill into cortical hole cuts a broader cancellous swath to create a location for the ball of the snap.
  • the peg hole may be 5mm
  • the mushroom cap head hole section diameter may be 7mm.
  • Other sizes may be appropriate for the peg hole such as about 1mm, about 2mm, about 3mm, about 4mm, about 5mm, about 6mm, about 7mm, about 8mm.
  • Other sizes may be appropriate for the mushroom cap head hole section, such as about 9 mm about 3mm, about 4mm, about 5mm, about 6mm, about 7mm, about 8mm, and about 9mm.
  • a hydrophilic polymer of the snap may then swell and hold the implant into place.
  • FIG. 1 ACL graft fixation
  • FIG. 1 ACL graft fixation
  • FIG. 1 ACL graft fixation
  • FIG. 1 ACL graft fixation
  • FIG. 1 ACL graft fixation
  • FIG. 1 ACL graft fixation
  • FIG. 1 ACL graft fixation
  • FIG. 1 ACL graft fixation
  • FIG. 1 ACL graft fixation
  • the implant undersurface may comprise an in-growth matrix.
  • at least a portion of the implant adjacent to the femur comprises bone in-growth materials.
  • Such an implant can be attached by a series of tabs with or without holes, using screws, rivets, stabilizers, staples, tacks, washers, pins, snaps, or Sutures and suture anchors, for non-limiting example.
  • the polymer of the implant substitutes for periosteum when the implant comprises living chondrocytes (e.g. Carticel) as the in-growth matrix on a surface of the implant.
  • the polymer of the implant substitutes for periosteum when the implant comprises living chondrocytes (e.g. Carticel) as the in-growth matrix within an implant embodiment configured to reveal and/or release said chondrocytes over time and/or upon implantation.
  • living chondrocytes e.g. Carticel
  • the bone in-growth undersurface may be used for long term fixation of the tabs or rim. That is, whereas it is important for the surgery to secure the implant to the joint surface in the most desirable corrective location, it is also important in some embodiments to prepare the anatomic undersurface of bone by abrading it, removing about 0.5mm of cortical bone so as to expose the underlying oxygen, blood, and nutrients of the patient to the undersurface of the implant that can gradually become incorporated into the limb bone. As this healing occurs over the course of weeks and months to one year post operation, the localized tacking sites may become less relevant and potentially inert.
  • the implant may comprise a biodegradable (bioresorbable) polymer or other material.
  • the couplers may additionally and/or alternatively be biodegradable or durable (non-bioabsorbable). Once the implant is in place, it may serve to at least one of: pad defects, cushion the joint, and restore the original damage to the joint components.
  • the end goal is to apply minimally morbid treatment that may refurbish arthritic limb regions, leaving only the small skin scar and remote memory of the healed physical mishap.
  • Undersurface implant materials may involve used of the art and science from Artelon or Gore-Tex research, as each has advantages and limitations.
  • Several implant options per joint damage area may be available to enjoy the primary surgeons manipulation to fit the clinically recovery requirements best.
  • the implant comprises an in-growth patch on at least one of the first portion configured to engage the femur, the second portion configured to engage the second bone (whether the tibia or the patella), the side portion, and the appendage.
  • tissue is removed to facilitate in-growth.
  • the walls of the implant embodying features of the invention may be composite structures.
  • the innermost layer may be impervious to preclude escape of inflation or other filling media
  • a central layer may be porous or otherwise contain treatment or cell regeneration agents
  • the outer layer may be a thin, but strong layer of a thermoplastic, such as a thermoplastic polyurethane for non-limiting example, which has microporosity sufficient to allow passage or egress of treatment or cell regeneration agents from the central layer (or second layer).
  • the degree of microporosity to enable egress of treatment or cell regeneration agents from the central layer is found in polymer layers such as Chronoflex (e.g., ChronoFlexAR®, ChronoFlex AL®, ChronoFlec C®) or BIONATE (e.g., BIONATE I, BIONATE II, BIONATE 55D, BIONATE 65D, BIONATE 75D, BIONATE 80A, BIONATE 90A, BIONATE 55 or BIONATE 80).
  • the external wall (and/or the bone engaging surface) of the implant may be coated and/or impregnated with a latticework of polymer that is surface sprayed or layered on the outside (or bone engaging surface) of the implant to promote cartilage tissue regeneration.
  • This most external surface coating may contain living chondrocytes (for example, as is provided in the Carticel procedure by the Genzyme company), and/or may contain stem cells with or without directed gene mutations to enhance adherence of the coating to the implant.
  • the bone engaging surface may comprise peaks and troughs.
  • the living cells may be imposed in between (and/or provided in the) troughs of the implant surface while the surface areas of prominence (the peaks of the surface) may be used for at least one of: space validation, traction, and cell protection.
  • the implant embodying features of the invention may be used in a series of treatments wherein the first treatment involves use of autologous or minimally manipulated allograph interpositional tissues or xenograph, the second treatment involves the use of the same type of tissue added to stem cells or chondrocytes and the third treatment involving deployment of the implant if the first two fail or are ineffective.
  • the implant may comprise materials which allow for bone in-growth following implantation.
  • the implant may comprise vacuoles of pharmacologic substances.
  • the vacuoles may be on a bone-engaging portion of the implant.
  • the implant comprises bubbles comprising an active substance such as a pharmacologic substance or other active substance.
  • the implant comprises spaces filled with an active substance such as a pharmacologic substance (pharmacologic agent) or other active substance (active agent).
  • the active substance comprises iatrogenically gene mutated cells.
  • the implant may be inserted into the vacated space following removal of an infected routine total joint replacement. Current treatment of infected prostheses range from IV antibiosis, through arthroscopic washout to single or two stage replantations.
  • Dendritic Macromolecules may deliver agent en masse from certain embodiments of the implant.
  • the delivery in such situations may be via controllable size and structure, and may incorporate individual agent molecules or "hubs" via covalent bonds.
  • Any combination of the nanoscopic developments can be created or assembled into the implants described herein and can be distributed, or oozed, or leaked, or expulsed from, or absorbed into as cleansing a noxious environment, or any combination thereof.
  • Combined alternating forces such as materials that suck up or absorb noxious leukokynins or cathepsins while released useful viscolubricants such as Synvisc, Hyalgan or Orthovisc can be constructed to accommodate clinical need consistent with physical joint damage mandates or aligned with and consider of the natural history of disease processes so as to maximize either ones anticipated inevitable chronic deterioration or to thwart the adverse affects delaying degradation from arthritic or pathophysiologic processes.
  • Symptoms for the patient requiring an implant described herein may include, for non-limiting example, osteoarthritis or rheumatoid or gouty arthritis.
  • an implant for placement on both condyles (medial and lateral) of the distal femur is called a dual compartment implant since it covers both condyles of the femur.
  • the implant covers the "H" distal femoral cartilage segment (made up of both femoral condyles and the trochlear groove in between).
  • the implant may absorb diffuse force, endure the millions of annual cyclic loads of both knee joints (including the patella-femur joint and the femur-tibia joints), along with rotational and shear forces up to six times body weight, at least.
  • the implant comprises attachment tabs or attachment elements over the sides of both condyles medially and laterally. In some embodiments, the implant comprises attachment tabs or attachment elements in the intercondylar notch (or slot). In some embodiments, the implant comprises attachment tabs or attachment elements superiorly at the distal end of the femur anteriorly. In some embodiments, posterior reigns or suture-like lanyards cinch up the implant from inside the posterior intercondylar notch toward another connection site around the femur.
  • the implant comprises strings, reigns, lassos, and/or lanyards that may pass from the posterior of the implant via the intercondylar notch anteriorly to join with themselves and/or other coupling devices.
  • These couplers may be pre-coupled to the implant, and the implant and its couplers may be configured to be pulled (or cinched) from the anterior of the implant once the implant is in its general location relative to the condyle in order to finally position the implant about the condyle-in particular in order to cinch the implant about the posterior of the condyle.
  • the coupler as described are adapted to move the implant to its final position with conformity to the condyle's posterior with minimal disturbance to the joint structures at the joint's posterior (minimal cutting, minimal moving, and or minimal detachment, for non-limiting example).
  • at least a portion of the ligamentary structure of the knee is spared.
  • implants as described generally herein may be also and/or alternatively be used in conjunction with the tibia and/or the patella.
  • implant components may be inserted to restore natural function to the knee.
  • the surgeon may elect to place the implant so that it opposes metal, polymer, or another surface reconstructive material.
  • Coupling devices to be used as part of the dual compartment implant may include any of those mentioned or described herein, for example.
  • Such coupling devices may comprise at least one of strings (i.e. drawstrings), reigns, lassos, sutures, and lanyards.
  • the strings, reigns, lassos, sutures, and/or lanyards may join with themselves and/or other coupling devices.
  • the strings, reigns, lassos, sutures and/or lanyards may be directed not only into bone with or without anchors, but also through ligaments, tendons or loose segments of cartilage that the surgeon intends to preserve.
  • Figure 1 depicts an embodiment of the implant 20 in a 2D view configured for dual condyle (distal femur) coverage.
  • Figure 1 depicts an embodiment of the knee implant 20 having appendages 4a, 4b, 4c, 4d, including holes 8a, 8b, 8c, 8d and tabs 10a, 10b extending from a balloon 6 and including slots 26a, 26b to accommodate ligaments (not shown) of the knee joint.
  • Couplers as described elsewhere herein may be used to couple the implant 20 to the distal femur. In some embodiments, there may only tabs, only holes, or only appendages, or combinations thereof.
  • the tabs 10a, 10b contain holes.
  • the couplers create the holes 8a, 8b, 8c, 8d, or other holes (not shown) when the implant is placed against the distal femur 24.
  • the holes are pre-formed in the appendage prior to implantation.
  • the holes are reinforced as described elsewhere herein.
  • the holes are within the peripheral rim of the knee implant. In some embodiments, the holes are within the region of the intercondylar notch medially and/or laterally.
  • the holes are through the polymer. In some embodiments, the holes are through a reinforced rim. As shown here, the appendages in some embodiments may be different in shape and/or size to accommodate the differences in condyle size and/or shape. For example the medial condyle tends to be larger than the lateral condyle, and thus appendage 4d that is intended to wrap over the medial condyle may be longer and/or wider than the appendage 4c intended to wrap over the lateral condyle.
  • the slots may be different in shape and/or size and/or position to accommodate the ligaments and/or tendons of the joint or other structures and functions of the joints of the knee, and to allow for placement of the implant with minimal disturbance (cutting, manipulation, for example) of the joint components such as tendons, ligaments, and other soft or hard tissues.
  • slot 26a is shaped and positioned to accommodate the cruciate ligaments of the knee, at least.
  • the implant as shown in Figure 1 can have regions 4a, 4b, 4c, 4d where no inflation exists and may be composed of solid or compliant materials.
  • the implant comprises a Dyneema® mesh.
  • the implant may comprise Dyneema® fiber.
  • the implant comprises Dyneema Purity® fiber. In some embodiments, the implant comprises a Dyneema Purity® UG fiber. In some embodiments, the implant comprises a Dyneema Purity® VG fiber.
  • the implant may comprise a fiber.
  • the implant may comprise a polyethylene.
  • the implant may comprise a polyethylene fiber.
  • Figure 2 depicts an embodiment of the knee implant 20 having appendages 4a, 4b, 4c, 4d, including holes 8a, 8b, 8c, 8d and tabs 10a, 10b extending from a balloon 6 and including slots 26a, 26b to accommodate ligaments of the knee joint as well as side views of the same knee implant.
  • Couplers as described elsewhere herein may be used to couple the implant 20 to the distal femur.
  • there may only tabs, only holes, or only appendages, or combinations thereof.
  • there may be other ways to couple the implant to the distal femur, as described elsewhere herein sutures, drawstrings, skirts, glue, etc).
  • the couplers create the holes 8a, 8b, 8c, 8d, or other holes (not shown) when the implant is placed against the distal femur.
  • the holes are pre-formed in the appendage prior to implantation.
  • the holes are reinforced as described elsewhere herein.
  • the appendages in some embodiments are different in shape and/or size to accommodate the differences in condyle size and/or shape. For example the medial condyle tends to be larger than the lateral condyle, and thus appendage 4d that is intended to wrap over the medial condyle may be longer and/or wider than the appendage 4c intended to wrap over the lateral condyle.
  • slot 26a is shaped and positioned to accommodate the cruciate ligaments of the knee, at least.
  • the balloon has a first wall 28 adapted to be adjacent the femur that is of a greater thickness than the second wall 30.
  • the first wall 28 is configured to have therapeutic benefits (pharmacologic, healing, and/or in-growth properties) as described elsewhere herein.
  • the second wall 30 may additionally and/or alternatively be configured to have a therapeutic effect (pharmacologic, healing, and/or in-growth properties).
  • FIG. 3 depicts an example of a knee implant 20 having appendages 4a, 4b, 4c, 4d, including holes 8a, 8b, 8c, 8d and tabs 10a, 10b extending from a balloon 6 and including slots 26a, 26b to accommodate ligaments of the knee joint as well as side views of the same knee implant.
  • Couplers as described elsewhere herein may be used to couple the implant 20 to the distal femur. In some embodiments, there may only tabs, only holes, or only appendages, or combinations thereof.
  • the couplers create the holes 8a, 8b, 8c, 8d, or other holes (not shown) when the implant is placed against the distal femur.
  • the holes are pre-formed in the appendage prior to implantation.
  • the holes are reinforced as described elsewhere herein.
  • the appendages in some embodiments are different in shape and/or size to accommodate the differences in condyle size and/or shape.
  • the medial condyle tends to be larger than the lateral condyle, and thus appendage 4d that is intended to wrap over the medial condyle may be longer and/or wider than the appendage 4c intended to wrap over the lateral condyle.
  • Shown in the embodiment depicted in Figure 3 are the different hole placements from the side view, showing the differences in positioning of the holes to accommodate the differences in anatomic structure and size of the condyles.
  • the slots may be different in shape and/or size and/or position to accommodate the ligaments and/or tendons of the joint or other structures and functions of the joints of the knee, and to allow for placement of the implant with minimal disturbance (cutting, manipulation, for example) of the joint components such as tendons, ligaments, and other soft or hard tissues.
  • slot 26a is shaped and positioned to accommodate the cruciate ligaments of the knee, at least.
  • the balloon has a first wall 28 adapted to be adjacent the femur that is of approximately the same thickness than the second wall 30.
  • the first wall 28 is configured to have therapeutic benefits (pharmacologic, healing, and/or in-growth properties) as described elsewhere herein.
  • the second wall 30 may additionally and/or alternatively be configured to have a therapeutic effect (pharmacologic, healing, and/or in-growth properties).
  • the balloon 6 may be singular as depicted, or in certain embodiments, include a plurality of microscopic vesicular structures.
  • Figure 4A depicts an example of the knee implant 20 having appendages 4a-4d including ten tabs 10a-10j extending from a balloon 6 and including a slot 26a to accommodate components (such as ligaments or other tissues whether soft tissues, hard tissues, tendons, and/or others) of the knee joint (not shown).
  • the tabs 10a-10j are not shown with holes in this embodiment, however if screws are used as couplers, such holes may be pre-drilled or formed in situ by the screws. Additionally and/or alternatively, staples, washers, pins, snaps, or sutures may be used (as described elsewhere herein) in order to couple the implant to the bone (femur, for example).
  • FIG. 4B depicts an embodiment of the knee implant 20 having appendages 4a-4d including eight tabs 10a- 10h extending from a balloon 6 and including a slot 26a to accommodate components (such as ligaments or other tissues whether soft tissues, hard tissues, tendons, and/or others) of the knee joint (not shown).
  • the implant comprises 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, and/or 20 tabs.
  • the tabs may be located on either side of the condyles, including the superior, mid, and posterior portions. Any tab may be also and/or alternatively located inside the medial and intercondylar notch.
  • Figure 5 depicts an example of the knee implant 32 curved to simulate curvature about the condyles of a femur, the implant having appendages 4a-4d extending from an uninflated balloon (not shown) and including slots 26a, 26b to accommodate components (such as ligaments or other tissues whether soft tissues, hard tissues, tendons, and/or others) of the knee joint (not shown).
  • This figure also shows an implant comprising a solid compliant material, having no balloon whatsoever.
  • the implant may comprise additional curvatures and/or slots to accommodate other ligaments and/or tissues.
  • the implant is configured to conform about various hard and/or soft tissues of the joint, such as bone, ligaments, tendons, etc.
  • the balloon is inflated once the implant is positioned within the joint.
  • the balloon is partially inflated prior to being positioned within the joint. In other examples, the balloon is at least partially inflated prior to being positioned within the joint. In some examples, the balloon is fully inflated prior to being positioned within the joint. In some examples, the implant is configured to allow an operator to adjust the amount of balloon inflation in situ (whether by adding inflation medium or removing inflation medium, or both, or neither). Couplers as described elsewhere herein may be used to couple the implant 32 to the distal femur.
  • Figure 6A depicts a top-down view of an example of the knee implant 32 curved to simulate curvature about the condyles of a femur, the implant having appendages 4a-4d extending from two inflated balloons 6, 34 and including a slot 26a to accommodate components of the knee joint.
  • Figure 6B depicts a bottom-up or anterior oblique view of the same embodiment of the knee implant 32 curved to simulate curvature about the condyles of a femur, the implant having appendages 4a-4d extending from two inflated balloons 6, 32 and including a slot 26a to accommodate components of the knee joint. Couplers as described elsewhere herein may be used to couple the implant 32 to the distal femur.
  • the appendages 4a- 4d in some embodiments are different in shape and/or size to accommodate the differences in condyle size and/or shape.
  • the medial condyle tends to be larger than the lateral condyle, and thus appendage 4d that is intended to wrap over the medial condyle may be longer and/or wider than the appendage 4c intended to wrap over the lateral condyle.
  • the dimensions of the balloon 34 that is adapted for placement over the medial condyle may be a different shape and/or size than the balloon 6 over the lateral condyle (the medial condyle being larger, thus the balloon 34 may be larger for that location)
  • the inflation medium might be different in one balloon (or a portion thereof) than in the other balloon (or another chamber within the same balloon), or there may be need for a different shaped balloon in one location than in another location. Examples provided herein can accommodate these requirements based on materials of fillers, appendages, balloons, walls, and dimensions and chamber options of the implant and its components.
  • Figure 7 depicts a top-down view of an example of the knee implant 32 curved to simulate curvature about the condyles of a femur, the implant having appendages 4a-4d extending from an inflated balloon 6 and including slots to accommodate components of the knee joint. Couplers as described elsewhere herein may be used to couple the implant 32 to the distal femur. As shown here, the appendages 4a-4d in some examples are different in shape and/or size to accommodate the differences in condyle size and/or shape.
  • the medial condyle tends to be larger than the lateral condyle, and thus appendage 4d that is intended to wrap over the medial condyle may be longer and/or wider than the appendage 4c intended to wrap over the lateral condyle.
  • the dimensions of the portion of the balloon that is adapted for placement over the medial condyle may be a different shape and/or size than the portion of the balloon over the lateral condyle (the medial condyle being larger, thus the balloon may be larger for that location)
  • the inflation medium might be different in a portion or chamber of an implant having a plurality of inflation chambers in a single balloon, or there may be need for a non-symmetric balloon. Examples provided herein can accommodate these requirements based on materials of fillers, appendages, balloons, walls, and dimensions and chamber options of the implant and its components.
  • Figure 8 depicts a side view of an example of the knee implant 32 curved to simulate curvature about at least one condyle of a femur, the implant having appendages 4b, 4d extending from an uninflated balloon (not shown).
  • This depiction covers the maximum anticipated distal femoral contour; other iterations may be smaller, or shorter covering limited areas of the circumference of the femoral curvatures.
  • This figure also provides a lateral view for a solid implant (without a chamber therein) wherein the material thickness and/or layering provide cushioning.
  • Figure 9A depicts a side view of an example of the knee implant 20 curved about at least one condyle 22 of a femur 24, the implant 20 having appendages 4b, 4d extending from an uninflated or minimally inflated balloon 6.
  • the knee is positioned essentially in extension (straight), showing the tibia 36, fibula 38, and patella 40 of the knee.
  • this view of the implant and bones is greatly simplified for ease of understanding of the implant and the joint relative (and approximate) positions and placement.
  • Couplers as described elsewhere herein may be used to couple the implant 20 to the distal femur 24 and/or the condyle 22 thereof (in this image the medial condyle, at least since it is primarily a one-side view of the joint and implant).
  • Fig 9A and the implant depicted show of the femur with opposition to the other surfaces of both knee joints (between femur and tibia, and femur and patella), the areas of contact varying according to activity, forces, and range of motion. Other implant iterations may apply to opposing surfaces.
  • Figure 9B depicts a side view of an example of the knee implant 20 curved about at least one condyle 22 of a femur 24, the implant 20 having appendages 4b, 4d extending from an inflated balloon 6.
  • the knee is positioned essentially in extension (straight), showing the tibia 36, fibula 38, and patella 40 of the knee.
  • this view of the implant and bones is greatly simplified for ease of understanding of the implant and the joint relative (and approximate) positions and placement.
  • Couplers as described elsewhere herein may be used to couple the implant 20 to the distal femur 24 and/or the condyle 22 thereof (in this image the medial condyle, at least since it is primarily a one-side view of the joint and implant).
  • the balloon second wall 30 is closer to and/or contacting the tibial plateau 42 (articular surface) when the balloon 6 is inflated.
  • Figure 9C depicts a side view of an example of the knee implant 20 curved about at least one condyle 22 of a femur 24, the implant 20 having appendages 4b, 4d extending from an inflated balloon 6 and having couplers 44a, 44b (which may be, for non-limiting example, staples or screws, pins, or snaps) coupling the appendages 4b, 4d to the femur.
  • the knee is positioned essentially in extension (straight), showing the tibia 36, fibula 38, and patella 40 of the knee.
  • the medium of inflated and specific balloon location and durometry with the material of the implant may also be constructed so as to force the bones opposed, e.g. the femur and tibia, into a more natural limb alignment such as six (6) degrees valgus.
  • the implant inflation and pressures or balloon location may be adjusted from the population norms thus customizing this implant to the clinical case under consideration.
  • Fixation devices may be appropriately applied at various knee range of motion intervals from full extension (zero degrees) to full flexion (usually 135 degrees) as the knee is adjusted and the mplant secured under anesthesia.
  • Figure 10A depicts a side view of an example of the knee implant 20 curved about at least one condyle 22 of a femur 24, the implant 20 having appendages 4b, 4d extending from an inflated balloon 6 and showing the inflation medium 46 moved anteriorly toward the patella 40 when the knee joint is slightly flexed.
  • the dynamic nature of the implant material and/or content may be responsive to body forces as a physiological rather than rigid structure.
  • the filling of space inside the joint may add stability to the patient and to the joint.
  • Figure 10B depicts a side view of an embodiment of the knee implant 20 curved about at least one condyle 22 of a femur 24, the implant 20 having appendages 4b, 4d extending from an inflated balloon 6 and having couplers 44a, 44b (which may be, for non-limiting example, staples or screws, pins or snaps) coupling the appendages 4b, 4d to the femur 24 and showing the inflation medium 46 moved anteriorly toward the patella 40 when the knee joint is slightly flexed.
  • couplers 44a, 44b which may be, for non-limiting example, staples or screws, pins or snaps
  • Figure 14 depicts an embodiment of the knee implant 20 having appendages 4a, 4b, 4c, 4d, including holes 8a, 8b, 8c, 8d and tabs 10a, 10b and including slots 26a, 26b to accommodate ligaments of the knee joint as well as side views of the same knee implant.
  • Couplers as described elsewhere herein may be used to couple the implant 20 to the distal femur.
  • there may only tabs, only holes, or only appendages, or combinations thereof.
  • there may be other ways to couple the implant to the distal femur, as described elsewhere herein sutures, drawstrings, skirts, glue, etc).
  • the couplers create the holes 8a, 8b, 8c, 8d, or other holes (not shown) when the implant is placed against the distal femur.
  • the holes are pre-formed in the appendage prior to implantation.
  • the holes are reinforced as described elsewhere herein.
  • the appendages in some embodiments are different in shape and/or size to accommodate the differences in condyle size and/or shape. For example the medial condyle tends to be larger than the lateral condyle, and thus appendage 4d that is intended to wrap over the medial condyle may be longer and/or wider than the appendage 4c intended to wrap over the lateral condyle.
  • slot 26a is shaped and positioned to accommodate the cruciate ligaments of the knee, at least.
  • the implant has a first wall 28 adapted to be adjacent the femur that is of approximately the same thickness than the second wall 30.
  • the first wall 28 is configured to have therapeutic benefits (pharmacologic, healing, and/or in-growth properties) as described elsewhere herein.
  • the second wall 30 may additionally and/or alternatively be configured to have a therapeutic effect (pharmacologic, healing, and/or in-growth properties).
  • the thickness of the implant in certain locations is variable to add cushioning to the implant as well as to provide joint spacing.
  • the material is not variable in thickness, but provides the same cushioning and/or joint spacing for the bones of the joint.
  • the central region in the embodiment of Figure 14 is thicker material to add at least one of: cushioning, buffering, joint space, restore cushioning, and to respond to clinical need.
  • any of the balloons described herein with regard to any of the figures may add cushioning, padding, strength, durability, flexibility, or any other aspect noted herein, and need not be a chamber per se, nor be inflatable per se. Rather they are merely distinguishable in certain embodiments from the walls which are on either side of them in composition or function or both.
  • the balloon and its interior is not materially different in composition or function from one of the walls. In some examples, they are not materially different in composition or function from either of the walls.
  • Figures 15A, 15B , and 15C show several views of an embodiment of an implant which has no definable chamber, rather the material of the implant itself provides the cushion to the bones of the joint (at least).
  • the implant in 15A, 15B, and 15C is generally H or V-shaped, having a slot 26b that is significantly smaller than as shown other embodiments (for example Figures 3 , 4 , 5 , 6A , 6B , 7 , 14 ).
  • an implant shaped generally like Figures 15A, 15B , and 15c may comprise a chamber which, if the implant were shown in cross section, may comprise a different material than the wall of the implant itself, or may be the same material but with different geometric or chemical or physical properties, as noted herein.
  • Figures 15A, 15B , and 15C depict an embodiment of the knee implant 20 having appendages 4a, 4b, 4c, 4d and tabs 10a, 10b, 10c, 10d, 10e, 10f, 10g, 10h and including slots 26a, 26b to accommodate ligaments of the knee joint.
  • Couplers as described elsewhere herein may be used to couple the implant 20 to the distal femur.
  • there may be other ways to couple the implant to the distal femur, as described elsewhere herein sutures, drawstrings, skirts, glue, etc).
  • the couplers create holes (not shown) when the implant is placed against the distal femur.
  • the holes are pre-formed in the appendage prior to implantation.
  • the holes are reinforced as described elsewhere herein.
  • the appendages in some embodiments are different in shape and/or size to accommodate the differences in condyle size and/or shape. For example the medial condyle tends to be larger than the lateral condyle, and thus appendage 4d that is intended to wrap over the medial condyle may be longer and/or wider than the appendage 4c intended to wrap over the lateral condyle.
  • the slots may be different in shape and/or size and/or position to accommodate the ligaments and/or tendons of the joint or other structures and functions of the joints of the knee, and to allow for placement of the implant with minimal disturbance (cutting, manipulation, for example) of the joint components such as tendons, ligaments, and other soft or hard tissues.
  • slot 26a is shaped and positioned to accommodate the cruciate ligaments of the knee, at least.
  • the thickness of the implant in certain locations is variable to add cushioning to the implant as well as to provide joint spacing.
  • the material is not variable in thickness, but provides the same cushioning and/or joint spacing for the bones of the joint.
  • Figure 16 depicts a knee implant embodiment that is generally H or V-shaped, having a slot 26b that is significantly smaller than other embodiments, and in this embodiment is effectively replaced with a tab 10i at the same location (e.g. 10i).
  • Figure 16 depicts an embodiment of the knee implant 20 having appendages 4a, 4b, 4c, 4d and tabs 10a, 10b, 10c, 10d, 10e, 10f, 10g, 10h, 10i and including a slots 26a to accommodate ligament(s) of the knee joint. Couplers as described elsewhere herein may be used to couple the implant 20 to the distal femur.
  • Contour lines 54a, 54b, for example, are also depicted in figure 16 , however these are not necessarily significant other than to show contour of parts of the implant 20, although they may be in the case where a mesh is provided in the implant.
  • the couplers create holes (not shown) when the implant is placed against the distal femur.
  • the holes are pre-formed in the appendage prior to implantation.
  • the holes are reinforced as described elsewhere herein.
  • the appendages in some embodiments are different in shape and/or size to accommodate the differences in condyle size and/or shape.
  • the medial condyle tends to be larger than the lateral condyle, and thus appendage 4d that is intended to wrap over the medial condyle may be longer and/or wider than the appendage 4c intended to wrap over the lateral condyle.
  • the slot 26a may be different in shape and/or size and/or position to accommodate the ligaments and/or tendons of the joint or other structures and functions of the joints of the knee, and to allow for placement of the implant with minimal disturbance (cutting, manipulation, for example) of the joint components such as tendons, ligaments, and other soft or hard tissues.
  • slot 26a is shaped and positioned to accommodate the cruciate ligaments of the knee, at least.
  • the thickness of the implant in certain locations is variable to add cushioning to the implant as well as to provide joint spacing.
  • the material is not variable in thickness, but provides the same cushioning and/or joint spacing for the bones of the joint.
  • an implant shaped generally like Figure 16 may or may hot comprise a chamber which, if the implant were shown in cross section, may comprise a several materials which may be the same as or different from any wall of the implant itself, or may be the same material but with different geometric or chemical or physical properties, as noted herein.
  • Figure 17 depicts a knee implant embodiment similar to Figure 16 which shows a posterior view including the location(s) 50a- 50d where a fill material such as cement may be placed.
  • the fill material may be added in any one location 50a, 50b, 50c, or 50d, or added in several of locations 50a, 50b, 50c, and 50d or likewise be added anywhere on the first or second wall of the implant which contacts the first, second, and/or third bone.
  • the fill material may be used to both cushion (as do balloons 6 in other figures) and/or secure the device to the bone in the case of a bone cement or a combination of these functions.
  • the cement may be used in an element that may or may not have any, some, or all of tabs 10a- 10i.
  • the cushion thus can act as a coupler (fixation element) and/or as a cushion and/or spacer for the joint bones.
  • the cushion (whether a fill material such as cement or another material) may also be placed adjacent to a first wall or second wall, and not necessarily between said first wall and second wall.
  • Figure 18 is an anterior-posterior view of an example of the implant 20 attached to a knee model.
  • the implant here comprises chambers 52a, 52b, 53c, at least (in this case, nano-inflated air pockets). Although sparsely shown in this embodiment, the frequency, size, etc. could be adapted to smaller chambers, larger chambers, more frequent chambers, more concentrated in particular areas of the implant, less concentrated in particular areas of the implant, or similarly adjusted.
  • the chambers can be diffuse, of any size, containing compressible gas (air), cells, pharmacologics, liquids, beads, metals, or other materials as noted herein.
  • Figure 19 depicts an implant 20 which is more squarely cut for interface with a femur, for example, which has been cut square such as is done in certain total knee arthroplasty procedures.
  • the implant in this situation may comprise a polymer alone (of soft or hard durometer) and/or metal.
  • the walls may be contiguous or include a chamber that is optionally filled or fillable as noted herein.
  • tabs are shown in Figure 19 , these are optional in embodiments where another attachment element (fixation element) is used such as cement or a metal pin or screw or snap through an appendage of the device.
  • Figures 20A and 20B depict a knee implant embodiment that is generally V-shaped or Y-shaped, and in this embodiment the slot 26b of other embodiments, or the tab 10i of other embodiments is effectively replaced with an appendage 4e at the same location.
  • Figure 20A depicts an embodiment of the knee implant 20 having appendages 4c, 4d, and 4e and holes 8a (not shown, in Fig. 20B ), 8b (not shown, in Fig. 20B ), 8c (not shown, in Fig. 20B ), 8d, 8e, 8f, 8g, 8h, 8i, (not shown, substantially similarly positioned as 8e on the same edge as 8a-8c of Fig.
  • FIG. 20A 20A
  • 8j (not shown, substantially similarly positioned as 8d on the same edge as 8a-8c of Fig. 20A ), and including a slot 26a to accommodate ligament(s) of the knee joint.
  • Couplers as described elsewhere herein may be used to couple the implant 20 to the distal femur through slots 8a-8j.
  • Contour lines are also depicted in Figures 20A and 20B , however these are not necessarily significant other than to show contour of parts of the implant 20, although they may be in the case where a mesh is provided in the implant. In some embodiments, there may only tabs, only holes, or only appendages, or combinations thereof.
  • the tabs comprise holes.
  • the couplers create holes (not shown) when the implant is placed against the distal femur.
  • the holes are within the peripheral rim of the knee implant.
  • the holes are within the region of the intercondylar notch medially and/or laterally.
  • the holes are through the polymer.
  • the holes are through a reinforced rim.
  • the holes are pre-formed in the appendage prior to implantation.
  • the holes are reinforced as described elsewhere herein.
  • the appendages in some embodiments are different in shape and/or size to accommodate the differences in condyle size and/or shape.
  • the medial condyle tends to be larger than the lateral condyle, and thus appendage 4d that is intended to wrap over the medial condyle may be longer and/or wider than the appendage 4c intended to wrap over the lateral condyle.
  • the slot 26a may be different in shape and/or size and/or position to accommodate the ligaments and/or tendons of the joint or other structures and functions of the joints of the knee, and to allow for placement of the implant with minimal disturbance (cutting, manipulation, for example) of the joint components such as tendons, ligaments, and other soft or hard tissues.
  • slot 26a is shaped and positioned to accommodate the cruciate ligaments of the knee, at least.
  • the thickness of the implant in certain locations is variable to add cushioning to the implant as well as to provide joint spacing.
  • the material is not variable in thickness, but provides the same cushioning and/or joint spacing for the bones of the joint.
  • an implant shaped generally like Figures 20A or 20B may or may not comprise a chamber which, if the implant were shown in cross section, may comprise a several materials which may be the same as or different from any wall of the implant itself, or may be the same material but with different geometric or chemical or physical properties, as noted herein.
  • thickness of between the first wall (part configured to touch the femur condyle) and the second wall (part configured to touch the tibia) is shown for example in the slot 26a (which may be called a notch herein), thus showing a side wall as described elsewhere herein to provide the thickness to the implant at the condyle(s).
  • the implant comprises a Dyneema® mesh.
  • the implant may comprise Dyneema® fiber.
  • the implant comprises Dyneema Purity® fiber.
  • the implant comprises a Dyneema Purity® UG fiber.
  • the implant comprises a Dyneema Purity® VG fiber.
  • the implant may comprise a fiber.
  • the implant may comprise a polyethylene.
  • the implant may comprise a polyethylene fiber.
  • the implant may instead be configured to couple to or emerge from the tibia and/or patella.
  • the implant may instead be configured to couple to the tibia. It is the intention and understanding that the implant is suited for this purpose in certain embodiments with adjustments to account for dimensional differences of the tibia.
  • Most descriptions provided herein are directed to embodiments coupling the implant to the femur, however, this is primarily for ease of description and continuity, and does not preclude embodiments wherein the implant is coupled to the tibia.
  • the implant may be coupled to two bones (at least), for example to both a tibia and a femur.
  • Some embodiments of the implant are configured to repair isolated lesions wherein osteochondral defects as in osteonecrosis create craters in the cartilage that need 'filling in' with a patch.
  • Various size lesions of cartilage defects can be accommodated by the implants provided herein which may have balloons of at least one of: at most about 0.5 cm in diameter, at most about 0.75 cm in diameter, at most about 1 cm in diameter, at most about 1.25 cm in diameter, at most about 1.5 cm in diameter, at most about 1.75 cm in diameter, at most about 2 cm in diameter, at most about 2.25 cm in diameter, at most about 2.5 cm in diameter, at most about 2.75 cm in diameter, at most about 3 cm in diameter, at most about 3.25 cm in diameter, at most about 3.5 cm in diameter, at most about 3.75 cm in diameter, at most about 0.5 cm in length along the longest length of the balloon, at most about 0.75 cm in length along the longest length of the balloon, at most about 1 cm in length along the longest length of the balloon, at most about 1.25
  • an implant configured to patch osteochondral defects.
  • the defects may occur due to injury, stress, naturally occurring, and/or may created or enhanced by a medical professional during a medical procedure.
  • the implant may be called a patch having the balloon and an attachment element (or elements-which may be called appendages) described herein and may be sized to fit within a defect in a manhole-cover type manner.
  • the implant may comprise balloon and attachment elements described elsewhere herein and may be configured to lay over a defect (full defect or partial defect).
  • the implant as described herein as used to patch or repair osteochondral defects may be called a patch or a patch implant.
  • the size of the balloon dimensions are prechosen based on the individual patient need, and the balloon size (dimensions, geometry, length, depth, for non-limiting examples) is pre-set.
  • the balloon comprises multiple chambers which may be inflated (or deflated) selectively to fill the defect in situ or just prior to implantation in order to adjust the implant's balloon size (dimensions, length, width, depth, geometry, for non-limiting example) as needed at the time of implantation.
  • the balloon (or any chamber thereof) of some examples can be secondarily inflated or deflated (or both) in situ.
  • Figures 11A, 11B , and/or 11C may be used to describe a patch implant described herein, having appendages 4a, 4c, extending from a balloon 6 (not shown in Figure 11A ) and including holes 8a-8h, and/or tabs 10a-10f which may be used with couplers (not shown) to couple the implant to a bone of the knee joint (which may be the femur, the tibia, or the patella).
  • FIG. 11A, 11B , and/or 11C are common to both the unicompartment knee implant (discussed elsewhere herein) and the patch implant, although dimensions may differ as described herein.
  • Figures 11A, 11B , and/or 11C may be used to describe the unicompartment knee implant and/or the patch implant.
  • Figure 11A depicts an example of the patch implant 2 curved to simulate curvature about one condyle of a femur, the implant 2 having appendages 4a, 4c, extending from an uninflated balloon (not shown) and including tabs 10a-10f and/or holes 8a-8h, which may be used with couplers (not shown, described elsewhere herein) to couple the implant 2 to the femur of the knee joint.
  • Figure 11B depicts an example of the patch implant 2 curved to simulate curvature about one condyle of a femur, the implant 2 having appendages 4a, 4c, extending from an inflated balloon 6 and including tabs 10a-10f and/or holes 8a-8h, which may be used with couplers (not shown, described elsewhere herein) to couple the implant 2 to the femur of the knee joint.
  • Figure 11A and 11B show the appearance of a compliant solid material for unicompartmental implantation.
  • Figure 11C depicts a bottom-up of gliding surface view of an example of the patch implant 2 curved to simulate curvature about one condyle of a femur, the implant 2 having appendages 4a, 4c, extending from an inflated balloon 6 or a padded central area of the implant and including tabs 10a-10f and/or holes 8a-8h, which may be used with couplers (not shown, described elsewhere herein) to couple the implant 2 to the femur of the knee joint.
  • the implant is configured to couple to a tibia.
  • the implant is configured to couple to a trochlear groove of a femur.
  • the implant is configured to couple to only a portion of a condyle of a femur.
  • Figures 12A, 12B , and/or 12C may be used to describe a patch implant described herein, having appendages 4a, 4c, extending from a balloon 6 and including holes 8a, 8b, 8c prefabricated into an uninflated area, and/or tabs 10a, 10b. 10c, 10d, 10e, 10f which may be used with couplers (not shown) to couple the implant to a bone of the knee joint (which may be the femur, the tibia, or the patella).
  • couplers not shown
  • FIG. 12A, 12B , and/or 12C are common to both the unicompartment knee implant (discussed elsewhere herein) and the patch implant, although dimensions may differ as described herein.
  • Figures 12A, 12B , and/or 12C may be used to describe the unicompartment knee implant and/or the patch implant.
  • Figure 12A depicts a bottom-up view of an example of the implant 2 (unicompartment or patch), the implant having appendages 4a, 4c, extending from a balloon 6 and including holes 8a, 8b, 8c, which may be used with couplers (not shown) to couple the implant 2 to the femur of the knee joint.
  • Figure 12B depicts a bottom-up view of an example of the implant 2 (unicompartment or patch), the implant having appendages 4a, 4c, extending from a balloon 6 and including tabs 10a, 10b and hole 8a which may be used with couplers (not shown) to couple the implant to the femur of the knee joint.
  • Figure 12C depicts a bottom-up view of an embodiment of the implant 2 (unicompartment or patch), the implant having appendages 4a, 4c, extending from a balloon 6 or padded weight bearing region of the implant and including tabs 10c, 10d, 10e, and 10f and hole 8a which may be used with couplers (not shown) to couple the implant to the femur of the knee joint.
  • the implant is configured to couple to a tibia. In some embodiments, the implant is configured to couple to a trochlear groove of a femur. In some examples, the implant is configured to couple to only a portion of a condyle of a femur. In some examples the implant is coupled to the patella.
  • the balloon 6 may extend from one surface of the implant as a focal protuberance to fill a defect, space, or to aide in alignment correct, or the balloon may be full thickness as differences in Figures 2 and 3 show respectively. In any example there may be a singular or multiple major balloons, if off a primary surface resembling bubble wrap, and there may be microscopic balloons or vacuoles containing gas, gel, or solid in the material matrix.
  • the implant may instead be configured to couple to the tibia or to the fibula or the patella. It is the intention and understanding that the implant is suited for this purpose in certain examples with adjustments to account for dimensional differences of these bones. Most descriptions provided herein are directed to embodiments coupling the implant to the femur, however, this is primarily for ease of description and continuity, and does not preclude examples wherein the implant is coupled to the tibia (or other bones). Likewise, as noted elsewhere herein, there are examples where the implant may be coupled to two bones (at least), for example to both a tibia and a femur.
  • an implant for placement on at least one condyle of the distal femur (a unicompartment implant-- named so due to their coverage of a single condyle of the femur).
  • the implant may be configured to be placed over the lateral condyle.
  • the implant may be configured to be placed over the medial condyle.
  • the implant may be configured to be placed over either the medial condyle or the lateral condyle.
  • Two unicompartment implants may be placed in the same knee, one over the medial condyle, one over the lateral condyle.
  • Figures 11A- 12C depict example examples of unicompartment implants.
  • the unicompartment implant comprises a balloon that is at least one of: at most about 1.5 cm in diameter, at most about 1.75 cm in diameter, at most about 2 cm in diameter, at most about 2.25 cm in diameter, at most about 2.5 cm in diameter, at most about 2.75 cm in diameter, at most about 3 cm in diameter, at most about 3.25 cm in diameter, at most about 3.5 cm in diameter, at most about 3.75 cm in diameter, at most about 4 cm in diameter, at most about 4.25 cm in diameter, at most about 4.5 cm in diameter, at most about 4.75 cm in diameter, at most about 5 cm in diameter, at most about 5.25 cm in diameter, at most about 5.5 cm in diameter, at most about 5.75 cm in diameter, at most about 6 cm in diameter, at most about 6.25 cm in diameter, at most about 6.5 cm in diameter, at most about 6.75 cm in diameter, at most about 7 cm in diameter, at most about 7.25 cm in diameter, at most about 7.5 cm in
  • the implant comprises attachment tabs or attachment elements over the anterior and/or posterior and/or medial side, and/or lateral side (and/or some combination thereof) of a condyle.
  • the implant comprises attachment tabs or attachment elements in the intercondylar notch.
  • the implant comprises attachment tabs or attachment elements superiorly at the distal end of the femur anteriorly.
  • the implant comprises strings, reigns, lassos, and/or lanyards that may pass from the posterior of the implant via the intercondylar notch anteriorly to join with themselves and/or other coupling devices.
  • posterior reigns or suture-like lanyards cinch up the implant from inside the posterior intercondylar notch toward another connection site around the femur.
  • couplers may be pre-coupled to the implant, and the implant and its couplers may be configured to be pulled (or cinched) from the anterior of the implant once the implant is in its general location relative to the condyle in order to finally position the implant about the eondyle-in particular in order to cinch the implant about the posterior of the condyle.
  • the coupler as described are adapted to move the implant to its final position with conformity to the condyle's posterior with minimal disturbance to the joint structures at the joint's posterior (minimal cutting, minimal moving, and or minimal detachment, for non-limiting example).
  • at least a portion of the ligamentary structure of the knee is spared.
  • Figure 10A depicts a side view of an example of the knee implant 20 curved about at least one condyle 22 of a femur 24, the implant 20 having appendages 4b, 4d extending from an inflated balloon 6 and showing the inflation medium 46 moved anteriorly toward he patella 40 when the knee joint is slightly flexed.
  • Figure 10B depicts a side view of an example of the knee implant 20 curved about at least one condyle 22 of a femur 24, the implant 20 having appendages 4b, 4d extending from an inflated balloon 6 and having couplers 44a, 44b (which may be, for non-limiting example, staples or screws, pins or snaps) coupling the appendages 4b, 4d to the femur 24 and showing the inflation medium 46 moved anteriorly toward the patella 40 when the knee joint is slightly flexed.
  • couplers 44a, 44b which may be, for non-limiting example, staples or screws, pins or snaps
  • Figures 11A, 11B , and/or 11C may be used to describe a unicompartment implant 2 (or unicompartment knee implant, terms which may be used interchangeably) described herein, having appendages 4a, 4c, extending from a balloon 6 (not shown in Figure 11 A) and including holes 8a-8h, and/or tabs 10a-10f which may be used with couplers (not shown) to couple the implant to a bone of the knee joint (which may be the femur, the tibia, or the patella).
  • FIG. 11A, 11B , and/or 11C are common to both the unicompartment knee implant and the patch implant (discussed elsewhere herein), although dimensions may differ as described herein.
  • Figures 11A, 11B , and/or 11C may be used to describe the unicompartment knee implant and/or the patch implant.
  • Figure 11A depicts an example of the unicompartment knee implant 2 curved to simulate curvature about one condyle of a femur, the implant 2 having appendages 4a, 4c, extending from an uninflated balloon (not shown) and including tabs 10a-10f and/or holes 8a-8h, which may be used with couplers (not shown, described elsewhere herein) to couple the implant 2 to the femur of the knee joint.
  • Figure 11B depicts an example of the unicompartment knee implant 2 curved to simulate curvature about one condyle of a femur, the implant having appendages 4a, 4c, extending from an inflated balloon 6 and including tabs 10a-10f and/or holes 8a-8h, which may be used with couplers (not shown, described elsewhere herein) to couple the implant 2 to the femur of the knee joint.
  • Figure 11C depicts a bottom-up view of an example of the unicompartment knee implant 2 curved to simulate curvature about one condyle of a femur, the implant 2 having appendages 4a, 4c, extending from an inflated balloon 6 and including tabs 10a-10f and/or holes 8a-8h, which may be used with couplers (not shown, described elsewhere herein) to couple the implant 2 to the femur of the knee joint.
  • the unicompartment implant including attachment tabs is at least one of: at most about 15 cm in length along the longest length of the implant, at most about 15.25 cm in length along the longest length of the implant, at most about 15.5 cm in length along the longest length of the implant, at most about 15.75 cm in length along the longest length of the implant, at most about 16 cm in length along the longest length of the implant, at most about 16.25 cm in length along the longest length of the implant, at most about 16.5 cm in length along the longest length of the implant, at most about 16.75 cm in length along the longest length of the implant, at most about 17 cm in length along the longest length of the implant, at most about 17.25 cm in length along the longest length of the implant, at most about 17.5 cm in length along the longest length of the implant, at most about 17.75 cm in length along the longest length of the implant, at most about 18 cm in length along the longest length of the implant, 18.25 cm in length along the longest length of the implant, at most about 18.5 cm in length along the longest length of the implant, at least one of
  • the unicompartment implant is longer than it is wide, and the longer portion of the implant wraps from the anterior of the condyle to the posterior of the condyle.
  • the length of the implant is longer on the outer edge of the implant than on the inner edge nearest the trochlear groove (whether used on the lateral or medial condyle).
  • the trochlear groove per se rather than either the medial or lateral compartment is reconstructed with the implant anatomically to oppose the undersurface of the patella.
  • Figures 12A, 12B , and/or 12C may be used to describe a unicompartment knee implant (unicompartment implant) described herein, having appendages 4a, 4c, extending from a balloon 6 and including holes 8a, 8b, 8c, and/or tabs 10a, 10b. 10c, 10d, 10e, 10f which may be used with couplers (not shown) to couple the implant to a bone of the knee joint (which may be the femur, the tibia, or the patella).
  • couplers not shown
  • FIG. 12A, 12B , and/or 12C are common to both the unicompartment knee implant and the patch implant (discussed elsewhere herein), although dimensions may differ as described herein.
  • Figures 12A, 12B , and/or 12C may be used to describe the unicompartment knee implant and/or the patch implant.
  • Figure 12A depicts a bottom-up view of an embodiment of the implant 2 (unicompartment or patch), the implant having appendages 4a, 4c, extending from a balloon 6 and including holes 8a, 8b, 8c, which may be used with couplers (not shown) to couple the implant 2 to the femur of the knee joint.
  • Figure 12B depicts a bottom-up view of an example of the implant 2 (unicompartment or patch), the implant having appendages 4a, 4c, extending from a balloon 6 and including tabs 10a, 10b and hole 8a which may be used with couplers (not shown) to couple the implant to the femur of the knee joint.
  • Figure 12C depicts a bottom-up view of an example of the implant 2 (unicompartment or patch), the implant having appendages 4a, 4c, extending from a balloon 6 and including tabs 10c, 10d, 10e, and 10f and hole 8a which may be used with couplers (not shown) to couple the implant to the femur of the knee joint.
  • the implant may instead be configured to couple to the tibia or to the fibula or the patella. It is the intention and understanding that the implant is suited for this purpose in certain examples with adjustments to account for dimensional differences of the particular bones. Most descriptions provided herein are directed to examples coupling the implant to the femur, however, this is primarily for ease of description and continuity, and does not preclude examples wherein the implant is coupled to the tibia (or other bones). Likewise, as noted elsewhere herein, there are examples where the implant may be coupled to two bones (at least), for example to both a tibia and a femur.
  • an implant having a balloon having a first and second chamber may be any of the Dual Compartment, Unicompartment, and Patch implants described herein.
  • the second chamber may be configured to replace and/or partially replace fibrocartilage meniscal loss.
  • the implant may have two lobes of chambers which may be alternatively described as two superimposed balloon radii in apposition to each other.
  • the implant may be configured to provide stability between the femur and tibia by providing a meniscus wedge.
  • the implant comprises a portion configured to replace and/or partially replace fibrocartilage meniscal loss. Such an example may not require a second chamber.
  • a chamber of the implant is configured to receive a solid piece configured to restore joint and/or bone alignment.
  • the chamber is configured to receive a plurality of solid pieces, each of which can be used to increase the space between a first bone and a second bone in order to restore and/or improve joint and/or bone alignment.
  • the solid pieces may be wedge-shaped, or be provided in various sizes and/or shapes.
  • the solid pieces may individually or together be used in a chamber or multiple chambers of the implant.
  • the solid piece (or pieces) may be used to ratchet adjacent bones to a desired distraction and/or alignment to restore and/or improve joint and/or bone alignment.
  • the solid piece may be put in a chamber of the implant, which may enclose or partially enclose the piece to hold the piece in place.
  • a block of biocompatible material such as PMMA or another bone-like substitute
  • the formed piece may then be put in a chamber of the implant, which may enclose or partially enclose the piece to hold the piece in place.
  • the inflation medium is a methyl methacrylate or other biocompatible hardening substance which can flow when initially put into the chamber, and hardens to become a rigid piece (or solid piece).
  • the methyl methacrylate or other biocompatible hardening substance may conform to the shape of the chamber, or may conform to the shape of a space between bones and/or other joint structures.
  • the methyl methacrylate or other biocompatible hardening substance may conform to a form chosen by the surgeon using tools and/or pressure to influence the final shape of the rigid piece formed by the methyl methacrylate or other biocompatible hardening substance upon hardening.
  • the solid piece (whether formed in situ or by a surgeon or pre-formed) may be cushioned by the implant.
  • the implant may comprise an inflatable chamber between the solid piece and the first bone.
  • the first bone is a femur.
  • the implant may comprise an inflatable chamber between the solid piece and the tibia.
  • the implant may comprise an inflatable chamber between the solid piece and the patella.
  • the implant may comprise an inflatable chamber between the solid piece and the second bone.
  • the implant may comprise a pad between the solid piece and the first bone as a cushion.
  • the first bone is a femur.
  • the implant may comprise a pad between the solid piece and the second bone as a cushion.
  • the second bone is a tibia.
  • the second bone is a patella.
  • the solid piece may provide at least one of about 1 degree of joint correction, about 2 degrees of joint correction, about 3 degrees of joint correction, about 4 degrees of joint correction, about 5 degrees of joint correction, about 6 degrees of joint correction, about 7 degrees of joint correction, about 8 degrees of joint correction, about 9 degrees of joint correction, and about 10 degrees of joint correction.
  • degrees of joint correction the term “about” can mean ranges of 1%, 5%, 10%, 25%, or 50%.
  • the implant can be used in a variety of joints where the implant replaces a bone on bone surface and cushions the interaction between the articular ends of any two bones, such as at the femoral tibial and patella femoral knee interfaces.
  • the implant can be used in a variety of joints where the implant replaces a bone on bone surface and cushions the interaction between the articular ends of any two bones, such as at the femoral-acetabular interspace of a patient's hip, the humerus and glenoid scapular component in the shoulder, the replacement of talus bone in the human ankle between the tibia and calcaneus and the like.
  • the rigidity can be reduced or enhanced to maximize conformation changes that arise during motion as enabled by the two opposing walls and intended inner space, coupled with considerations in any joint surgical reconstruction with accommodation to or amplification of the existing joint ligaments, tendons or dearth thereof.
  • the implant 10 may be deflated and removed by minimally invasive surgery, for example, after the implant has served its purpose of regenerating tissue or if another clinical condition warrants its removal. However, it may not be clinically necessary to remove the implant even if inflation is lost, since the two remaining functions of patching the injured cartilage, and delivering restorative cells may justify implant retention.
  • the implant (or a portion thereof, such as the balloon or balloon) is a weight bearing spacer that allows joint motions to approach normal, whether filling the space left by an entirely collapsed peripheral joint bone or the space of ablated cartilage proximate surfaces diffusely as in osteoarthritis or succinctly as in osteonecrotic defects or localized trauma.
  • the walls may be used as a membrane for holding living cells in proximity of the osteochondral defect long enough for the cells to attach (e.g. 24 hours) or to deeply adhere (up to 28 days) or return to normal (up to one year).
  • Weight bearing may be expected to increase as distal lower extremity joints are treated.
  • Shoulder subacromical bursa may be a target joint for an implant as described herein.
  • Rotator cuff tears may be addressed using an implant as described herein-as adjusted for the particular features, loading profile, and geometries of the joint.
  • 85% of octagenians have massive rotator cuff tears and often less than half normal upper extremity abduction and flexion capabilities. There may not be sufficient remnant supraspinatus and other rotator cuff tissues to pull together. Then the humeral head rides up, in a cephalad direction, rubbing the superior bone surface on a frequently spurred and downward sloping acromion.
  • a subacromial implant as described herein were implanted beneath the lateral (arthroscopically decompressed and prepared) acromion, the pain of bone on bone could be reduced, and the structural anatomy between the ball and socket (humeral head and glenoid fossa) could be improved.
  • a shoulder implant could cover the humeral head analogous to the hip redundant membrane wherein that membrane replaces a normal subacromial bursa.
  • a singular bladder beneath the acromion per se could pad the ball beneath it. For virtually every joint in the body (arms and legs, at least) there are similar potential implant uses.
  • the distal femur of the knee, and the distal humerus of the elbow are regions that interface each with two opposite joints. That is, an implant for the knee as designed with polymer capping of the femoral condyles and trochlear groove to provide cushioning of the femorotibial and patellafemoral joints.
  • an implant for the knee as designed with polymer capping of the femoral condyles and trochlear groove to provide cushioning of the femorotibial and patellafemoral joints.
  • the distal coverage enables padding restoration of the humeral-olecranon as well as the radio-capitellar (part of the humerus) joint interfaces.
  • the implant may cover the main or primary joint surface of the surgeon's choice contributing to arthritis, consequently reducing symptoms when treated, another alternative would be that the implant can cover any singular surface entirely or partially.
  • the implant may cover one surface allowing remnant cartilages in other usually opposing or opposite surfaces to glide against the implant polymer with smooth gliding joint motion.
  • This principle allows for retained joint linings or synovium to produce lubricating substances including enzymes for facile joint movement. It also avoids the wear debris that would accrue from polymer rubbing on polymer, as recently recognized in metal on metal prostheses.
  • the implant can cover more than one surface in a joint, such as the radiocapitallar joint wherein the distal humerus and the radial head receive prosthetic capping or interpositional application of polymers.
  • the surgical techniques may be individualized to fit patient need.
  • the implants may be combined with or comprise autologous or allograph tissues such as fascia lata. Surgeons may implant fascia lata above unreconstructable rotator cuff with consequent symptom relief.
  • Polymers can interface with any human tissue and/or with metals or polyethylenes or polyurethanes.
  • Living tissues that can be combined with implants provided herein for repair or reconstruction may be from the same patient (autograph), and cadaver or other member of the same species (allograph) or from another species (xenograph.)
  • Virtually any combination of polymer interpositioning is feasible with the implant concepts provided herein, as anatomy varies among patients in need, and clinical conditions differ with each person. Therefore, although the general or most common construct is expected to cover just one singular and the primary surface of a joint with an implant, any combination of surfaces can be involved allowing versatile custom applications of this implant and method of surgery.
  • implants as noted herein may be available in specified sizes, the material membrane elastic deformation and resilience may allow for calculated malleability toward goodness of fit.
  • the fit of implant over the affected joint surface is customized as paring preoperative findings of MRI or CT or PET imaging pathophysiology with intraoperative reconstructive need.
  • best fit implants may serve patient restorative requirement with least morbidity.
  • the shoulder mainly the glenohumeral joint, though as discussed above the subacromial space are useful loci for renewed padding when pathophysiologies warrant.
  • a Mumford procedure (resection of the distal clavicle) can be avoided by inserted an implant as described herein. Even the TMJ in the jaw may be amenable to therapy using the implants noted herein. Proceeding distally in the arm, the elbow has two relevant joints mentioned earlier, radiocapitellar and ulnohumeral.
  • the padding should be restored toward normal.
  • Wrist, thumb and finger joints are many and may respond to vesicular implants with better durometry and vicsolubricant delivery than tradition metal or silicon prostheses.
  • Legs started at the hip joint have been shown via Hip implant prototypes to be amenable to polymer capping. Variations per surgeon's choice could evoke special uses as for coverage of trochanteric bursae.
  • the many functions of the implants noted herein may be coupled with cosmetic aspects in order to restore bulk and soft tissue balance after scarring, injury or atrophy, or for purely cosmetic purposes.
  • Treatment for cosmesis especially when coupled with functional or visual injury deficits can provide a reduction in physiological as well as physical pain and discomfort. Therefore the extent minimally invasive implants restore the injured or diseased patient recipient to become hole, they are being used purposefully and as intended.
  • the knee joint is an initial focus of the figures wherein application to the largest bone (the distal femur) accommodates padding needs for the opposing patella and tibia.
  • the potential use of implants, however, over the contralateral surfaces is an option that should not be ruled out.
  • the supratalar, or tibia talar joint will be a useful location as may the subtalar area, depending on pathology present. Indications for use may depend on the patients symptoms, from the history and physical exam, based on studies such as roentgenograms, MRI or CT imaging, and may depend on test result from localized injections. For example, if a talus fracture pain were alleviated by sinus tarsi injection then implant insertion into the subtalar joint would be preferred.
  • the talonavicular and other foot/toe joints are all amenable to renewed padding via an implant noted herein..
  • Pets, or other animals may be served better by polymer joint capping than hip replacement for congenital dysplasia.
  • the successful treatment and rehabilitation of animals can favorably affect the implant recipient and animal's owner, as pets can provide functions necessary for activities of daily living (as a horse helping to plow a field) or an animal relieved of pain from injury or arthritis can also be a comfort to its owner.
  • kits comprising multiple implants described herein.
  • a kit may comprise multiple sizes of a single type of implant.
  • a kit may comprise various implant types, such as the patch, the unicompartment, and/or the dual compartment types of implants described herein.
  • a kit may comprise various couplers, which may be selected by the surgeon depending on his comfort and expertise, and/or based on the particular patient anatomy and/or needs.
  • the kit may further comprise any insertion tools and/or surgery tools that may uniquely assist in implanting the implant in the patient.
  • kits involving reparative implants, and insertional tools there may also be included software for translation of pre-injury data and/or postoperative data collection and analysis, as well as custom implants may be provided.
  • Implantation of implants may depend on the size of joint surface intended for reconstruction by use of the implant. This may be based upon the nature and extent of injury, and upon the expectations of the patient and surgeon.
  • an arthroscope can be inserted in one side of the knee joint through a 0.5 cm wound, while the implant is inserted into the opposite joint line wound from 1 -10 cm in size.
  • the joint may be first inspected and debrided, performing an arthroscopic synovectomy, chondroplasty, and meniscectomy as needed. Additional distraction under general anesthesia with the knee at variable degrees of flex may allow for implant introduction, systematic peripheral attachment, balancing, and inflation, if warranted.
  • the implant may be selectively inflatable depending on the particular needs of the patient.
  • the filler of the interior of the implant may be rigid, semi-rigid, fluid, air, or combinations thereof, as described herein.
  • the implant may be used in conjunction with fibrocartilage repair or replacement.
  • the implant may be used without fibrocartilage repair or replacement.
  • the implant may be used in conjunction with boney osteotomy. In some examples, the implant may be used without boney osteotomy.
  • the method comprises providing an implant comprising strings, reigns, lassos, and/or lanyards that may pass from the posterior of the implant via the intercondylar notch anteriorly to join with themselves and/or other coupling devices.
  • posterior reigns or suture-like lanyards cinch up the implant from inside the posterior intercondylar notch toward another connection site around the femur.
  • the methods comprise conforming the implant posterior to the condyle by pulling the strings (or reigns, or lassos, or lanyards or the like) of the implant.
  • Such couplers strings, reigns, lassos, lanyards, etc
  • couplers i.e. strings, reigns, lassos, lanyards, etc
  • the implant and its couplers may be configured to be pulled (or cinched) from the anterior of the implant once the implant is in its general location relative to the condyle in order to finally position the implant about the condyle-in particular in order to cinch the implant about the posterior of the condyle.
  • the coupler as described are adapted to move the implant to its final position with conformity to the condyle's posterior with minimal disturbance to the joint structures at the joint's posterior (minimal cutting, minimal moving, and or minimal detachment, for non-limiting example).
  • at least a portion of the ligamentary structure of the knee is spared.
  • the implant is inserted arthroscopically through a cannula about 10 mm in diameter with the implant in the deflated construct, and once inside the prepared joint space and secured therein by the skirt or tabs, the implant is distended or inflated with gas, gel, fluid or fluid that becomes a resilient solid to fill the original natural space of about 0.5 cm between the bones of the joint (between at least two bones of the joint). If the implant is not inserted through a cannula, it may be inserted through an open incision from one to forty centimeters in length at the surgeon's discretion.
  • Tensioning may be by the surgeon's sense of proper pressure application aided by a gauged syringe for insertion of viscolubricants such as Synvisc, Hyalgan, Supartz and/or analgesics such as lidocaine gel.
  • the insertion of liquids to the joint per se may be directly, through a cannula to the joint space previously in place for debridement, and or via a cannula or tube that is not part of the original implant assembly.
  • the implant is inserted and appropriately fixed to avoid extrusion or dislocation thereof. This may be via attachment of the implant tabs and/or by a combination of tab use plus intended friction created by implant surface coverings (analogous to Velcro) or a draw string at the smaller base of the implant.
  • attachment tabs are positioned on the implant to both secure the implant to the joint components, and to enable a physician to ensure the implant has a minimum amount of slack that could create wrinkles or loose areas to avoid unnecessary friction and/or wear of the implant of the patient's anatomy.
  • Figures depicted herein show examples of properly situated attachment tabs configured for these dual purposes. In some examples, fewer tabs are needed to achieve these goals.
  • the balloon under compression may fill such areas.
  • the implant in some examples is configured to allow hyaline and/or cartilage cells to fill any irregularities or craters in the joint components and grow to refurbish natural joint contour.
  • cell growth may create renewed hyaline cartilage, and/or blood/fibrin and scar to create fibrocartilage filler material.
  • Each attachment tab insert site may be clinically determined centripitally around the implant during surgery, driving slots or holes sequentially with an osteotome or drill immediately followed by insertion of the triangled tab extension into the bone slots or screw respectively.
  • the implant were viewed like a clockface the first tab could be tacked/tapped in a 2 o'clock, then 7, 10, 4, 11,5, 12, 6 (wherein # 2, 7, 10, 4 are over the bilateral femurs superior/inferior to collateral ligaments, 11, 12 are superior at the distal anterior femur beneath the upper patella, and 5, 6 are inside the intercondylar notch anterior to cruciates).
  • the metal clips could be set angled at about 120 degrees, as greater than 90 can favorably distract/hold the implant to tighter fit analogous to a mylar compliant balloon or stretch sock fitting over a protuberance as opposed to a piece of (non-compliant) paper that results is wrinkles and areas of incongruence between the implant and bone end. Reducing dislodgement tendency and snugging the polymer once stretched to best fit may avoid the failure history as illustrated in the Danish Polymer hip cap solid crescent shaped hip resurfacing implants which lacked inflation, surface stability, accommodation, and fixation.
  • Inflation may also be specified by clinical need, and modifications in the implant multi-cell (multi-compartment) construction allows for selective inflation with substances ranging from gas to solid, including gels or semi-solids that can as part of material layered integrity either provide calculated hardness (durometer) to overcome and resist limb adjacent bone mal-alignment, and/or to deliver new regenerative tissues for restoration of natural anatomy of time. That is, certain sections of the implant may be electively inflated of left without expansion, to adjust to fit as matching a normal or uninjured contralateral limb for the involved patient.
  • substances ranging from gas to solid including gels or semi-solids that can as part of material layered integrity either provide calculated hardness (durometer) to overcome and resist limb adjacent bone mal-alignment, and/or to deliver new regenerative tissues for restoration of natural anatomy of time. That is, certain sections of the implant may be electively inflated of left without expansion, to adjust to fit as matching a normal or uninjured contralateral limb for the involved patient.
  • a goal of embodiments of implants described herein is to maintain remnant living tissue by using minimally invasive technologies, smaller incisions when they serve the patient equally to larger, sacrificing the least normal tissue as possible.
  • Implants described herein assist and improve on current treatment options available by avoiding as much as possible the ablative bone and cartilage resecting, ligament removing total knee arthroplasty and instead to restore the padding lost in injury or disease or surgery.
  • Examples from within the techniques include electing to repair rather than reconstruct anterior cruciate ligaments in certain situations, proved warranted and effective at a p ⁇ 0.3 statistical level. Whereas Carticel chondrocyte implantation is useful to enable articular surface regrowth with hyaline, rather than scar/fibrocartilage from picking/drilling, the massive morbidity from periosteal harvesting is unnecessary.
  • the amount of weight bearing allowed may be analogous to the procedures written by this primary surgery for Carticel implanted cases, following the principles that excessive amounts and repetitions of stress upon reconstructed areas should be avoided for 6-12 weeks after surgery.
  • the knee implant surgeries per se are expected to take less than one hour, involve less than 1 cc blood loss, require wounds less than or equal to 10 cm overall (depending on the embodiment of the implant), and the end result intends to permit early full weight bearing.
  • Zealous sports activities may be restricted until the bone in-growth and cartilage renewal is reasonably expected, between 2 and 12 months after surgery depending upon the amount of joint tissue replaced.
  • the removal of the implant may be needed, and embodiments of the implants described herein are configured for removal arthroscopically, and with the allowance to perform all regular older routine accepted techniques ranging from joint debridement to drilling, partial or total replacement.
  • the implant is configured for removal and replacement with a replacement implant-either immediately (within a week), or after a period of longer time (for example, after about 6 weeks to 1 year in the case of infection once all foreign bodies are removed and depending upon the surgeon's and/or infectious disease consultant's opinion
  • the implant is inserted by minimally invasive surgery, in some embodiments; however, in other embodiments, the implant may not be inserted minimally invasive surgery.
  • the implant is delivered through an incision that is about 12,7mm (0.5 inches) long. In some embodiments, the implant is delivered through an incision that is about 1 centimeter long. In some embodiments, the implant is delivered through an incision that is at most about 25,4mm (1 inch) long. In some embodiments, the implant is delivered non-arthroscopically through an incision that is at least 1 centimeter long. In some embodiments, the implant is delivered through an incision that is at most about 19,0mm (0.75 inches) long.
  • the implant is delivered through an incision that is at most about 12,7mm (0.5 inches) long. In some embodiments, the implant is delivered through an incision that is about 8 centimeters long. In some embodiments, the implant is delivered through an incision that is about 9 centimeters long. In some embodiments, the implant is delivered through an incision that is about 10 centimeters long. In some embodiments, the implant is delivered through an incision that is about 11 centimeters long. In some embodiments, the implant is delivered through an incision that is about 12 centimeters long. In some embodiments, the implant is delivered through an incision that is over about 10 centimeters long. In some embodiments, the implant is delivered through an incision that is at up to about 40 centimeters long.
  • the implant is delivered through multiple incisions. In some embodiments, the implant is delivered non-arthroscopically. In other embodiments, the implant is delivered arthroscopically. With respect to incision length, the term "about” can mean ranges of 1%, 5%, 10%, 25%, or 50%.
  • the implant is configured to be delivered to the joint arthroscopically. In some embodiments, the implant is configured to fit within a cannula having a distal end inner diameter of at most about 10 millimeters. In some embodiments, the implant is configured to fit within a cannula having a distal end inner diameter of at most about 9 millimeters. In some embodiments, the implant is configured to fit within a cannula having a distal end inner diameter of at most about 5 millimeters. With respect to cannula distal end inner diameter, the term "about” can mean ranges of 1%, 5%, 10%, 25%, or 50%.
  • the implant is configured to fold in order to fit within a cannula having a distal end inner diameter of at most about 10 millimeters. In some embodiments, the implant is configured to fold in order to fit within a cannula having a distal end inner diameter of at most about 9 millimeters. In some embodiments, the implant is configured to fold in order to fit within a cannula having a distal end inner diameter of at most about 5 millimeters. With respect to cannula distal end inner diameter, the term "about” can mean ranges of 1%, 5%, 10%, 25%, or 50%.
  • the implant is configured to be delivered to a joint through a cannula having a distal end inner diameter of at most about 10 millimeters. In some embodiments, the implant is configured to be delivered to a joint through a cannula having a distal end inner diameter of at most about 9 millimeters. In some embodiments, the implant is configured to be delivered to a joint through a cannula having a distal end inner diameter of at most about 5 millimeters. With respect to cannula distal end inner diameter, the term "about” can mean ranges of 1%, 5%, 10%, 25%, or 50%.
  • the implant may be provided as a deflated balloon for insertion into the joint space.
  • the implant may be provided as folded balloon that may be collapsed like an umbrella for insertion into the joint space.
  • the implant may be provided as collapsed balloon that is of an irregular folded pattern to minimize its folded (or collapsed) size for insertion into the joint space.
  • the implant is configured to blow up (or expand) to take the form of the expanded, distracted, debrided joint.
  • the implant replaces periosteum.
  • the implant is implanted to preserve bone as compared to a typical arthroplasty procedure of the joint. In some embodiments, the implant is implanted to preserve cartilage as compared to a typical arthroplasty procedure of the joint. In some embodiments, the implant is implanted with minimal soft tissue dissection as compared to a typical arthroplasty procedure of the joint. In some embodiments, the implant is implanted without joint dislocation. In some embodiments, once implanted, the joint is adaptable to revision surgery.
  • the joint retains at least one of: about 90% of normal joint function, about 95% of normal joint function, about 85% of normal joint function, about 80% of normal joint function, about 75% of normal joint function, about 70% of normal joint function, about 65% of normal joint function, about 60% of normal joint function, about 55% of normal joint function, about 50% of normal joint function, at least 95% of normal joint function, at least 90% of normal joint function, at least 85% of normal joint function, at least 80% of normal joint function, at least 75% of normal joint function, at least 70% of normal joint function, at least 65% of normal joint function, at least 60% of normal joint function, at least 55% of normal joint function, at least 50% of normal joint function, about 50%- about 75% of normal joint function, about 50%- about 70% of normal joint function, about 60- about 70% of normal joint function, about 70%- about 80% of normal joint function, about 70%- about 90% of normal joint function, about 80%- about 95% of normal joint function, about 80%- about 90% of normal joint function,
  • an upper portion of the implant has a first wall, a second wall and a side wall which define at least in part the interior.
  • a skirt depends from the first wall and secures the first wall to the end of the patient's femur.
  • An upper portion may be configured to engage the corresponding acetabulum of the patient's pelvic bone.
  • the skirt surrounds the head of the patient's femur and secures the implant thereto.
  • the upper portion of the implant creates overlapping layers, like a redundant membrane, in the side wall between the first and second walls and to accommodate the normal movement of the first or second. This provides greater motion between the femur and the acetabulum and also provides implant stabilization over the head of the femur. This structure also accommodates variation in individual joints that occur from patient to patient.
  • the first wall does not extend across the entire end of the patient's femur.
  • the implant may be designed so that first wall may extend over the head of the femur.
  • the second wall and the side wall tend to roll as the femur moves within the acetabulum.
  • the cartilage lining the joint is prepared by removing hyaline or fibro cartilage flaps or tears, and areas of chondral advanced fissuring are excised or debrided to create precisely defined defects surrounded by stable normal remnant hyaline cartilage with vertical edges in relation to the damaged surface. It is these defects of the cartilage previously normal surface into which new living cells may be injected or otherwise inserted, and allowed to aggregate by the implant interpositional arthroplasty proximate expanded compressive external wall material. Synovitis invading the joint periphery may be vaporized and extracted conventionally or by the use of steam.
  • Joint preparation is usually performed under a brief general anesthetic of outpatient surgery.
  • a muscle relaxant combined with traction e.g. 267N (60 pounds force) for a hip implant
  • traction e.g. 267N (60 pounds force) for a hip implant
  • traction e.g. 267N (60 pounds force) for a hip implant
  • Increasing the joint space may be necessary and allows the surgeon to wash out noxious enzymes, to remove invasive synovitis, to remove loose bodies, to prepare osteochondral defects ideally and otherwise prepare the joint for the implant.
  • Partial or complete inflation of the implant may precede release of traction in some embodiments.
  • regeneration agents or cells are inserted with the implant or as a fluid or 3-D template prior to release of traction and wound closure.
  • cell regeneration agent e.g. stem cell application
  • cell regeneration agent e.g. stem cell application
  • the intraoperative technologist may "dial in the cells" to regenerate areas of maximum pathophysiology while the surgeon debrides or otherwise prepares the joint and inserts the implant, placing the cells at the best time.
  • Cell implantation may also occur as a secondary or tertiary reconstructive treatment adjunct.
  • An example resilient implant may be deployed within a patient's hip structure comprising the head of the patient's femur and the acetabulum of the patient's pelvic hip bone.
  • the resilient implant embodying features of the invention is disposed within the space between the femur and the acetabulum.
  • the implant is shaped like a half an orange rind or a hemisphere for a hip joint.
  • the implant has a first wall which is secured to the head of the femur by a plurality of depending tabs (or appendages).
  • the tabs may be attached to the femur by a suitable adhesive or mechanically such as by a screw or pin or snap.
  • the second wall the implant engages the acetabulum, but it also may be provided with tabs and the like for securing the second wall the acetabulum.
  • the side wall extends between the first and second walls to form an interior which receives filling material through tube (also called a conduit herein, or may be called an inflation port).
  • tube also called a conduit herein, or may be called an inflation port.
  • the implant would also be appropriate for the humeral head in the shoulder or one condyle of the knee or of the humerus, but other shapes may be desired for other joint configurations whether relatively flat as in the thumb base, or more inflated toward a ballooning construct as in the ankle when the talus bone is collapsed.
  • the implant (or a portion thereof), is a weight bearing spacer that allows joint motions to approach normal, whether filling the space left by an entirely collapsed peripheral joint bone or the space of ablated cartilage proximate surfaces diffusely as in osteoarthritis or succinctly as in osteonecrotic defects or localized trauma.
  • the walls may be used as a membrane for holding living cells in proximity of the osteochondral defect long enough for the cells to attach (e.g. motion is believed to be primarily between the spaced walls (or portions) of the implant peripherally secured to joint structures, although some motion may occur between the implant and the joint surfaces (as with current bipolar hip hemiarthroplasties)).
  • the implant may be provided with a slot extending from the periphery of the implant to a centrally located passage through the implant to accommodate the ligament of the head of the femur for hip implants. Knee implants may have two slots leading to separate passages for receiving the anterior and posterior cruciate ligaments. Implants for other locations may have similar variable structures to accommodate anatomical features. Implant walls should have sufficient inherent flexibility to mold to the existing deformities imposed by either natural ligament, bone, tendon or remaining cartilage deformities of the internal joint space, and thus filled as a cushion. A separate portal or tube (not shown) or the existing conduit (tube or valve), may be used to extract noxious inflammatory enzymes that can be aspirated at appropriate clinical intervals. Viscolubricants can be injected into the interior of the resilient arthroplasty device through existing conduit or through a long needle to aide in distension, expansion, and/or lubrication (with predetermined microporosity).
  • the ankle version of the arthroplasty implant comprises a square transverse cross-section that must take into account supratalar ankle dorsi/plantar flexion, subtalar eversion/inversion motions, ligament fixation- needs, and the accommodation to existing bony architecture as implant variables accounting for the ipsilateral joint pathophysiology.
  • the implant has a first wall, a second wall and a side wall which extends between the first and second wall.
  • the exterior of the implant may have a mesh material with a plurality of chords (or appendages) for securing the implant to adjacent bones or to remnant ligaments which are attached to adjacent bones.
  • the implant may be inflated with gas and/or liquid to open wider the space between the tibia above and the calcaneus below to accommodate collapse of the talus bone as in the flattening which succeeds talus fracture with avascular necrosis, or it may be filled with a liquid that becomes a resilient solid.
  • the instant center of the implant's rotation will be constantly changing, with the talus implant mainly stable and with the tibia moving over it.
  • the axial load between the distal tibia through the talar implant to the dorsal calcaneus may be loaded during stance and especially while walking on a level plane for supratalar motion
  • the lateral forces may be loaded particularly with subtalar motion while walking on an uneven plane or with inversion/eversion.
  • the first inflation medium imparts rigidity in the implant. In some examples, the first inflation medium imparts cushion in the implant. In some examples, the inflation medium chosen for the first inflation medium, and/or the particular choice of chamber (in examples having multiple chambers) filled with such first inflation medium aligns the joint. In some examples, the inflation medium chosen for the first inflation medium, and/or the particular choice of chamber (in examples having multiple chambers) filled with such first inflation medium aligns the bones of the joint. In some examples, the inflation medium chosen for the first inflation medium, and/or the particular choice of chamber (in examples having multiple chambers) filled with such first inflation medium changes the bone alignment.
  • the inflation medium chosen for the first inflation medium, and/or the particular choice of chamber (in examples having multiple chambers) filled with such first inflation medium improves joint alignment. In some examples, the inflation medium chosen for the first inflation medium, and/or the particular choice of chamber (in examples having multiple chambers) filled with such first inflation medium restores, at least in part, joint alignment. In some examples, individual chambers of the interior are selectively inflated with a first inflation medium and/or a second inflation medium. In some examples, individual chambers of the interior are selectively inflated with a first inflation medium and/or a second inflation medium in order to reconstruct the joint and/or bones of the joint.
  • the interior comprises a honeycomb structure. In some examples, the interior comprises a mesh structure. In some examples, the interior comprises a sponge structure.
  • the dimensions of the various implant walls may vary depending upon the material properties thereof as well as the needs for a particular joint.
  • the spacing between the first and second wall within the interior can vary from about 0.5 mm to about 5 mm for most joints (except for the implant for an ankle when an entire collapsed bone space is being replaced), preferably about one to five centimeters to fill between the tibia and calcaneus.
  • the amount of inflation of the implant per se may be directly proportional to the amount of talus bone collapse between the distal tibia and proximal calcaneus - thus as much as 5 cm implant distension or expansion may be required to be maintained between superior and inferior surfaces of the talus, while as much as 10 cm anterior and posterior expansion may be required for the ankle implant between the posterior soft tissues such including the Achilles tendon and the anterior navicular bone as relates to the talus.
  • the method of insertion for the hip joint invention may be a minimally invasive approach, ideally arthroscopically facilitated, as long as the surgical timing and result quality permit smaller incisions.
  • the hip patient may be placed in the lateral decubitus position (lying non-operative side down on the operating table) with a stabilizing operating table pole and pad apparatus positioned to fix the pelvis.
  • the external stabilizing table and attachments may include a padded metal pole beneath the pubis or pelvic bone from posterior to anterior, along with other external anterior and posterior pelvic stabilizing paddles.
  • the affected leg may be attached beneath the knee with a distracting mechanism that applies about 267N (60 pounds) of distal force to open the hip joint about 1 cm once the patient is under general anesthesia.
  • the hip joint is arthroscopically debrided through at least one anterior 0.5 cm incision and one posterior 0.5 cm incision, to remove from the femoral head acetabular (ball and socket) joint arthritic debris such as synovitis, loose bodies and noxious inflammatory enzymes.
  • a larger open incision may be needed.
  • a smoothing or electronic/ultrasonic/steam or other chondroplasty method may be performed to make the remaining cartilage smoother to better accommodate the hip implant, and protuberant osteophytes or lateral bone overgrowths may be arthroscopically removed or if needed by open excision.
  • a lateral hip incision may be required between 2 and 10 centimeters in length to deal with deformities and/or to insert the implant. In cases of major deformities appropriate reconstruction may add to the basic procedure.
  • the hip implant may be inserted laterally and fixed via the skirt or tabs or at least one appendage to the adjacent structures including the peripheral femoral head and/or acetabular rim.
  • the implant is inserted arthroscopically through a cannula about 10 mm in diameter with the implant in the deflated construct, and once inside the prepared joint space and secured therein by the skirt or tabs, the implant may be distended or inflated with gas, gel, fluid or fluid that becomes a resilient solid to fill the original natural space of about 0.5 cm between the upper acetabulum and lower femoral head, covering as much of the upper hip joint as required as the implant expands to fit the space.
  • the method of insertion of the ankle implant generally may be through an anterior surgical ankle approach or tendon separating incision from the distal tibia to the proximal talus (or calcaneus if the talus is absent), removing and reconstructing portions of the superior and inferior ankle extensor retinacula only to the extent required to gain access to the cleared tibiotalar space.
  • the ankle joint may be prepared arthroscopically under general anesthesia, and may benefit from distal distraction as in total ankle joint replacement surgeries with the DePuy Agility technique pinning above and below the ankle joint and then distracting it.
  • the degree of distraction required in all joints to which this invention is applied may depend both on the nature anatomy and located pathophysiology that must be accommodated on a case by case basis and said distraction may be a combination of body position using gravitational forces and/or superimposed distracting devices.
  • the surgeon may be developing the interval between the extensor hallucis longus and anterior tibial tendons. Injury tissue is removed, and the implant inserted fitting as preplanned.
  • the implant surface may be provided with roughness, e.g.
  • fixation cords or tabs to connect to proximate ligaments or adjacent boney structures may be used at the surgeon's discretion to balance implant location stability and integrity, with the need for functional joint movements.
  • a method for restoring a joint comprising: providing an implant configured for deployment between a first bone and at least one second bone of a joint, the implant further comprising a balloon comprising a first portion that is configured to engage the first bone of the joint, a second portion that is configured to engage at least one second bone of the joint, a side portion connecting the first portion and the second portion, in which the side portion facilitates relative motion between the first portion and the second portion, and an interior that is optionally inflatable with a first inflation medium; and coupling a first appendage of the balloon to the first bone of the joint.
  • the first bone may be one of a tibia, a femur and a patella.
  • the second bone may be one of a tibia, a patella and a femur.
  • first portion comprises a first wall
  • second portion comprises a second wall
  • side portion comprises a side wall
  • the method comprises providing an in-growth patch on at least one of the first portion configured to engage the first bone (e.g. a femur, a tibia, or a patella, in the case of the knee device), the second portion configured to engage the second bone, the side portion, and the appendage.
  • the in-growth patch may be configured to encourage and/or promote tissue in-growth, such as bone in-growth, for non-limiting example.
  • the patch may be as large as the portion itself (whether the first portion the second portion, the side portion, or the appendage) or may be smaller than the portion (such as in the shape of a strip or other shaped patch).
  • the in-growth patch may comprise a surface irregularity or roughness.
  • the in-growth patch may be Velcro-like.
  • the implant comprises an in-growth patch on the first portion and/or the second portion, from (and in some examples including) a first appendage to a second appendage.
  • the in-growth patch aids in securing the implant to the bone.
  • the in-growth patch comprises beads and/or bead-like elements attached to the implant. Such an in-growth patch may be configured to simulate trabecular bone space of a normally cancellous latticework.
  • the beads are sintered beads of various sizes. In some embodiments, the beads are sintered beads about 400 microns in size.
  • the term "about” can mean ranges of 1%, 5%, 10%, 25%, or 50%.
  • the first bone and/or the second bone is roughened to acquire a bleeding bone to facilitate in-growth.
  • about 0.5 mm of cortical tissue is removed to facilitate in-growth.
  • the method comprises coupling a second appendage of the balloon to the first bone of the joint. In some examples, the method comprises coupling a second appendage of the balloon to at least one second bone of the joint. In some examples, the method comprises coupling a second appendage of at least one of the first portion, the second portion, and the side portion to at least one of the first bone and at least one second bone of the joint. In some examples, coupling at least one of the first appendage and the second appendage provides ligamentary-like support to the first bone and at least one second bone of the joint. In some examples, coupling at least one of the first appendage and the second appendage provides ligamentary-like support to the joint.
  • first appendage and the second appendage are configured to provide tendon-like support to the first bone and the at least one second bone of the joint. In some examples, the first appendage and the second appendage are configured to provide tendon-like support to the joint.
  • the method comprises providing an inflation port in communication with the interior of the balloon for inflation of the interior of the balloon with the first inflation medium. In some examples, the method comprises using an inflation port of the implant that is in communication with the interior of the balloon to inflate the interior of the balloon with the first inflation medium. In some examples, the method comprises puncturing the balloon to inflate the interior of the balloon with the first inflation medium. In some examples, the method comprises providing a balloon having self-sealing capability. In some examples, the method comprises providing a balloon having self-sealing capability upon inflation of the interior of the balloon with the first inflation medium. In some examples, the method comprises providing a balloon comprising a seal capable of closing the interior of the balloon.
  • the method comprises providing a balloon having an interior comprising a plurality of inflatable chambers.
  • the interior comprises a plurality of individually inflatable chambers.
  • the method comprises inflating a first chamber of the plurality of inflatable chambers with a first inflation medium.
  • the first chamber and the inflation medium is selected based on the particular needs of the patient. For non-limiting example, if the patient has bone loss due to an injury, the chamber may be selected at the location of the missing bone, and may be filled with a rigid inflation medium (or one that becomes rigid once in the chamber) in order to replace the missing and/or damaged bone.
  • a chamber may be chosen to restore alignment of the joint, and inflated with an appropriate inflation medium to impart both alignment and cushion to the joint.
  • the method comprises inflating a second chamber of the plurality of individually inflatable chambers with a second inflation medium.
  • the balloon is a composite structure.
  • the balloon comprises layers of porous and/or non-porous materials, or otherwise contains treatment or cell regeneration agents.
  • a first layer of the balloon is a thin, but strong layer of a thermoplastic, such as a thermoplastic polyurethane, for non-limiting example, which has microporosity sufficient to allow passage or egress of treatment or cell regeneration agents from a second layer.
  • the second layer may be a central layer (which lies between the first layer and a third layer or a fourth layer or more layers).
  • the first layer may comprise a bone engaging surface in some embodiments.
  • the degree of microporosity to enable egress of treatment or cell regeneration agents from the second layer is found in polymer layers such as Chronoflex (e.g., ChronoFlexAR®, ChronoFlex AL®, ChronoFlec C®) or BIONATE (e.g., BIONATE I, BIONATE II, BIONATE 55D, BIONATE 65D, BIONATE 75D, BIONATE 80A, BIONATE 90A, BIONATE 55 or BIONATE 80).
  • the bone engaging surface of the implant may be coated and/or impregnated with a latticework of polymer that is surface sprayed or layered on the bone engaging surface of the implant to promote cartilage tissue regeneration.
  • This bone engaging surface coating may contain living chondrocytes (for example, as is provided in the Carticel procedure by the Genzyme company), and/or may contain stem cells with directed gene mutations to enhance adherence of the coating to the implant.
  • the bone engaging surface may comprise peaks and troughs.
  • the living cells may be provided in troughs while the surface peaks may be used for at least one of: space validation, traction, and cell protection.
  • the first inflation medium imparts rigidity in the implant. In some examples, the first inflation medium imparts cushion in the implant. In some examples, the inflation medium chosen for the first inflation medium, and/or the particular choice of chamber (in examples having multiple chambers) filled with such first inflation medium aligns the joint. In some examples, the inflation medium chosen for the first inflation medium, and/or the particular choice of chamber (in embodiments having multiple chambers) filled with such first inflation medium aligns the bones of the joint. In some examples, the inflation medium chosen for the first inflation medium, and/or the particular choice of chamber (in examples having multiple chambers) filled with such first inflation medium changes the bone alignment.
  • the inflation medium chosen for the first inflation medium, and/or the particular choice of chamber (in examples having multiple chambers) filled with such first inflation medium improves joint alignment. In some examples, the inflation medium chosen for the first inflation medium, and/or the particular choice of chamber (in examples having multiple chambers) filled with such first inflation medium restores, at least in part, joint alignment. In some examples, individual chambers of the interior are selectively inflated with a first inflation medium and/or a second inflation medium. In some examples, individual chambers of the interior are selectively inflated with a first inflation medium and/or a second inflation medium in order to reconstruct the joint and/or in order to reconstruct bones of the joint.
  • a joint is comprised of the interface between (a) a first bone and a first cartilage; and (b) a second bone and a second cartilage, wherein the first cartilage is separated from the second cartilage by a space (e.g., joint space) and the cushion expands to fit the joint space.
  • a space e.g., joint space
  • the cushion expands to fit the joint space between the first bone and second cartilage or the first bone and second bone.
  • the cushion expands to fit the spaces of the "knee joint" or "knee joints”.
  • the cushion may expand to fit the spaces of the femoral tibial involved on standing or walking on a level plane, and the cushion may expand to fit the spaces of the patella femoral bones of the knee more involved on stair ascent and descent.
  • pressures behind the knee cap or patella when lying are zero, when standing are 0.7 times body weight, and when going up and down the patella femoral pressures are 3 - 4 times body weight.
  • the implants accommodate some or all of the normal body functional pressures and complex space movements, as described above, and can also be used in other joints such as the elbow, ankle, or hip.
  • the normal flexion up to 120 degrees, extension of 20 degrees, abduction of 50 degrees, internal and external rotation of 45 degrees may produce variable axial, shear, and cyclic loads which the implant by design may accommodate and endure as up to 6 times body weight, consistent with a tire on a car that allows for cyclic loads different when driving straight or turning corners.
  • the implant embodying features of the present invention provides more physiologic motion and shock absorption within the joint and has combined characteristics of anatomic design symmetry, balanced rigidity with sufficient attachment connections to adjacent normal structures, and durability that meet the needs of joint reconstruction.
  • the opposing internal surfaces of the first and second walls of the invention may either move together in synchrony or in opposite directions from one another (e.g. the superior wall moving medially in the hip and the inferior wall moving laterally).
  • the implant may be fixed to a concave surface of the joint (e.g., the acetabular hip cup) or to a convex surface of the joint (e.g. the dorsal femoral head surface), to both, or to neither (e.g., having an interference fit within the joint with an expanding balloon or cushion that fills the existing space).
  • the implant may be inserted arthroscopically like a deflated balloon and then inflated through a cannula into the ankle or hip (or other joint structure) to act as a cushion or renewed interface for painless and stable limb motion.
  • joint capsular and adjacent ligament tissue as well as bone may be left in place to preserve the natural body, unless interfering with reconstructed limb function.
  • the application of steam in addition to removing damaged debris, can smooth out and reform the joint surface.
  • the high temperature of the steam tends to weld cracks or fissures which can be present in the cartilage surface of a damaged joint.
  • Smoothing of joint surface cartilage with steam welds or seals existing cracks or flaps in the cartilage, especially superficially as the lamina splendors, which melt together to provide a white shiny gliding joint surface.
  • the steam can be used to stabilize the periphery of the defect in the joint surface via capsulorrhaphy or joint tightening. Open mechanical and chemical debridement may also be employed to prepare the surfaces for the implant.
  • an impregnated transfer medium or cell template may be used, as described by Histogenics and Tygenix chondrocytes delivery systems wherein the position of concentrated cells is mechanically placed about the implant at areas of greatest cartilage damage to promote regrowth, or as in Carticel wherein watery cells are implanted beneath a periosteal membrane (a wall of the implant serving as the membrane), prior to completion of the inflation or expansion of the implant.
  • a syringe or gauged device with measured screw-home pressure is used to inflate the implant.
  • the deflated implant is advanced through the diaphragm of a delivery cannula (such as the Acufex from Smith & Nephew) or through the open incision site into the joint. It can be inflated by the attached cannula using a common syringe, inserting several cc's of filler material. Inserted contents and locations of cell placements depend on areas of need and joint size. In some embodiments of the methods several cc's of filler material and a viscolubricant in the interior of the implant allows distension, cushioning, and gliding movements. Cell regeneration agents are placed in the areas of greatest need.
  • a delivery cannula such as the Acufex from Smith & Nephew
  • Methods of living cell e.g., stem cell, differentiated cell, pluripotent cell, post-mitotic cell
  • chondrocyte placement depend on the lesions and specific implant construct. Direct infusion into the joint with completion of implant inflation may press the cells into the hyaline surface, whereupon they attach within the first 24 hours. As a result, the patient may be forced to remain sedentary and the joint where the implant is deployed, non-weight bearing for the first day after surgery. Deeper osteochondral defects can be treated by 'hyper-perfusion of cells' via either 3-D cell transfer templates, or microneedle injection as used in treatment of diabetic patients for blood sugar testing and insulin/transdermal drug delivery.
  • bone graft may be packed into the base of the defect followed by addition of a cell/tissue application.
  • the cannula attached to the implant may be sealed and detached, or left in place for periodic aspiration of noxious enzymes as for the Cox-1, Cox-2, and 5-Lox systems, followed by reinsertion of activated substances including viscolubricants, or even more cells (e.g., stem cells, differentiated cells, pluripotent cells, post-mitotic cells).
  • Implants embodying features of the invention may be designed for permanent or temporary deployment within a joint structure.
  • the implant may be formed of suitable bioabsorbable materials so that the implant may be absorbed within a particular predetermined time frame.
  • suitable bioabsorbable materials include polylactic acid, polyglycolic acid, polycaprolactone, copolymers, blends and variants thereof.
  • One present method of forming the implant is to apply numerous layers of polymer such as ChronoFlex (e.g., ChronoFlexAR®, ChronoFlex AL®, ChronoFlec C®), ChronoPrene TM , ChronoSil®, ChronoThane P TM , ChronoThane T TM , HydroMed TM , HydroThane TM , or PolyBlend TM in a solvent and evaporating the solvent after applying each layer.
  • ChronoFlex e.g., ChronoFlexAR®, ChronoFlex AL®, ChronoFlec C®
  • ChronoPrene TM e.g., ChronoSil®, ChronoThane P TM , ChronoThane T TM , HydroMed TM , HydroThane TM , or PolyBlend TM in a solvent and evaporating the solvent after applying each
  • the coupling aspects including but not limited to skirting or fixation tabs of the present implant prevent joint migration during use.
  • the implant is adapted to restore natural joint function. In some embodiments, the implant is adapted to preserve viable joint tissue. In some embodiments, the implant is adapted to be placed with minimal surgery as compared to joint replacement therapy currently marketed. In some embodiments, the implant is adapted to permit weight bearing post surgery within at least one of: about 1 week, within about 1 day, within about 2 days, within about 3 days, within about 4 days, within about 5 days, within about 6 days, within about 10 days, within about 2 weeks, within about 3 weeks, within about 4 weeks, within about 5 weeks, within about 6 weeks. In some embodiments, the implant is adapted to permit weight bearing post surgery after about 1 day wherein full weight bearing is allowed in about 6 weeks.
  • the term "about” can be a range of 1 day, 2 days, or 3 days, in some embodiments.
  • the implant is adapted to allow for faster recovery and resumption of normal activities as compared to joint replacement therapy currently marketed.
  • the balloon (or a portion thereof) is adapted to conform to the patient's anatomy.
  • the implant (or a portion thereof) is adapted to conform to the patient's anatomy.
  • the inflation medium is adapted to absorb a force (or forces) exerted on the joint.
  • the inflation medium is adapted to absorb a force (or forces) exerted on the bones of the joint.
  • the inflation medium is adapted to absorb a force (or forces) exerted on at least one bone of the joint.
  • the balloon is adapted to absorb shocks exerted on at least one of a bone, multiple bones, a ligament of the joint, ligaments of the joint, a tendon of the joint, tendons of the joint, and the joint in general.
  • the implant is adapted to restore natural cartilage cushion with cells (e.g., stem cells, differentiated cells, pluripotent cells, post-mitotic cells).
  • the implant is adapted to restore natural cartilage cushion with stem cells.
  • the balloon (or a portion thereof) is adapted to renew joint space. In some examples, the balloon (or a portion thereof) is adapted to reduce pain as compared to the pain felt prior to the implantation of the implant. In some examples, the balloon (or a portion thereof) is adapted to restore joint function. In some examples, the implant (or a portion thereof) is adapted to renew joint space. In some examples, the implant (or a portion thereof) is adapted to reduce pain as compared to the pain felt prior to the implantation of the implant. In some examples, the implant (or a portion thereof) is adapted to restore joint function.
  • the implant is adapted to reverse arthritis in the joint. In some embodiments, the implant is adapted to prevent, reduce, or ameliorate arthritis in the joint. In some embodiments, the implant is adapted to reduce pain associated with arthritis in the joint.
  • the balloon (or a portion thereof) is adapted to be placed into a debrided limb joint arthroscopically. In some examples, the balloon is adapted to pad cartilage defects. In some examples, the balloon is inflated to cushion the joint. In some examples the implant is adapted to deliver stem cells to at least one of the joint and a bone of the joint. In some examples the implant is adapted to deliver living chondrocytes to at least one of the joint and a bone of the joint. In some examples, the implant is adapted to deliver cells to at least one of the joint and a bone of the joint. In some examples, the cells are at least one of stem cells, differentiated cells, pluripotent cells, and post-mitotic cells.
  • the implant is adapted to provide a new articular surface for the joint. In some examples, the implant is adapted to act as a spacer in the joint. In some examples, the implant is adapted to space the bones of the joint apart for proper joint articulation. In some examples, the implant is adapted to space the bones of the joint apart for reduced bone-on-bone rubbing.
  • the implant is configured to at least one of: pad cartilage, cushion the joint, deliver a pharmacologic substance, remove noxious enzymes, debride upon implantation, debride the joint following implantation, deliver a therapeutic substance, deliver a biologic substance, and deliver living stem cells.
  • the implant is configured to deliver a chemotherapeutic agent to a bone or other surrounding tissues.
  • the implant is configured to deliver an anti-infectious medication to a bone or other surrounding tissues.
  • the implant is configured to deliver at least one of an antibiotic antifungals, and analgesics agent.
  • the implant is configured to be selectively inflated to realign limbs.
  • a method comprising: implanting a knee implant as described herein into a subject, wherein the implant reverses arthritis in the subject.
  • a method comprising: implanting a knee implant as described herein into a subject, wherein the implant prevents, reduces, or ameliorates arthritis in the subject.
  • a method comprising: implanting a knee implant as described herein into a subject, wherein the implant reduces pain associated with arthritis in the subject.
  • a method comprising: implanting a knee implant as described herein into a knee joint of a subject and treating a component of the knee joint of the subject with at least one of an allograph tissue, an autograph tissue, and an xenograph tissue.
  • the tissue comprises a cell.
  • the tissue comprises a plurality of cells.
  • the cell is a stem cell, differentiated cell, pluripotent cell, or post-mitotic cell.
  • the implanting step is at least one of: prior to the treating step, simultaneous with the treating step, and following the treating step.
  • a method comprising: implanting a knee implant as described herein into a subject, wherein the implant is configured to at least one of: restore joint function and control arthopathies.
  • the implanting spares existing anatomy.
  • a method comprising: debriding a femur condyle of a knee joint of a subject, and implanting a knee implant as described herein into the knee joint of the subject, whereby the implant is configured to anneal to the cartilage of the subject.
  • the debriding is achieved by steam application.
  • a method comprising implanting a knee implant as described herein into a joint previously treated with a joint replacement.
  • the method comprises removing the joint replacement prior to implanting the knee implant.
  • the method comprises clearing infectious matter from the joint and/or surrounding tissues.
  • the method comprises implanting a second implant of any implant described herein following removing the implant previously implanted in the joint.
  • the method comprises replacing the joint of the subject following removing the implant previously implanted in the joint.
  • the method comprises debriding the bone of the joint, and implanting an implant of any implant described herein.
  • the method comprises repeating the debriding and implanting steps.
  • the surgical techniques may be individualized to fit patient need.
  • the implants may be combined with or comprise autologous or allograph tissues such as fascia lata. Surgeons may implant fascia lata above unreconstructable rotator cuff with consequent symptom relief.
  • Polymers can interface with any human tissue and/or with metals or polyethylenes or polyurethanes.
  • Living tissues that can be combined with implants provided herein for repair or reconstruction may be from the same patient (autograph), and cadaver or other member of the same species (allograph) or from another species (xenograph.)
  • Virtually any combination of polymer interpositioning is feasible with the implant concepts provided herein, as anatomy varies among patients in need, and clinical conditions differ with each person. Therefore, although the general or most common construct is expected to cover just one singular and the primary surface of a joint with an implant, any combination of surfaces can be involved allowing versatile custom applications of this implant and method of surgery.
  • implants may be available in specified sizes, the material membrane elastic deformation and resilience may allow for calculated malleability toward goodness of fit.
  • the fit of implant over the affected joint surface can be customized as paring preoperative findings of MRI or CT or PET imaging pathophysiology with intraoperative reconstructive need.
  • best fit implants may serve patient restorative requirement with least morbidity.
  • the implants may be implanted typically during an outpatient surgery, wherein the joint is first arthroscopically debrided and cartilage prepared, similar to the methods used in a Carticel procedure. Cartilage or osteochondral size defects and alignment problems are studied, and measurements taken. Considerations to materials stretch are acknowledged as polyurethanes gain 50% pliability with 100 hours exposure to serum, and 30% additional malleability by heating to 37 degrees C. Thus, implant presentation in the OR may aim for best fit and accommodate patient need.
  • Intraoperative hyaline cartilage biopsy acquiring e.g. 400 mg of normal hyaline articular tissue from the intercondylar notch (as would be wasted with notchplasty) or from the joint periphery (outside articulating regions) may allow for chondrocytes autologous acquisition.
  • Currently such specimens may be sent to Genzyme Corp. for 2-4 weeks cloning of cells whereupon 2-3 bottles containing e.g. 1 cc of cells, 93% viability, 12 million cells per bottle, are delivered on an exact day to the operating room for placement in the Carticel cartilage regenerative procedure securing the liquid cells beneath a harvested periosteal membrane.
  • the polymer may substitute for the periosteum thus reducing surgical morbidity markedly and changing an otherwise major open procedure into an arthroscopically facilitated outpatient treatment option through a small arthrotomy.
  • the intraoperative biopsy may be given to the technician in the operating room in early surgery, for insertion into the stem cells generation machine.
  • living autologous chondrocytes may be 'spun down' and separated, then returning the living cells to the primary surgeon.
  • the implant has been pulled up over the prepared defects and sufficient fixation sites have been locked into place so that the implant is secure in its general location over the distal femoral surface, for example.
  • An unattached portion of the implant is lifted, the newly procured cells inserted potentially on a soft matrix to hold cells inside the prepared defect, and the implantation is completed sealing the living cells for the purpose of articular surface regeneration. After 24 hours the cells are fixed as the aggregate to the surface of the defect into which they were introduced.
  • chondrocytes were implanted (autologous or potentially allograph) they may mature and in the course of a year the durometry may come to resemble normal hyaline articular cartilage.
  • the other biologic activity promoted during implantation surgery is the bone in-growth onto the tab undersurface and/or periphery. This fixation at the secondary level in proposed to decrease the probability of loosening of the prosthetic implant, one of the two most common causes of implant failure.
  • fixation comprises bone in-growth.
  • fixation comprises bone in-growth as described in Vasanji A, In vivo bone growth assessment in preclinical studies and clinical trials, Bonezone, 2012, p. 12-17 .
  • the methods of surgery may have certain constants and other variables mandated by materials and fixation management versus altering anatomies and joint forces.
  • a standardized implant method of surgery may be recommended with variations to be determined by the responsible surgeon.
  • One alternative implant construction involves the use of an upper portion of the implant having a net-like construction and filled with balls or ball bearing like elements that are larger than the openings in the netting.
  • the balls or ball bearing like elements provide motion to the implant.
  • the netting and ball bearing like elements may include regeneration agents as previously discussed, and the bearing construction may be directed toward favorable implant movement balanced with content disbursement.
  • the invention is intended primarily for human use but may be extended to mammalian use.
  • mammals include, but are not limited to, cats, dogs, sheep, horses, pigs, goats, cows, mice, and rats.
  • materials and structure may be of conventional design.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medical Informatics (AREA)
  • Prostheses (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)

Claims (10)

  1. Implant (20) configuré pour se déployer entre le fémur et le tibia d'une articulation du genou, l'implant comprenant
    une première surface qui est configurée pour s'engager dans un condyle médial et un condyle latéral du fémur de l'articulation du genou,
    une deuxième surface qui est configurée pour s'engager dans le tibia de l'articulation du genou,
    un premier appendice (4c) configuré pour accoupler la première surface à un premier condyle du fémur de l'articulation du genou,
    un deuxième appendice (4d) configuré pour accoupler la première surface à un deuxième condyle du fémur de l'articulation du genou, et
    une fente entre le premier appendice et le deuxième appendice, où le premier appendice et le deuxième appendice amortissent le fémur et le tibia,
    caractérisé en ce que la première surface, la deuxième surface, le premier appendice (4c) et le deuxième appendice (4d) sont constitués ensemble d'une seule feuille de polymère pratiquement sans séparation entre la première surface et la deuxième surface.
  2. Implant selon la revendication 1, comprenant au moins un élément d'attache dans l'encoche intercondylaire.
  3. Implant selon la revendication 1, comprenant au moins un élément accessoire configuré pour s'accoupler avec l'extrémité distale du fémur au niveau antérieur.
  4. Implant selon la revendication 1, comprenant au moins une rêne postérieure configurée pour remonter l'implant depuis l'intérieur d'une encoche intercondylaire postérieure vers un site de raccordement autour du fémur.
  5. Implant selon la revendication 1, comprenant au moins une lanière de type suture configurée pour remonter l'implant depuis l'intérieur d'une encoche intercondylaire postérieure vers un site de raccordement autour du fémur.
  6. Implant selon la revendication 1, comprenant une matrice de croissance sur au moins une partie de l'implant adjacent au fémur.
  7. Implant selon la revendication 6, où la matrice de croissance comprend des chondrocytes vivants.
  8. Implant selon la revendication 7, où l'implant est composé d'un polymère bioabsorbable configuré pour libérer les chondrocytes au fil du temps.
  9. Implant selon la revendication 1, comprenant un agent pharmacologique sur au moins une partie de l'implant adjacent au fémur.
  10. Implant selon la revendication 1, où l'implant est composé de vacuoles de substances pharmacologiques.
EP12827020.4A 2011-09-01 2012-08-30 Dispositif d'arthroplastie avec interposition élastique Active EP2750629B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161530324P 2011-09-01 2011-09-01
PCT/US2012/053207 WO2013033447A2 (fr) 2011-09-01 2012-08-30 Dispositif d'arthroplastie avec interposition élastique

Publications (3)

Publication Number Publication Date
EP2750629A2 EP2750629A2 (fr) 2014-07-09
EP2750629A4 EP2750629A4 (fr) 2015-03-25
EP2750629B1 true EP2750629B1 (fr) 2016-07-13

Family

ID=47757177

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12827020.4A Active EP2750629B1 (fr) 2011-09-01 2012-08-30 Dispositif d'arthroplastie avec interposition élastique

Country Status (3)

Country Link
US (2) US9757241B2 (fr)
EP (1) EP2750629B1 (fr)
WO (1) WO2013033447A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10045851B2 (en) 2011-09-01 2018-08-14 Iorthopedics, Inc. Resilient interpositional arthroplasty device
USD833613S1 (en) 2011-01-19 2018-11-13 Iorthopedics, Inc. Resilient knee implant
US10307257B2 (en) 2010-01-22 2019-06-04 Iorthopedics, Inc. Resilient knee implant and methods

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008224435B2 (en) 2007-03-15 2014-01-09 Ortho-Space Ltd. Prosthetic devices and methods for using same
JP5425797B2 (ja) * 2007-11-02 2014-02-26 バイオメット ユーケイ リミテッド 置換術用人工関節
US9808345B2 (en) 2008-07-24 2017-11-07 Iorthopedics, Inc. Resilient arthroplasty device
WO2011091005A2 (fr) 2010-01-22 2011-07-28 Grotz R Thomas Implant de genou souple et procédés associés
US9289307B2 (en) 2011-10-18 2016-03-22 Ortho-Space Ltd. Prosthetic devices and methods for using same
EP2630935B1 (fr) 2012-02-27 2014-12-31 Arthrex, Inc. Bloc d'extension glénoïde
US20140364955A1 (en) * 2013-06-10 2014-12-11 Bradley R. Smith Orthopedic shock damper system
DE102013227136B4 (de) * 2013-12-23 2020-12-31 Mathys Ag Bettlach Beschichtetes Hemiprothesen-Implantat
GB2535767A (en) * 2015-02-27 2016-08-31 Idr-Biomed Ltd Buffer for femoral head and neck excision
US11684260B2 (en) 2015-03-23 2023-06-27 Tracpatch Health, Inc. System and methods with user interfaces for monitoring physical therapy and rehabilitation
US10582891B2 (en) 2015-03-23 2020-03-10 Consensus Orthopedics, Inc. System and methods for monitoring physical therapy and rehabilitation of joints
US11272879B2 (en) 2015-03-23 2022-03-15 Consensus Orthopedics, Inc. Systems and methods using a wearable device for monitoring an orthopedic implant and rehabilitation
CN107708526A (zh) * 2015-03-23 2018-02-16 合意骨科有限公司 关节传感器系统及其操作方法
EP4275610A3 (fr) * 2015-07-13 2023-12-27 Mako Surgical Corp. Procédé de calcul de longueur de jambe d'extrémités inférieures
US10959761B2 (en) 2015-09-18 2021-03-30 Ortho-Space Ltd. Intramedullary fixated subacromial spacers
FI126495B (en) * 2015-11-04 2017-01-13 Traceray Oy bone implants
US10905568B2 (en) * 2016-02-29 2021-02-02 Pva Medical, Llc Prosthetic limb socket with variable hardness
EP3216406A1 (fr) * 2016-03-11 2017-09-13 Universität Basel Procede de preparation de portions d'un implant en plusieurs parties ou d'une osteosynthese en plusieurs parties
AU2016400080B2 (en) * 2016-03-28 2019-10-17 Wright Medical Technology, Inc. Anterior resurfacing talar plate
US10245148B2 (en) 2016-04-25 2019-04-02 Howmedica Osteonics Corp. Flexible snap-fit prosthetic component
AU2016416373A1 (en) * 2016-07-26 2019-02-07 Raycont Ltd. Cementless joint resurfacing system
US10195035B1 (en) * 2016-12-30 2019-02-05 Newtonoid Technologies, L.L.C. Responsive biomechanical implants and devices
US11045981B2 (en) 2017-01-30 2021-06-29 Ortho-Space Ltd. Processing machine and methods for processing dip-molded articles
US10022233B1 (en) * 2017-12-04 2018-07-17 Duke University Orthopedic implant for sustained drug release
US10925746B2 (en) * 2018-07-25 2021-02-23 Orthopedix, Inc. Patient specific carpal implant
US10918487B2 (en) * 2018-07-25 2021-02-16 Orthopedix, Inc. Prosthetic implant caps
US10863928B1 (en) 2020-01-28 2020-12-15 Consensus Orthopedics, Inc. System and methods for monitoring the spine, balance, gait, or posture of a patient

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE391122B (sv) 1971-01-25 1977-02-07 Cutter Lab Protes i form av en ryggradsbroskskiva och forfarande for framstellning derav
US3864758A (en) 1973-08-31 1975-02-11 Sam Savo Yakich Hip joint bearing prosthesis
DE2501080A1 (de) 1975-01-13 1976-07-15 Georg Dr Med Patzer Gelenkendoprothese mit dauerschmierung
US4052753A (en) * 1976-08-02 1977-10-11 Dedo Richard G Knee spacer and method of reforming sliding body surfaces
US4219892A (en) 1979-02-05 1980-09-02 Rigdon Robert W Knee brace for preventing injury from lateral impact
US4344193A (en) * 1980-11-28 1982-08-17 Kenny Charles H Meniscus prosthesis
US4502161A (en) * 1981-09-21 1985-03-05 Wall W H Prosthetic meniscus for the repair of joints
US4467479A (en) 1982-02-05 1984-08-28 Brody Garry S Method of surgically repairing an injured human joint and a prosthetic device therefor
CH671691A5 (fr) 1987-01-08 1989-09-29 Sulzer Ag
US4919668A (en) * 1988-08-08 1990-04-24 Rosenbaum Robert S Temporomandibular joint disc implant
US4919667A (en) * 1988-12-02 1990-04-24 Stryker Corporation Implant
US5441508A (en) * 1989-04-27 1995-08-15 Gazielly; Dominique Reinforcement and supporting device for the rotator cuff of a shoulder joint of a person
FR2646343B1 (fr) * 1989-04-27 1991-12-20 Gazielly Dominique Dispositif de renfort et de soutien de la coiffe des rotateurs d'une articulation d'epaule d'individu
FR2657007B1 (fr) * 1990-01-12 1998-01-02 Innovations Technolog Ste Civi Piece femorale pour prothese du genou et procede pour la realisation d'un bandage propre a son equipement.
US5344459A (en) * 1991-12-03 1994-09-06 Swartz Stephen J Arthroscopically implantable prosthesis
US5429133A (en) 1992-12-18 1995-07-04 Neoprobe Corporation Radiation responsive laparoscopic instrument
ATE293395T1 (de) 1994-01-26 2005-05-15 Kyphon Inc Verbesserte aufblasbare vorrichtung zur verwendung in chirurgischen protokollen im bezug auf die fixierung von knochen
US6248110B1 (en) 1994-01-26 2001-06-19 Kyphon, Inc. Systems and methods for treating fractured or diseased bone using expandable bodies
US6209621B1 (en) 1995-07-07 2001-04-03 Depuy Orthopaedics, Inc. Implantable prostheses with metallic porous bead preforms applied during casting and method of forming the same
US20020143402A1 (en) 1995-09-04 2002-10-03 Limber Ltd. Hip joint prostheses
FR2747914B3 (fr) 1996-04-30 1998-05-15 Raoult Andre Prothese partielle du genou
AU7178698A (en) 1996-11-15 1998-06-03 Advanced Bio Surfaces, Inc. Biomaterial system for in situ tissue repair
US9603711B2 (en) * 2001-05-25 2017-03-28 Conformis, Inc. Patient-adapted and improved articular implants, designs and related guide tools
US8882847B2 (en) * 2001-05-25 2014-11-11 Conformis, Inc. Patient selectable knee joint arthroplasty devices
US8617242B2 (en) * 2001-05-25 2013-12-31 Conformis, Inc. Implant device and method for manufacture
US6258126B1 (en) * 1997-09-09 2001-07-10 Depuy Orthopaedics, Inc. Cushioned joint prosthesis
US6056777A (en) * 1998-02-27 2000-05-02 Mcdowell; Charles L. Method and device for regenerating cartilage in articulating
US5997582A (en) 1998-05-01 1999-12-07 Weiss; James M. Hip replacement methods and apparatus
US6099531A (en) * 1998-08-20 2000-08-08 Bonutti; Peter M. Changing relationship between bones
US6132468A (en) * 1998-09-10 2000-10-17 Mansmann; Kevin A. Arthroscopic replacement of cartilage using flexible inflatable envelopes
US7491235B2 (en) * 1999-05-10 2009-02-17 Fell Barry M Surgically implantable knee prosthesis
US7338524B2 (en) * 1999-05-10 2008-03-04 Fell Barry M Surgically implantable knee prosthesis
US20050033424A1 (en) * 1999-05-10 2005-02-10 Fell Barry M. Surgically implantable knee prosthesis
US6783546B2 (en) 1999-09-13 2004-08-31 Keraplast Technologies, Ltd. Implantable prosthetic or tissue expanding device
US7060100B2 (en) * 1999-10-08 2006-06-13 Ferree Bret A Artificial disc and joint replacements with modular cushioning components
US6875235B2 (en) * 1999-10-08 2005-04-05 Bret A. Ferree Prosthetic joints with contained compressible resilient members
HUP0500988A2 (en) * 1999-12-17 2006-01-30 Cartificial As A prosthetic device for insertion into a joint cavity of a joint of a vertebrate and an instrument for inserting said device
FR2803190A1 (fr) 2000-01-04 2001-07-06 Bernard Wirth Protheses intra-articulaires souples
JP2004521666A (ja) 2000-08-28 2004-07-22 アドバンスト バイオ サーフェイシズ，インコーポレイティド 哺乳動物の関節を増強する方法およびシステム
JP4202134B2 (ja) 2000-12-15 2008-12-24 スパイノロジー インコーポレイテッド 線維輪補強バンド
US6482209B1 (en) * 2001-06-14 2002-11-19 Gerard A. Engh Apparatus and method for sculpting the surface of a joint
US20030163202A1 (en) * 2002-02-06 2003-08-28 Lakin Ryan C. Modular resurfacing prosthetic
US7066958B2 (en) * 2002-05-10 2006-06-27 Ferree Bret A Prosthetic components with partially contained compressible resilient members
US20040006393A1 (en) * 2002-07-03 2004-01-08 Brian Burkinshaw Implantable prosthetic knee for lateral compartment
US6827739B2 (en) * 2002-08-26 2004-12-07 Zimmer Technology, Inc. Easily assembled provisional orthopaedic implant
DE60336002D1 (de) * 2002-10-07 2011-03-24 Conformis Inc Minimal invasives gelenkimplantat mit einer den gelenkflächen angepassten dreidimensionalen geometrie
AU2003902467A0 (en) 2003-05-19 2003-06-05 Boris Rjazancev A prosthetic component, a method of attaching a prosthetic component to a bone, a method of performing knee replacement surgery and a frame for application to a knee joint during knee replacement surgery
US20070112458A1 (en) 2003-06-25 2007-05-17 Honda Motor Co., Ltd. Assist transportation method and its device
DE10328949A1 (de) * 2003-06-27 2005-01-13 Arno Friedrichs Hüftgelenkendoprothese
DE10339605A1 (de) 2003-08-28 2005-04-14 Hendrik Priebs Einteiliges gekapseltes Kugelgelenk, insbesondere Hüftgelenk, das auf einer elastischen Kunststoffblase basiert und an Stelle des Knorpels zwischen Hüftkopf und Hüftpfanne mit Hilfe zweier Wülste am Rand dieser vernäht wird
US20050208095A1 (en) 2003-11-20 2005-09-22 Angiotech International Ag Polymer compositions and methods for their use
US20050171604A1 (en) * 2004-01-20 2005-08-04 Alexander Michalow Unicondylar knee implant
US7297146B2 (en) 2004-01-30 2007-11-20 Warsaw Orthopedic, Inc. Orthopedic distraction implants and techniques
US20050197711A1 (en) 2004-03-03 2005-09-08 Cachia Victor V. Catheter deliverable foot implant and method of delivering the same
US20070100457A1 (en) * 2004-03-04 2007-05-03 Hyde Edward R Jr Paramagnetic liquid interface
KR100623397B1 (ko) 2004-04-14 2006-09-20 (주)오티스바이오텍 인공고관절장치
US7260335B2 (en) 2004-07-30 2007-08-21 Ricoh Company, Limited Image-information detecting device and image forming apparatus
US20060047341A1 (en) 2004-08-24 2006-03-02 Trieu Hai H Spinal disc implants with reservoirs for delivery of therapeutic agents
US20060058892A1 (en) 2004-09-16 2006-03-16 Lesh Michael D Valved tissue augmentation implant
US20090088846A1 (en) * 2007-04-17 2009-04-02 David Myung Hydrogel arthroplasty device
US7559932B2 (en) 2004-12-06 2009-07-14 Dfine, Inc. Bone treatment systems and methods
US7678116B2 (en) 2004-12-06 2010-03-16 Dfine, Inc. Bone treatment systems and methods
US8828080B2 (en) 2005-02-22 2014-09-09 Barry M. Fell Method and system for knee joint repair
WO2006097932A2 (fr) 2005-03-17 2006-09-21 Active Implants Corporation Dispositifs d'implant
US20070100461A1 (en) * 2005-04-12 2007-05-03 The University Of Vermont And State Agriculture College Knee prosthesis
US7291169B2 (en) * 2005-04-15 2007-11-06 Zimmer Technology, Inc. Cartilage implant
US8403985B2 (en) * 2005-11-02 2013-03-26 Zimmer, Inc. Joint spacer implant
US7744630B2 (en) 2005-11-15 2010-06-29 Zimmer Spine, Inc. Facet repair and stabilization
US8449614B2 (en) 2005-12-08 2013-05-28 Anova Corporation Sutures for use in the repair of defects in the anulus fibrosus
US8070821B2 (en) * 2005-12-27 2011-12-06 Howmedica Osteonics Corp. Hybrid femoral implant
US7833269B2 (en) * 2006-01-25 2010-11-16 Warsaw Orthopedic, Inc Osteochondral implant procedure
US20070179607A1 (en) * 2006-01-31 2007-08-02 Zimmer Technology, Inc. Cartilage resurfacing implant
AU2007212085B2 (en) 2006-02-07 2011-11-17 Spinalcyte, Llc Methods and compositions for repair of cartilage using an in vivo bioreactor
US8333805B2 (en) * 2006-03-20 2012-12-18 Howmedica Osteonics Corp. Composite joint implant
WO2007125060A1 (fr) 2006-04-28 2007-11-08 Zimmer Gmbh Implant
US20070276491A1 (en) 2006-05-24 2007-11-29 Disc Dynamics, Inc. Mold assembly for intervertebral prosthesis
US8236057B2 (en) 2006-06-12 2012-08-07 Globus Medical, Inc. Inflatable multi-chambered devices and methods of treatment using the same
EP2076218B1 (fr) * 2006-10-09 2016-03-09 Active Implants Corporation Dispositif de prothèse de ménisque
US8192491B2 (en) * 2006-10-09 2012-06-05 Active Implants Corporation Meniscus prosthetic device
US20080097606A1 (en) * 2006-10-19 2008-04-24 Cragg Andrew H Knee joint prosthesis and hyaluronate compositions for treatment of osteoarthritis
US7670381B2 (en) * 2007-02-26 2010-03-02 Marvin Schwartz Prosthesis for interpositional location between bone joint articular surfaces and method of use
AU2008224435B2 (en) 2007-03-15 2014-01-09 Ortho-Space Ltd. Prosthetic devices and methods for using same
WO2008122595A2 (fr) 2007-04-05 2008-10-16 Cinvention Ag Implant thérapeutique biodégradable pour réparation osseuse ou cartilagineuse
US20080255664A1 (en) * 2007-04-10 2008-10-16 Mdesign International Percutaneously deliverable orthopedic joint device
US20090043344A1 (en) 2007-08-06 2009-02-12 Zimmer, Inc. Methods for repairing defects in bone
US9107769B2 (en) * 2007-08-27 2015-08-18 Kent M. Samuelson Systems and methods for providing a femoral component
US7972380B2 (en) * 2007-09-17 2011-07-05 Linares Medical Devices, Llc Artificial joint support between first and second bones
AU2008312405A1 (en) 2007-10-19 2009-04-23 Synthes Gmbh Hemi-prosthesis
US8979938B2 (en) * 2007-11-08 2015-03-17 Linares Medical Devices, Llc Artificial knee implant including liquid ballast supporting / rotating surfaces and incorporating flexible multi-material and natural lubricant retaining matrix applied to a joint surface
US8361147B2 (en) * 2008-04-09 2013-01-29 Active Implants Corporation Meniscus prosthetic devices with anti-migration features
US7991599B2 (en) * 2008-04-09 2011-08-02 Active Implants Corporation Meniscus prosthetic device selection and implantation methods
US7611653B1 (en) * 2008-04-09 2009-11-03 Active Implants Corporation Manufacturing and material processing for prosthetic devices
WO2009149093A1 (fr) * 2008-06-02 2009-12-10 University Of Medicine And Dentistry Of New Jersey Remplacement de fibrocartilage produit par génie tissulaire
US7976578B2 (en) * 2008-06-04 2011-07-12 James Marvel Buffer for a human joint and method of arthroscopically inserting
JP2011524209A (ja) 2008-06-13 2011-09-01 ピボット・メディカル，インコーポレーテッド 関節伸延のための方法および装置
JP5752035B2 (ja) 2008-07-07 2015-07-22 バイオミメディカ インコーポレイテッド 疎水性ポリマーに由来する親水性相互貫入ポリマーネットワーク
US9808345B2 (en) 2008-07-24 2017-11-07 Iorthopedics, Inc. Resilient arthroplasty device
ES2686906T3 (es) 2008-08-29 2018-10-22 Smed-Ta/Td, Llc Implante ortopédico
ES2880332T3 (es) 2008-11-24 2021-11-24 Implantica Patent Ltd Almohadilla de espuma para su inserción en una articulación de rodilla
US9277999B2 (en) * 2009-02-27 2016-03-08 University of Pittsburgh—of the Commonwealth System of Higher Education Joint bioscaffolds
US8945222B2 (en) 2009-03-20 2015-02-03 Linares Medical Devices, Llc Wear compensating joint assembly incorporating a pressurized fluid injectable reservoir upwardly biasing a hardened plastic with a wear surface
US20100256758A1 (en) 2009-04-02 2010-10-07 Synvasive Technology, Inc. Monolithic orthopedic implant with an articular finished surface
EP3170478A1 (fr) * 2009-07-10 2017-05-24 Kirk Promotion LTD. Dispositif d'articulation de la hanche
WO2011032043A1 (fr) * 2009-09-11 2011-03-17 Articulinx, Inc. Dispositifs orthopédiques en forme de disque
US9168144B2 (en) 2009-09-14 2015-10-27 Evgeny Rivin Prosthesis for replacement of cartilage
US8257444B2 (en) * 2009-09-21 2012-09-04 Linares Medical Devices, Llc End surface mounted plugs incorporated into an artificial joint and including cushioned soft plastic between outer hardened plastic layers
US20110082424A1 (en) 2009-10-02 2011-04-07 Barnhouse Michael P Method and apparatus for bone graft insertion
US8636806B2 (en) * 2009-10-02 2014-01-28 Said G. Osman Biologic diarthrodial joint
GB2476124A (en) * 2009-12-08 2011-06-15 R Thomas Grotz Inflatable arthroplasty implant
US10307257B2 (en) * 2010-01-22 2019-06-04 Iorthopedics, Inc. Resilient knee implant and methods
WO2011091005A2 (fr) * 2010-01-22 2011-07-28 Grotz R Thomas Implant de genou souple et procédés associés
US20130018479A1 (en) * 2010-01-22 2013-01-17 Grotz R Thomas Resilient interpositional hip arthroplasty device
US8834568B2 (en) * 2010-02-04 2014-09-16 Paul S. Shapiro Surgical technique using a contoured allograft cartilage as a spacer of the carpo-metacarpal joint of the thumb or tarso-metatarsal joint of the toe
US8747479B2 (en) * 2011-04-26 2014-06-10 Michael A. McShane Tibial component
CN202200304U (zh) * 2011-05-17 2012-04-25 赵德政 一种封闭润滑的仿生关节装置
GB201109515D0 (en) * 2011-06-07 2011-07-20 Imp Innovations Ltd Implant and implant system
EP2750629B1 (fr) 2011-09-01 2016-07-13 R. Thomas Grotz Dispositif d'arthroplastie avec interposition élastique
US8734523B2 (en) * 2012-05-31 2014-05-27 Howmedica Osteonics Corp. Limited motion tibial bearing
WO2014055480A1 (fr) * 2012-10-02 2014-04-10 Mccullen Seth Dispositifs implantables pour une réparation ou une régénération musculosquelettique
US9345577B2 (en) * 2013-03-14 2016-05-24 Microaire Surgical Instruments Llc Balloon implant device
AU2014276354A1 (en) * 2013-06-01 2016-01-28 Narendra Damle "an implant set having modularity with conformity for total knee replacement"
CA2919546C (fr) * 2013-08-21 2018-11-06 Laboratoires Bodycad Inc. Implant orthopedique adapte a l'anatomie et procede de fabrication associe
US20170014237A1 (en) * 2014-03-11 2017-01-19 Stichting Katholieke Universiteit, more particularly Radbound Universiteit Nijmegen Meniscus prosthesis
SA114360001B1 (ar) * 2014-10-26 2015-09-01 محيل غلاب العتيبي عبدالله استبدال غضروف الركبة بطرف صناعي
US9855146B2 (en) * 2015-08-24 2018-01-02 Arthrex, Inc. Arthroscopic resurfacing techniques

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10307257B2 (en) 2010-01-22 2019-06-04 Iorthopedics, Inc. Resilient knee implant and methods
US10307258B2 (en) 2010-01-22 2019-06-04 Iorthopedics, Inc. Resilient interpositional arthroplasty device
US10617527B2 (en) 2010-01-22 2020-04-14 Iorthopedics, Inc. Resilient knee implant and methods
USD833613S1 (en) 2011-01-19 2018-11-13 Iorthopedics, Inc. Resilient knee implant
US10045851B2 (en) 2011-09-01 2018-08-14 Iorthopedics, Inc. Resilient interpositional arthroplasty device

Also Published As

Publication number Publication date
US10045851B2 (en) 2018-08-14
EP2750629A4 (fr) 2015-03-25
US9757241B2 (en) 2017-09-12
EP2750629A2 (fr) 2014-07-09
WO2013033447A2 (fr) 2013-03-07
US20170312088A1 (en) 2017-11-02
US20140316526A1 (en) 2014-10-23
WO2013033447A3 (fr) 2013-05-02

Similar Documents

Publication Publication Date Title
US10045851B2 (en) Resilient interpositional arthroplasty device
US10092405B2 (en) Method of treating a patient's joint using a resilient arthroplasty device
US10004605B2 (en) Resilient knee implant and methods
US10307258B2 (en) Resilient interpositional arthroplasty device
US20160058548A1 (en) Resilient medically inflatable interpositional arthroplasty device
US20160095706A1 (en) Resilient interpositional hip arthroplasty device
US9486320B2 (en) Subchondral treatment of osteoarthritis in joints
Gibson et al. Matrix-induced autologous chondrocyte implantation
US20220387179A1 (en) Implant for repair and regeneration of soft tissue
Credille et al. Cell-Based Cartilage Repair (MACI and DeNovo)
Di Matteo Aragonite-based scaffold for the treatment of knee osteochondral defects: results of a prospective multi-center trial at 2 years' follow-up
Filardo et al. Novel Nano-Composite Multilayered Biomaterial for the Treatment of Patellofemoral Cartilage Lesions
Miniaci Partial Surface Replacements: Indications, Techniques, and Results
Cartucho et al. Massive Rotator Cuff Tears and Rotator Cuff Arthropathy
Jenny et al. Free Papers

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140219

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20150223

RIC1 Information provided on ipc code assigned before grant

Ipc: A61L 27/58 20060101ALI20150217BHEP

Ipc: A61F 2/20 20060101AFI20150217BHEP

Ipc: A61L 27/14 20060101ALI20150217BHEP

Ipc: A61L 27/54 20060101ALI20150217BHEP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602012020533

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: A61F0002200000

Ipc: A61F0002380000

RIC1 Information provided on ipc code assigned before grant

Ipc: A61L 27/18 20060101ALI20151123BHEP

Ipc: A61F 2/20 20060101ALI20151123BHEP

Ipc: A61F 2/38 20060101AFI20151123BHEP

Ipc: A61F 2/30 20060101ALI20151123BHEP

Ipc: A61L 27/38 20060101ALI20151123BHEP

Ipc: A61L 27/34 20060101ALI20151123BHEP

Ipc: A61L 27/54 20060101ALI20151123BHEP

Ipc: A61L 27/14 20060101ALI20151123BHEP

Ipc: A61L 27/56 20060101ALI20151123BHEP

Ipc: A61L 27/58 20060101ALI20151123BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20160201

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 811664

Country of ref document: AT

Kind code of ref document: T

Effective date: 20160715

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 5

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602012020533

Country of ref document: DE

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20160713

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 811664

Country of ref document: AT

Kind code of ref document: T

Effective date: 20160713

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160713

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161113

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160713

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160713

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160713

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160713

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160713

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161013

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160713

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161014

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160713

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160713

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160713

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160713

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160713

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161114

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602012020533

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160713

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160831

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160713

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160831

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160713

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160713

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160713

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161013

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160713

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160713

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

26N No opposition filed

Effective date: 20170418

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 6

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160830

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160830

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160713

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20171109 AND 20171115

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602012020533

Country of ref document: DE

Representative=s name: HERNANDEZ, YORCK, DIPL.-ING., DE

Ref country code: DE

Ref legal event code: R081

Ref document number: 602012020533

Country of ref document: DE

Owner name: IORTHOPEDICS, INC., LAS VEGAS, US

Free format text: FORMER OWNER: GROTZ, R. THOMAS, NOVATO, CALIF., US

REG Reference to a national code

Ref country code: FR

Ref legal event code: CA

Effective date: 20180215

Ref country code: FR

Ref legal event code: TP

Owner name: IORTHOPEDICS, INC., US

Effective date: 20180216

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160713

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20120830

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160713

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160831

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160713

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160713

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20230706

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20230703

Year of fee payment: 12

Ref country code: DE

Payment date: 20230705

Year of fee payment: 12